image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
392007e6842061606b0995780950182e89ec276f0bf9bfc18e9f25667c5bca1a.png | simple | <table><tr><td>Sample</td><td>mPEG-acid (g)</td><td>Chitosan (g)</td><td>EDC (g)</td><td>NHS (g)</td></tr><tr><td>mPEG-g5-Chitosan</td><td>0.43</td><td>0.50</td><td>0.20</td><td>0.12</td></tr><tr><td>mPEG-g6-Chitosan</td><td>0.43</td><td>0.45</td><td>0.20</td><td>0.12</td></tr><tr><td>mPEG-g7-Chitosan</td><td>0.43</td><td>0.40</td><td>0.20</td><td>0.12</td></tr><tr><td>mPEG-g8-Chitosan</td><td>0.43</td><td>0.35</td><td>0.20</td><td>0.12</td></tr><tr><td>mPEG-g11-Chitosan</td><td>0.43</td><td>0.30</td><td>0.20</td><td>0.12</td></tr><tr><td>mPEG-g13-Chitosan</td><td>0.24</td><td>0.25</td><td>0.20</td><td>0.12</td></tr></table> |
0f01f1e06d143c61d125ae4737c2473748c59aa37638c32221b076aa55e06dfe.png | complex | <table><tr><td> </td><td>N</td><td>%</td></tr><tr><td>Total number of patients</td><td>14</td><td> </td></tr><tr><td>Age</td><td> </td><td> </td></tr><tr><td>Median (Range)</td><td colspan="2">69.5 (38–88)</td></tr><tr><td>Gender</td><td> </td><td> </td></tr><tr><td>Male</td><td>9</td><td>64</td></tr><tr><td>Female</td><td>5</td><td>36</td></tr><tr><td>Race</td><td> </td><td> </td></tr><tr><td>White</td><td>14</td><td>100</td></tr><tr><td>Performance Status (PS)</td><td> </td><td> </td></tr><tr><td>0</td><td>7</td><td>50</td></tr><tr><td>1</td><td>7</td><td>50</td></tr><tr><td>Extra-lymphatic sites involved</td><td> </td><td> </td></tr><tr><td>0</td><td>8</td><td>57</td></tr><tr><td>1</td><td>1</td><td>7</td></tr><tr><td>2</td><td>3</td><td>21</td></tr><tr><td>>2</td><td>2</td><td>14</td></tr><tr><td>Elevated LDH</td><td>6</td><td>43</td></tr><tr><td>Bone Marrow Involvement</td><td>1</td><td>7</td></tr><tr><td>B symptom</td><td>0</td><td>0</td></tr><tr><td>Mediastinal mass</td><td>0</td><td>0</td></tr><tr><td>Lymph node or aggregate with a diameter >5 cm</td><td>5</td><td>36</td></tr><tr><td>Prior Treatment</td><td> </td><td> </td></tr><tr><td>Prior Chemotherapy</td><td>14</td><td>100</td></tr><tr><td>Prior Immunotherapy</td><td>4</td><td>29</td></tr><tr><td>Prior Radiation Therapy</td><td>4</td><td>29</td></tr><tr><td>Prior Surgery (with therapeutic intent)</td><td>1</td><td>7</td></tr><tr><td>Prior Bone Marrow Transplant*</td><td>3</td><td>21</td></tr><tr><td>Other Prior Therapy**</td><td>1</td><td>7</td></tr></table> |
aa20c2f8d13195d90d1292f9b5ca58f8baeec29ebbed52940131954549c6ac44.png | simple | <table><tr><td>Protein</td><td>Gene symbol</td><td>Gene ID</td><td>Sequence 5′- 3′ F</td><td>Sequence 5′- 3′ R</td></tr><tr><td>Lipocalin2</td><td>Lcn2</td><td>16819</td><td>ATATGCACAGGTATCCTCAG</td><td>GAAACGTTCCTTCAGTTCAG</td></tr><tr><td>CD163</td><td>Cd163</td><td>93671</td><td>AGTCTGCTCACGATACATAG</td><td>TCCTTCTGGAATAGATTGGG</td></tr></table> |
a591ee38fd010de21fe86d7ba988dc4b29295b71f498ea75e349192e4423e2b6.png | simple | <table><tr><td>SNP marker</td><td>Position (bp)*</td><td>Location</td><td>SNP†</td><td>MAF‡</td><td><i>P</i> value§</td><td>SLI association¶</td></tr><tr><td>rs7806058</td><td>146007792</td><td>Intron 1</td><td>A/G</td><td>0.35</td><td>ns</td><td>−</td></tr><tr><td>rs6946112</td><td>146059217</td><td>Intron 1</td><td>C/T</td><td>0.27</td><td>ns</td><td>−</td></tr><tr><td>rs12703803</td><td>146062909</td><td>Intron 1</td><td>T/G</td><td>0.29</td><td>ns</td><td>−</td></tr><tr><td>rs2058377</td><td>146090070</td><td>Intron 1</td><td>A/G</td><td>0.31</td><td>ns</td><td>−</td></tr><tr><td>rs12667234</td><td>146111176</td><td>Intron 1</td><td>A/G</td><td>0.30</td><td>ns</td><td>−</td></tr><tr><td>rs2888335</td><td>146124574</td><td>Intron 1</td><td>T/C</td><td>0.30</td><td>ns</td><td>−</td></tr><tr><td>rs7805539</td><td>146160278</td><td>Intron 1</td><td>G/A</td><td>0.28</td><td>ns</td><td>−</td></tr><tr><td>rs4726793</td><td>146276890</td><td>Intron 1</td><td>A/G</td><td>0.20</td><td>ns</td><td>−</td></tr><tr><td>rs10277654</td><td>146352576</td><td>Intron 1</td><td>T/C</td><td>0.44</td><td>ns</td><td>−</td></tr><tr><td>rs7794745</td><td>146489606</td><td>Intron 2</td><td>A/T</td><td>0.26</td><td>ns</td><td>−</td></tr><tr><td>rs6945085</td><td>146691220</td><td>Intron 3</td><td>T/C</td><td>0.09</td><td>ns</td><td>−</td></tr><tr><td>rs1024676</td><td>146715861</td><td>Intron 3</td><td>C/T</td><td>0.38</td><td>ns</td><td>−</td></tr><tr><td>rs10282158</td><td>146738067</td><td>Intron 3</td><td>T/A</td><td>0.06</td><td>ns</td><td>−</td></tr><tr><td>rs7812091</td><td>146740577</td><td>Intron 3</td><td>T/C</td><td>0.38</td><td>ns</td><td>−</td></tr><tr><td>rs10500170</td><td>146848251</td><td>Intron 8</td><td>A/G</td><td>0.16</td><td>ns</td><td>−</td></tr><tr><td>rs1603453</td><td>146908919</td><td>Intron 8</td><td>T/A</td><td>0.11</td><td>ns</td><td>−</td></tr><tr><td>rs1603450</td><td>146913540</td><td>Intron 8</td><td>G/A</td><td>0.18</td><td>0.0426*</td><td>−</td></tr><tr><td>rs10251377</td><td>147117454</td><td>Intron 10</td><td>A/G</td><td>0.25</td><td>ns</td><td>−</td></tr><tr><td>rs851715</td><td>147526906</td><td>Intron 13</td><td>A/G</td><td>0.32</td><td>ns</td><td>+</td></tr><tr><td>rs1177007</td><td>147546371</td><td>Intron 13</td><td>A/G</td><td>0.31</td><td>ns</td><td>−</td></tr><tr><td>rs10246256</td><td>147554807</td><td>Intron 13</td><td>T/C</td><td>0.31</td><td>ns</td><td>+</td></tr><tr><td>rs2710102</td><td>147574390</td><td>Intron 13</td><td>C/T</td><td>0.49</td><td>0.0239*</td><td>+</td></tr><tr><td>rs759178</td><td>147575112</td><td>Intron 13</td><td>G/T</td><td>0.49</td><td>0.0248*</td><td>+</td></tr><tr><td>rs17236239</td><td>147582305</td><td>Intron 13</td><td>A/G</td><td>0.35</td><td>0.0851</td><td>+</td></tr><tr><td>rs2538976</td><td>147585819</td><td>Intron 13</td><td>G/A</td><td>0.50</td><td>0.0535</td><td>+</td></tr><tr><td>rs2538963</td><td>147599446</td><td>Intron 13</td><td>G/A</td><td>0.32</td><td>ns</td><td>−</td></tr><tr><td>rs2710117</td><td>147601772</td><td>Intron 14</td><td>A/T</td><td>0.38</td><td>0.0771</td><td>+</td></tr><tr><td>rs10240503</td><td>147674978</td><td>Exon 15</td><td>A/G</td><td>0.11</td><td>ns</td><td>−</td></tr><tr><td>rs12155129</td><td>147856865</td><td>Intron 17</td><td>A/G</td><td>0.06</td><td>ns</td><td>−</td></tr><tr><td>rs11980146</td><td>147956733</td><td>Intron 20</td><td>A/G</td><td>0.34</td><td>ns</td><td>−</td></tr></table> |
46f3002c47a840826f71d7f2391a1af129317055af1c0d3bd0f987941c2f81f1.png | simple | <table><tr><td>CHR</td><td>GENE</td><td>SNP</td><td>OR</td><td>L95</td><td>U95</td><td>P</td></tr><tr><td>19</td><td><i>APOE</i></td><td>rs157580</td><td>0.51</td><td>0.45</td><td>0.59</td><td><i>3.30E-21</i></td></tr><tr><td>5</td><td><i>HMGCR</i></td><td>rs3846662</td><td>1.16</td><td>1.02</td><td>1.32</td><td><i>0.02</i></td></tr><tr><td>12</td><td><i>MMAB/MVK</i></td><td>rs7298565</td><td>0.88</td><td>0.78</td><td>1</td><td><i>0.05</i></td></tr><tr><td>5</td><td><i>TIMD4/HAVCR1</i></td><td>rs1363232</td><td>0.89</td><td>0.78</td><td>1.01</td><td>0.06</td></tr><tr><td>15</td><td><i>LIPC</i></td><td>rs1532085</td><td>0.89</td><td>0.78</td><td>1.01</td><td>0.07</td></tr><tr><td>16</td><td><i>CETP</i></td><td>rs9989419</td><td>1.12</td><td>0.98</td><td>1.27</td><td>0.09</td></tr><tr><td>19</td><td><i>NCAN</i></td><td>rs2304130</td><td>1.16</td><td>0.92</td><td>1.47</td><td>0.21</td></tr><tr><td>20</td><td><i>HNF4A</i></td><td>rs1800961</td><td>0.8</td><td>0.55</td><td>1.16</td><td>0.24</td></tr><tr><td>18</td><td><i>LIPG</i></td><td>rs4939883</td><td>1.09</td><td>0.92</td><td>1.28</td><td>0.32</td></tr><tr><td>16</td><td><i>LCAT</i></td><td>rs2271293</td><td>0.91</td><td>0.75</td><td>1.1</td><td>0.33</td></tr><tr><td>1</td><td><i>SORT1</i></td><td>rs646776</td><td>1.07</td><td>0.92</td><td>1.24</td><td>0.4</td></tr><tr><td>1</td><td><i>GALNT2</i></td><td>rs10779835</td><td>0.95</td><td>0.84</td><td>1.08</td><td>0.44</td></tr><tr><td>9</td><td><i>TTC39B</i></td><td>rs471364</td><td>1.07</td><td>0.88</td><td>1.3</td><td>0.48</td></tr><tr><td>2</td><td><i>APOB</i></td><td>rs506585</td><td>1.05</td><td>0.9</td><td>1.23</td><td>0.53</td></tr><tr><td>19</td><td><i>LDLR</i></td><td>rs2228671</td><td>0.96</td><td>0.79</td><td>1.17</td><td>0.66</td></tr><tr><td>2</td><td><i>APOB</i></td><td>rs693</td><td>0.98</td><td>0.87</td><td>1.11</td><td>0.78</td></tr><tr><td>16</td><td><i>CETP</i></td><td>rs3764261</td><td>0.99</td><td>0.86</td><td>1.13</td><td>0.86</td></tr><tr><td>9</td><td><i>ABCA1</i></td><td>rs3847303</td><td>0.99</td><td>0.82</td><td>1.19</td><td>0.92</td></tr></table> |
3fd203c97aeb26d6667668b97b0fc410bdc68a472f79120797211f7ce87c8f75.png | simple | <table><tr><td></td><td>Years</td><td>Survival rate (%)</td><td>95% confidence interval</td></tr><tr><td>Overall survival</td><td>2</td><td>90</td><td>80; 100</td></tr><tr><td></td><td>3</td><td>78</td><td>64; 96</td></tr><tr><td></td><td>5</td><td>69</td><td>53; 90</td></tr><tr><td>Disease-free survival</td><td>2</td><td>85</td><td>72; 100</td></tr><tr><td></td><td>3</td><td>85</td><td>72; 100</td></tr><tr><td></td><td>5</td><td>79</td><td>65; 98</td></tr></table> |
58103f1e2d176e48d7384e766fd1d6f56317620c5f5fb646ff62957dd5d3e104.png | simple | <table><tr><td>Score</td><td>Symptoms</td></tr><tr><td>Grade 1</td><td>Local paraesthesia (anesthesia, tingling, stinging)</td></tr><tr><td>Grade 2</td><td>Hypersecretion (sweat, saliva)</td></tr><tr><td>Grade 3</td><td>Impaired vision, hearing, speech, dysphagia</td></tr><tr><td>Grade 4</td><td>Bilateral ptosis</td></tr><tr><td>Grade 5</td><td>Severe dyspnea</td></tr><tr><td>Grade 6</td><td>Severe consciousness disorders, motor and respiratory paralysis</td></tr></table> |
cf74c60a70c58c7dc74d04c1a58ed6692aff9b127e995a787c941c823accc70e.png | simple | <table><tr><td>Cell type</td><td>Species</td><td>Passage</td><td>Culture method</td><td>Reference</td></tr><tr><td>Chondrocyte</td><td>Human</td><td>P2</td><td>Monolayer + 3D</td><td>[7]</td></tr><tr><td>ADSC</td><td>Human</td><td>P4</td><td>Monolayer + 3D</td><td>[8]</td></tr><tr><td>SDSC</td><td>Human</td><td>P2</td><td>Monolayer + 3D</td><td>[11]</td></tr><tr><td>BMSC</td><td>Human</td><td>P2</td><td>Monolayer + 3D</td><td>[11]</td></tr><tr><td>Chondrocyte</td><td>Human</td><td>P2</td><td>Monolayer</td><td>[11]</td></tr><tr><td>Chondrocyte</td><td>Rabbit</td><td>P0-P4</td><td>Monolayer</td><td>[12]</td></tr><tr><td>Chondrocyte</td><td>Human</td><td>P0-P4</td><td>Monolayer</td><td>[13]</td></tr><tr><td>SDSC</td><td>Human</td><td>P4-P7</td><td>Monolayer + 3D</td><td>[14]</td></tr><tr><td>Chondrocyte</td><td>Human</td><td>P0-P4</td><td>Monolayer + 3D</td><td>[15]</td></tr><tr><td>BMSC</td><td>Human</td><td>P1-P4</td><td>Monolayer + 3D</td><td>[15]</td></tr></table> |
644aa57d6a6df895a5337818b0b77054d5287563bd61de4206a9b900baba8919.png | complex | <table><tr><td rowspan="2">Num. of genes</td><td colspan="2">RSVM</td><td colspan="2">SVM-RFE</td><td colspan="2">SVM-<i>t</i></td></tr><tr><td>CV2</td><td>Mean SV</td><td>CV2</td><td>Mean SV</td><td>CV2</td><td>Mean SV</td></tr><tr><td>7129</td><td>22.09%</td><td>51.34</td><td>22.09%</td><td>51.34</td><td>22.09%</td><td>51.34</td></tr><tr><td>6060</td><td>20.93%</td><td>46.78</td><td>22.09%</td><td>51.35</td><td>20.93%</td><td>50.85</td></tr><tr><td>5151</td><td>20.93%</td><td>45.07</td><td>22.09%</td><td>51.40</td><td>19.77%</td><td>50.20</td></tr><tr><td>4378</td><td>20.93%</td><td>44.24</td><td>22.09%</td><td>51.42</td><td>18.60%</td><td>49.24</td></tr><tr><td>3721</td><td>20.93%</td><td>43.99</td><td>22.09%</td><td>51.35</td><td>15.12%</td><td>48.22</td></tr><tr><td>3163</td><td>20.93%</td><td>43.53</td><td>22.09%</td><td>51.34</td><td>15.12%</td><td>47.60</td></tr><tr><td>2689</td><td>20.93%</td><td>43.38</td><td>22.09%</td><td>51.36</td><td>15.12%</td><td>47.38</td></tr><tr><td>2286</td><td>20.93%</td><td>43.12</td><td>20.93%</td><td>51.86</td><td>15.12%</td><td>46.71</td></tr><tr><td>1943</td><td>22.09%</td><td>43.17</td><td>20.93%</td><td>52.79</td><td>12.79%</td><td>46.05</td></tr><tr><td>1652</td><td>22.09%</td><td>43.26</td><td>20.93%</td><td>52.51</td><td>12.79%</td><td>45.10</td></tr><tr><td>1404</td><td>22.09%</td><td>43.12</td><td>20.93%</td><td>51.84</td><td>13.95%</td><td>43.78</td></tr><tr><td>1193</td><td>22.09%</td><td>42.87</td><td>20.93%</td><td>52.33</td><td>10.47%</td><td>42.60</td></tr><tr><td>1014</td><td>22.09%</td><td>42.86</td><td>20.93%</td><td>51.15</td><td>8.14%</td><td>41.84</td></tr><tr><td>862</td><td>22.09%</td><td>42.24</td><td>22.09%</td><td>51.64</td><td>8.14%</td><td>41.50</td></tr><tr><td>733</td><td>22.09%</td><td>41.47</td><td>22.09%</td><td>52.21</td><td>9.30%</td><td>41.03</td></tr><tr><td>623</td><td>22.09%</td><td>41.55</td><td>23.26%</td><td>51.72</td><td>12.79%</td><td>40.07</td></tr><tr><td>530</td><td>22.09%</td><td>40.85</td><td>23.26%</td><td>51.28</td><td>11.63%</td><td>39.71</td></tr><tr><td>450</td><td>22.09%</td><td>40.40</td><td>23.26%</td><td>50.59</td><td>10.47%</td><td>39.20</td></tr><tr><td>382</td><td>22.09%</td><td>39.08</td><td>23.26%</td><td>50.70</td><td>9.30%</td><td>38.34</td></tr><tr><td>325</td><td>22.09%</td><td>38.62</td><td>23.26%</td><td>50.77</td><td>11.63%</td><td>37.43</td></tr><tr><td>276</td><td>22.09%</td><td>38.52</td><td>24.42%</td><td>49.21</td><td>9.30%</td><td>36.62</td></tr><tr><td>235</td><td>22.09%</td><td>38.71</td><td>24.42%</td><td>48.27</td><td>11.63%</td><td>36.06</td></tr><tr><td>200</td><td>22.09%</td><td>37.28</td><td>24.42%</td><td>47.67</td><td>12.79%</td><td>35.59</td></tr><tr><td>170</td><td>22.09%</td><td>36.33</td><td>24.42%</td><td>45.84</td><td>12.79%</td><td>35.13</td></tr><tr><td>144</td><td>22.09%</td><td>36.19</td><td>23.26%</td><td>44.64</td><td>15.12%</td><td>33.88</td></tr><tr><td>122</td><td>24.42%</td><td>35.43</td><td>24.42%</td><td>42.81</td><td>15.12%</td><td>33.48</td></tr><tr><td>104</td><td>24.42%</td><td>34.30</td><td>24.42%</td><td>40.87</td><td>15.12%</td><td>32.59</td></tr><tr><td>88</td><td>24.42%</td><td>32.87</td><td>29.07%</td><td>39.02</td><td>16.28%</td><td>31.99</td></tr><tr><td>75</td><td>24.42%</td><td>31.28</td><td>26.74%</td><td>36.56</td><td>17.44%</td><td>31.92</td></tr><tr><td>64</td><td>26.74%</td><td>29.84</td><td>25.58%</td><td>34.08</td><td>16.28%</td><td>31.80</td></tr><tr><td>54</td><td>26.74%</td><td>27.41</td><td>25.58%</td><td>30.07</td><td>17.44%</td><td>31.97</td></tr><tr><td>46</td><td>26.74%</td><td>25.94</td><td>26.74%</td><td>27.50</td><td>15.12%</td><td>31.90</td></tr><tr><td>39</td><td>25.58%</td><td>24.42</td><td>25.58%</td><td>25.10</td><td>12.79%</td><td>32.30</td></tr><tr><td>33</td><td>23.26%</td><td>22.53</td><td>29.07%</td><td>23.09</td><td>11.63%</td><td>32.66</td></tr><tr><td>28</td><td>20.93%</td><td>20.42</td><td>26.74%</td><td>19.87</td><td>15.12%</td><td>32.97</td></tr><tr><td>24</td><td>20.93%</td><td>18.86</td><td>24.42%</td><td>19.31</td><td>13.95%</td><td>33.16</td></tr><tr><td>20</td><td>23.26%</td><td>16.94</td><td>25.58%</td><td>16.59</td><td>16.28%</td><td>33.51</td></tr><tr><td>17</td><td>23.26%</td><td>15.83</td><td>24.42%</td><td>15.71</td><td>16.28%</td><td>33.58</td></tr><tr><td>14</td><td>22.09%</td><td>16.42</td><td>23.26%</td><td>16.15</td><td>17.44%</td><td>34.08</td></tr><tr><td>12</td><td>24.42%</td><td>17.72</td><td>26.74%</td><td>17.03</td><td>16.28%</td><td>34.55</td></tr><tr><td>10</td><td>25.58%</td><td>19.76</td><td>26.74%</td><td>19.95</td><td>13.95%</td><td>35.15</td></tr><tr><td>8</td><td>24.42%</td><td>22.45</td><td>29.07%</td><td>22.60</td><td>15.12%</td><td>36.01</td></tr><tr><td>7</td><td>24.42%</td><td>23.64</td><td>27.91%</td><td>24.16</td><td>16.28%</td><td>36.44</td></tr><tr><td>6</td><td>29.07%</td><td>25.35</td><td>27.91%</td><td>25.97</td><td>17.44%</td><td>36.87</td></tr><tr><td>5</td><td>27.91%</td><td>27.86</td><td>30.23%</td><td>28.73</td><td>18.60%</td><td>37.50</td></tr></table> |
506c73f8845b2ad3cf381808d65c673cd7413051edea62f7e3372b6208b5d68d.png | simple | <table><tr><td></td><td>Group 1</td><td>Group 2</td><td>p</td></tr><tr><td></td><td>N =58</td><td>N= 219</td><td></td></tr><tr><td>All-cause mortality, N (%)</td><td>5 (8.6%)</td><td>42 (19.9%)</td><td>0.05</td></tr><tr><td>Non-fatal ACS, N (%)</td><td>2 (3.4%)</td><td>32 (14.6%)</td><td>0.03</td></tr><tr><td>Stroke, N (%)</td><td>0 (0%)</td><td>5 (2.9%)</td><td>0.2</td></tr><tr><td>MACCE, N (%)</td><td>7 (12.0%)</td><td>70 (31.9%)</td><td><0.01</td></tr></table> |
10ae116fbb41d478a89ff056ef939eed03ddb86eb3e34a776f5ab015bc5059f0.png | complex | <table><tr><td></td><td></td><td>Baseline</td><td>60 mins</td><td>120 mins</td><td>180 mins</td><td>240 mins</td></tr><tr><td rowspan="2">EE</td><td>CON</td><td>4.29 ± 0.28</td><td>4.57 ± 0.41</td><td>4.28 ± 0.26</td><td>4.29 ± 0.35</td><td>4.42 ± 0.33</td></tr><tr><td>INS</td><td>4.01 ± 0.24</td><td>3.88 ± 0.14</td><td>3.91 ± 0.21<sup>∗</sup></td><td>3.78 ± 0.24</td><td>3.90 ± 0.16</td></tr><tr><td rowspan="2">RER</td><td>CON</td><td>0.89 ± 0.04</td><td>0.80 ± 0.05</td><td>0.83 ± 0.02</td><td>0.82 ± 0.02</td><td>0.85 ± 0.02</td></tr><tr><td>INS</td><td>0.89 ± 0.04</td><td>0.94 ± 0.02<sup>∗</sup></td><td>0.94 ± 0.02<sup>∗∗</sup></td><td>0.92 ± 0.04</td><td>0.91 ± 0.02</td></tr><tr><td rowspan="2">CHO ox</td><td>CON</td><td>0.17 ± 0.03</td><td>0.09 ± 0.03</td><td>0.12 ± 0.01</td><td>0.10 ± 0.02</td><td>0.13 ± 0.02</td></tr><tr><td>INS</td><td>0.16 ± 0.03</td><td>0.20 ± 0.02<sup>∗</sup></td><td>0.19 ± 0.02<sup>∗∗</sup></td><td>0.16 ± 0.03</td><td>0.17 ± 0.02</td></tr><tr><td rowspan="2">FAT ox</td><td>CON</td><td>0.04 ± 0.01</td><td>0.09 ± 0.02</td><td>0.06 ± 0.01</td><td>0.07 ± 0.01</td><td>0.06 ± 0.01</td></tr><tr><td>INS</td><td>0.04 ± 0.01</td><td>0.02 ± 0.01<sup>∗</sup></td><td>0.02 ± 0.01<sup>∗∗</sup></td><td>0.03 ± 0.01</td><td>0.03 ± 0.01</td></tr></table> |
9e624384d9f81a57a732cc837a8452e2938ea4eced752a67aa148ed2f916e5bb.png | complex | <table><tr><td></td><td colspan="8">Library name</td></tr><tr><td></td><td>AA9</td><td>B421</td><td>CHORI-514</td><td>MCF7</td><td>PM-1</td><td>CHORI-510</td><td>CHORI-518</td><td>CHORI-520</td></tr><tr><td>Clinical sample designation</td><td>AA9</td><td>B421</td><td>S104</td><td>MCF-7</td><td>25-48</td><td>860-7</td><td>BT-474</td><td>SK-BR-3</td></tr><tr><td>Organ site</td><td>Brain</td><td>Breast</td><td>Breast</td><td>Breast cancer adenocarcinoma (metastasis - pleural effusion)</td><td>Prostate metastasis</td><td>Ovarian carcinoma</td><td>Ductal carcinoma</td><td>Breast cancer adenocarcinoma (metastasis - pleural effusion)</td></tr><tr><td>Therapies applied</td><td>Radiotherapy</td><td>Chemotherapy 4 months before surgery (CMF)</td><td>No radiation therapy or chemotherapy before surgery</td><td>N/A</td><td>Hormone ablation, palliative radiotherapy</td><td>No therapy before surgery</td><td>N/A</td><td>N/A</td></tr><tr><td>Patient status</td><td>Deceased</td><td>Deceased, no recurrence</td><td>No recurrence for 10 years</td><td>N/A</td><td>Deceased</td><td>Tumor recurred within 13 months</td><td>N/A</td><td>N/A</td></tr><tr><td>Total amount of tumor material used for library construction (mg)</td><td>100</td><td>150 (20 mg effective)</td><td>100</td><td>N/A</td><td>50</td><td>200</td><td>N/A</td><td>N/A</td></tr><tr><td>Average clone size (± standard deviation; kb)</td><td>129.1 ± 38.3</td><td>136.4 ± 29.2</td><td>166.1 ± 53.2</td><td>148.0 ± 30</td><td>N/D</td><td>149.3 ± 28.8</td><td>179 ± 23</td><td>154 ± 25</td></tr></table> |
ec6b9005cbb472707c5e418bb82e3f977a449c5175918ce33baf7eac3a4d37cd.png | simple | <table><tr><td>Gene</td><td>Cell locale</td><td>Tissue</td><td>Modality of expression</td></tr><tr><td>HSPA8</td><td>Cytosol. Translocate to nucleus and nucleoli upon heat shock. Surface of embryonic stem cells</td><td>Highly expressed in all tisuses</td><td>Constitutive. Moderately induced by heat shock</td></tr><tr><td>HSPA2</td><td>Nucleus</td><td>Mostly in testis, skeletal and heart muscles, esophagous, brain</td><td>Constitutive</td></tr><tr><td>HSPA1A and HSPA1B</td><td>Cytosol. Nucleus and nucleoli upon heat shock</td><td>All tissues</td><td>Strongly induced by heat shock</td></tr><tr><td>HSPA1L</td><td>Mostly cytosol under basal conditions. Nucleus but not nucleoli upon heat shock</td><td>Spermatides</td><td>Constitutive. Not induced by heat shock</td></tr><tr><td>HSPA6</td><td>Cytosol. Nucleus</td><td>Most tissues</td><td>Induced by heat shock. No basal expression</td></tr><tr><td>HSPA5</td><td>Endoplasmic reticulum (ER)</td><td>All tissue</td><td>Induced by ER stressors</td></tr><tr><td>HSPA9B</td><td>Mitochondria. ER. Cytosol. Cytosolic vesicles. Membrane surface</td><td>Many tissues</td><td>Constitutive</td></tr><tr><td>STCH</td><td>Microsomas</td><td>All tissues</td><td>Constitutive</td></tr><tr><td>HSPA14</td><td>Cytosol. Associated to ribosomes</td><td>Many tissues (low expression)</td><td>Undetermined</td></tr><tr><td>HSPA4</td><td>Cytosolic (?)</td><td>Most tissues</td><td>Constitutive. Not induced by heat shock</td></tr><tr><td>HSPA4L</td><td>Cytosol. Nucleus upon heat shock</td><td>Mostly testis</td><td>Constitutive. Induced by heat shock in somatic cells but not in germ cells</td></tr><tr><td>HSPH1</td><td>Cytosol. Nucleus upon heat shock, possibly nucleoli</td><td>Most tissues</td><td>Constitutive. Induced by heat shock</td></tr><tr><td>HYOU1</td><td>ER. Cytosol (isoform 3)</td><td>Liver, pancreas. Highly expressed in cells with well developed ER</td><td>Induced by ER stressors</td></tr><tr><td>HSPA12A</td><td>Undetermined yet</td><td>Brain. Kidney. Muscle</td><td>Constitutive. Induced by stress</td></tr><tr><td>HSPA12B</td><td>Undetermined yet</td><td>Skeletal and heart muscles</td><td>Constitutive. Induced by stress</td></tr></table> |
1b6af52716846e52c0c7a722fd2c21d9c1532410d6654286283bdb503a92480e.png | complex | <table><tr><td rowspan="2"></td><td colspan="5">IAP</td><td></td></tr><tr><td>Normal (<i>n</i> =27)</td><td>Grade I (<i>n</i> = 55)</td><td>Grade II (<i>n</i> = 109)</td><td>Grade III (<i>n</i> = 78)</td><td>Grade IV (<i>n</i> = 32)</td><td><i>P</i>†</td></tr><tr><td>Shock</td><td>7 (26)</td><td>33 (60)</td><td>75 (69·8)</td><td>56 (72)</td><td>24 (75)</td><td>< 0·001</td></tr><tr><td>Renal failure</td><td>15 (56)</td><td>33 (60)</td><td>66 (60·6)</td><td>60 (77)</td><td>27 (84)</td><td>< 0·001</td></tr><tr><td>CRRT</td><td>0 (0)</td><td>12 (22)</td><td>31 (28·4)</td><td>34 (44)</td><td>21 (66)</td><td>< 0·001</td></tr><tr><td>Respiratory failure</td><td>10 (37)</td><td>32 (58)</td><td>76 (69·7)</td><td>55 (71)</td><td>28 (88)</td><td>0·007</td></tr><tr><td>Mechanical ventilation</td><td>5 (19)</td><td>29 (53)</td><td>62 (56·9)</td><td>53 (68)</td><td>27 (84)</td><td>0·007</td></tr><tr><td>Infected necrosis</td><td>3 (11)</td><td>9 (16)</td><td>30 (27·5)</td><td>32 (41)</td><td>9 (28)</td><td>0·005</td></tr><tr><td>Surgery</td><td>5 (19)</td><td>15 (27)</td><td>28 (25·7)</td><td>35 (45)</td><td>16 (50)</td><td>0·006</td></tr><tr><td>Decompressive laparotomy</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>3 (4)</td><td>6 (19)</td><td></td></tr><tr><td>Nutrition</td><td></td><td></td><td></td><td></td><td></td><td>0·009</td></tr><tr><td>None</td><td>–</td><td>9 (16)</td><td>32 (29·4)</td><td>16 (21)</td><td>6 (19)</td><td></td></tr><tr><td>Enteral</td><td>–</td><td>22 (40)</td><td>26 (23·9)</td><td>15 (19)</td><td>6 (19)</td><td></td></tr><tr><td>Parenteral</td><td>–</td><td>23 (42)</td><td>45 (41·3)</td><td>43 (55)</td><td>19 (59)</td><td></td></tr><tr><td>Enteral and parenteral</td><td>–</td><td>1 (2)</td><td>6 (5·5)</td><td>4 (5)</td><td>1 (3)</td><td></td></tr><tr><td>ICU LOS (days)*</td><td>5 (3–7)</td><td>6 (3–14·3)</td><td>10 (5–27)</td><td>18 (6·8–32·3)</td><td>11 (3·5–25)</td><td>< 0·001‡</td></tr><tr><td>Hospital LOS (days)*</td><td>15 (12–26)</td><td>22 (13–38)</td><td>24 (14–43)</td><td>30 (8–59)</td><td>17 (8–29)</td><td>< 0·001‡</td></tr><tr><td>Mortality</td><td>1 (4)</td><td>11 (20)</td><td>33 (30·3)</td><td>31 (40)</td><td>21 (66)</td><td>< 0·001</td></tr><tr><td>Cause of death</td><td></td><td></td><td></td><td></td><td></td><td>< 0·001</td></tr><tr><td>Initial SIRS</td><td>0 (0)</td><td>5 of 11 (45)</td><td>13 of 33 (39)</td><td>7 of 31 (23)</td><td>7 of 21 (33)</td><td></td></tr><tr><td>Pancreatic infection</td><td>0 (0)</td><td>2 of 11 (18)</td><td>4 of 33 (12)</td><td>9 of 31 (29)</td><td>7 of 21 (33)</td><td></td></tr><tr><td>Non‐pancreatic infection</td><td>0 (0)</td><td>1 of 11 (9)</td><td>7 of 33 (21)</td><td>3 of 31 (10)</td><td>2 of 21 (10)</td><td></td></tr><tr><td>Other</td><td>1 of 1 (100)</td><td>3 of 11 (27)</td><td>9 of 33 (27)</td><td>12 of 31 (39)</td><td>5 of 21 (24)</td><td></td></tr></table> |
1df7a2e9a01916c376e95694aac119f2a091ac74927cf5e8a81963d315268e1e.png | simple | <table><tr><td>Study (reference)</td><td>Patients</td><td>Molecular marker</td><td>Ethnicity (Country)</td><td>Evaluation criteria</td><td>Sample size</td><td>Chemotherapeutic regimens</td><td>Outcomes</td></tr><tr><td>Goekkurt 2006, [11]</td><td>Patients with advanced GC</td><td>TS, GSTs, MTHFR, ERCC1-118</td><td>European (Germany)</td><td>RECIST</td><td>52</td><td>5-Fu+cisplatin + leucovorin</td><td>RR and OS</td></tr><tr><td>Ruzzo 2006 [14]</td><td>Patients with advanced GC</td><td>TS, GSTs, MTHFR, ERCC1-118</td><td>European (Italy)</td><td>Others</td><td>175</td><td>fluorouracil/cisplatin</td><td>RR and OS</td></tr><tr><td>Shim 2010 [17]</td><td>Patients with recurrent or metastatic GC</td><td>GSTs</td><td>Asian (Korea)</td><td>RECIST</td><td>200</td><td>Paclitaxel/docetaxel +cisplatin</td><td>RR and OS</td></tr><tr><td>Park 2011 [18]</td><td>Patients with metastatic GC</td><td>ERCC1-118</td><td>Asian (Korea)</td><td>RECIST</td><td>108</td><td>S-1 + cisplatin</td><td>RR and OS</td></tr><tr><td>Han 2010 [19]</td><td>Patients with recurrent or metastatic GC</td><td>TS, ERCC1-118</td><td>Asian (Korea)</td><td>RECIST</td><td>38</td><td>5-Fu+leucovorin +oxaliplatin</td><td>RR and OS</td></tr><tr><td>Stocker 2009 [20]</td><td>Neoadjuvant chemotherapy for locally advanced GC without distant metastasis</td><td>ERCC1-118</td><td>European (Germany)</td><td>Others</td><td>178</td><td>5-Fu+leucovorin +cisplatin</td><td>RR and OS</td></tr><tr><td>Seo 2009 [21]</td><td>Patients with recurrent or metastatic GC</td><td>TS, GSTs, ERCC1-118</td><td>Asian (Korea)</td><td>RECIST</td><td>94</td><td>5-Fu+ oxaliplatin/irinotecan</td><td>RR, OS and toxicity</td></tr><tr><td>Liu 2011 [22]</td><td>Patients with advanced GC</td><td>GSTs, ERCC1-118</td><td>Asian (China)</td><td>NR</td><td>126</td><td>5-FU+leucovorin +oxaliplatin</td><td>OS</td></tr><tr><td>Ott 2008 [23]</td><td>Neoadjuvant chemotherapy for locally advanced GC without distant metastasis</td><td>GSTs</td><td>European (Germany)</td><td>Others</td><td>139</td><td>5-Fu+leucovorin + cisplatin</td><td>RR and OS</td></tr><tr><td>Li 2010 [24]</td><td>Patients with advanced GC</td><td>GSTs</td><td>Asian (China)</td><td>Others</td><td>92</td><td>5-Fu +oxaliplatin</td><td>RR, OS and toxicity</td></tr><tr><td>Lu 2004 [25]</td><td>Patients with advanced GC</td><td>MTHFR</td><td>Asian (China)</td><td>WHO</td><td>75</td><td>5-Fu+leucovorin</td><td>RR and toxicity</td></tr><tr><td>Huang 2009 [26]</td><td>Patients with GC after curative surgery</td><td>GSTs, ERCC1-118</td><td>Asian (China)</td><td>NR</td><td>102</td><td>5-Fu+leucovorin +oxaliplatin</td><td>OS</td></tr><tr><td>Shitara 2010 [27]</td><td>Patients with inoperable GC</td><td>TS, MTHFR</td><td>Asian (Japan)</td><td>NR</td><td>132</td><td>5-Fu et al.</td><td>OS and toxicity</td></tr><tr><td>Huang 2009 [28]</td><td>Patients with GC after curative surgery</td><td>TS, MTHFR</td><td>Asian (China)</td><td>NR</td><td>116</td><td>5-Fu+leucovorin et al.</td><td>OS</td></tr><tr><td>Ishida 2002 [29]</td><td>Patients with GC after surgery</td><td>TS</td><td>Asian (Japan)</td><td>NR</td><td>51</td><td>5-Fu et al.</td><td>OS</td></tr><tr><td>Keam 2008 [30]</td><td>Patients with recurrent or metastatic GC</td><td>GSTs, ERCC1-118</td><td>Asian (Korea)</td><td>WHO</td><td>73</td><td>5-Fu+leucovorin +oxaliplatin</td><td>RR and OS</td></tr><tr><td>Goekkurt 2009, [31]</td><td>Patients with advanced GC</td><td>TS, GSTs, MTHFR, ERCC1-118</td><td>European (Germany)</td><td>Others</td><td>134</td><td>5-Fu+leucovorin +oxaliplatin/cisplatin</td><td>RR, OS and toxicity</td></tr><tr><td>Ott 2006 [32]</td><td>Neoadjuvant chemotherapy for patients with locally advanced GC</td><td>TS, MTHFR</td><td>European (Germany)</td><td>Others</td><td>135</td><td>5-Fu+cisplatin</td><td>RR and OS</td></tr><tr><td>Ott 2011 [33]</td><td>Neoadjuvant chemotherapy for patients with locally advanced GC</td><td>MTHFR</td><td>European (Germany)</td><td>Others</td><td>144</td><td>5-Fu+leucovorin + cisplatin</td><td>OS</td></tr><tr><td>Lee 2005 [34]</td><td>Patients with advanced GC</td><td>TS, MTHFR</td><td>Asian (Korea)</td><td>NR</td><td>25</td><td>5-Fu et al.</td><td>OS</td></tr></table> |
1e7a77c60f8dab670da4556138883d143ef782140319595fbbfad866b8644f1b.png | simple | <table><tr><td> </td><td>Median total number of lymph nodes for patients with nodal involvement</td><td>Median total number of lymph nodes for patients without nodal involvement</td><td>P-value</td></tr><tr><td>PCG</td><td>13.0 (10–17)*</td><td>14.0 (11–18)*</td><td>0.654</td></tr><tr><td> </td><td>PCG</td><td>PSG</td><td> </td></tr><tr><td>Median number of involved lymph nodes</td><td>3.0 (1–6)*</td><td>2.5 (1–5)*</td><td>0.904</td></tr></table> |
46ea7e32e97dc3704e4d6d869660b1f096d9f442903c72c38893cd8c2d7a0fdb.png | simple | <table><tr><td> </td><td>Number of patients</td><td>cEPCs(%)</td><td><i>P</i></td></tr><tr><td>Stenosis</td><td> </td><td> </td><td>0.012</td></tr><tr><td> <70%</td><td>48</td><td>0.052 ± 0.022</td><td> </td></tr><tr><td> ≥70%</td><td>60</td><td>0.091 ± 0.035</td><td> </td></tr><tr><td>Number of intracranial symptomatic arteries</td><td> </td><td> </td><td>0.578</td></tr><tr><td> 1</td><td>30</td><td>0.065 ± 0.024</td><td> </td></tr><tr><td> 2</td><td>26</td><td>0.058 ± 0.033</td><td> </td></tr><tr><td> >2</td><td>52</td><td>0.067 ± 0.044</td><td> </td></tr></table> |
4d638475ed7734376b5bcc77c7ccd0911f3f87ab734b0d534c852e457ee2c735.png | complex | <table><tr><td rowspan="2">Sample</td><td colspan="4">CO (μmol·g<sup>−1</sup>)</td></tr><tr><td>Anhydride</td><td>Phenol</td><td>Carbonyl and Quinone</td><td>Pyrone and Chromene</td></tr><tr><td>RN1</td><td>–</td><td>–</td><td>380</td><td>620</td></tr><tr><td>RN1P</td><td>–</td><td>–</td><td>14</td><td>140</td></tr><tr><td>RN1A</td><td>137</td><td></td><td>1310</td><td>–</td></tr><tr><td>RN2</td><td>–</td><td>52</td><td>60</td><td>800</td></tr><tr><td>RN2D5</td><td>–</td><td>32</td><td>–</td><td>250</td></tr><tr><td>RN2D10</td><td>–</td><td>–</td><td>30</td><td>270</td></tr></table> |
7bf3102186645d7679844ac82fd8d4ca8eb814df40e9df9b8933517cd1f1dedc.png | simple | <table><tr><td>Indication</td><td>Number</td></tr><tr><td>Renal impairment and acidosis</td><td>20</td></tr><tr><td>Renal impairment and hyperkalaemia</td><td>0</td></tr><tr><td>Renal impairment, acidosis and hyperkalaemia</td><td>6</td></tr><tr><td>Renal impairment, acidosis and convulsions</td><td>2</td></tr><tr><td>Renal impairment, acidosis, hyperkalaemia and convulsions</td><td>3</td></tr><tr><td>Worsening renal function despite conservative measures</td><td>5</td></tr><tr><td>Worsening renal function and convulsions</td><td>1</td></tr><tr><td>Renal impairment and pulmonary oedema</td><td>1</td></tr><tr><td>Renal impairment, acidosis and pulmonary oedema</td><td>1</td></tr><tr><td>Total</td><td>39</td></tr></table> |
74671c7f8ac848b19eb9441cd171279a6923dbe7ca73ffbb580a45a776244db9.png | complex | <table><tr><td>Class of agent</td><td>Chemical/brand name</td><td>Preventive targets</td></tr><tr><td rowspan="5">Selective estrogen receptor modulators and other hormonal agents</td><td>Tamoxifen</td><td>Breast</td></tr><tr><td>Arzoxifene</td><td>Breast</td></tr><tr><td>Acolbifene</td><td>Breast</td></tr><tr><td>Raxoxifene/Evista®</td><td>Breast</td></tr><tr><td>Finasteride</td><td>Prostate</td></tr><tr><td rowspan="3">Nonsteroidal anti- inflammatory drugs</td><td>Celecoxib/Celebrex®</td><td>Colon, breast, prostate, bladder</td></tr><tr><td>Sulindac/Clinoril®</td><td>Esophagus, skin</td></tr><tr><td>Aspirin</td><td> </td></tr><tr><td>Minerals and micronutrients</td><td>Calcium compounds</td><td>Colon</td></tr><tr><td>Glucocorticoids</td><td>Budesonide</td><td>Lung</td></tr><tr><td>Retinoids</td><td>All-trans-retinoic acid tretinoin/Retin-A®</td><td>Cervix, esophagus, larynx, lung,</td></tr><tr><td> </td><td>9-cis-Retinoic acid alitretinoin/Panretin®</td><td>Nasopharynx, oral cavity, ovary</td></tr><tr><td> </td><td>13-cis-Retinoic acid isotreninoin/Accutane®</td><td> </td></tr><tr><td> </td><td>4-Hydroxyretinamide, (4-HPR) fenretinide</td><td> </td></tr></table> |
7841111e13aab9d10430e30682d157e6ac8d67552668d241169fd4de2c87118e.png | simple | <table><tr><td></td><td>Authors</td><td>Publication year</td><td>Patient number</td><td>Gender</td><td>Age</td><td>Open (O) or laparoscopic ablation (L)</td><td>Symptom related to lymphangioma</td><td>Left/right adrenal gland</td></tr><tr><td>1</td><td>Akand et al. [6]</td><td>2013</td><td>1</td><td>F</td><td>44</td><td>O</td><td>Pain</td><td>L</td></tr><tr><td>2</td><td>Sourial et al. [7]</td><td>2013</td><td>1</td><td>F</td><td>52</td><td>L</td><td><i>Nihil</i></td><td>L</td></tr><tr><td>3</td><td>Makni et al. [12]</td><td>2012</td><td>2</td><td>F/M</td><td>40/40</td><td>O/L</td><td><i>Nihil</i>/pain</td><td>2 L</td></tr><tr><td>4</td><td>Ellis et al. [2]</td><td>2011</td><td>9</td><td>6 F/3 M</td><td>28 to 56<sup>a</sup></td><td>Not precised</td><td>5 <i>Nihil</i>/4 pain</td><td>6 R/3 L</td></tr><tr><td>5</td><td>Chien et al. [13]</td><td>2008</td><td>8</td><td>6 F/2 M</td><td>31 to 59<sup>a</sup></td><td>Not precised</td><td>4 <i>Nihil</i>/2 pain/1 fever/1 HTN<sup>b</sup></td><td>4 R/4 L</td></tr><tr><td>6</td><td>Bettaïeb et al. [8]</td><td>2007</td><td>1</td><td>F</td><td>22</td><td>Not precised</td><td>Pain</td><td>L</td></tr><tr><td>7</td><td>Ates et al. [9]</td><td>2005</td><td>1</td><td>F</td><td>26</td><td>O</td><td>Weakness</td><td>R</td></tr><tr><td>8</td><td>Garcia et al. [10]</td><td>2004</td><td>1</td><td>F</td><td>22</td><td>Not precised</td><td>Pain</td><td>R</td></tr><tr><td>9</td><td>Longo et al. [11]</td><td>2000</td><td>1</td><td>F</td><td>30</td><td>O</td><td>Pain</td><td>R</td></tr><tr><td>10</td><td>Trojan et al. [3]</td><td>2000</td><td>1</td><td>M</td><td>40</td><td>Not precised</td><td><i>Nihil</i></td><td>R</td></tr></table> |
a1a140866d9558537935844888375c740ff96389e0b5ea6e8f88f593e433e004.png | complex | <table><tr><td colspan="2">Primary screening</td><td rowspan="2">Triage test</td><td rowspan="2">Test positivity (%)<sup>1</sup></td><td colspan="2">Sensitivity (95%-CI)</td><td colspan="2">Specificity (95%-CI)</td><td colspan="2">PPV (95%-CI)</td><td colspan="2">NPV (95%-CI)</td></tr><tr><td>Test</td><td>Threshold</td><td>CIN2+</td><td>CIN3+</td><td>CIN2+</td><td>CIN3+</td><td>CIN2+</td><td>CIN3+</td><td>CIN2+</td><td>CIN3+</td></tr><tr><td>Cytology</td><td>ASCUS+</td><td>none</td><td>7.5</td><td>61* (44-77)</td><td>74<sup>#</sup> (52-90)</td><td>94 (93-96)</td><td>94 (92-95)</td><td>28 (18-39)</td><td>22 (13-32)</td><td>98.6 (97.6-99.2)</td><td>99.4 (98.7-99.8)</td></tr><tr><td></td><td></td><td>HR-HPV of ASCUS</td><td>5.1</td><td>56 (38-72)</td><td>70 (47-87)</td><td>97 (96-98)</td><td>96 (95-98)</td><td>38 (25-52)</td><td>30 (18-44)</td><td>98.4 (97.4-99.1)</td><td>99.3 (98.6-99.7)</td></tr><tr><td>GP5+/6+ PCR</td><td>HR-HPV</td><td>none</td><td>14.0</td><td>86* (70-95)</td><td>96<sup>#</sup> (78-99)</td><td>88 (86-90)</td><td>88 (86-90)</td><td>21 (15-29)</td><td>15 (10-22)</td><td>99.5 (98.7-99.8)</td><td>99.9 (99.4-100.0)</td></tr><tr><td></td><td></td><td>ASCUS+</td><td>3.2</td><td>47 (30-64)</td><td>70 (47-87)</td><td>98 (97-99)</td><td>98 (97-99)</td><td>50 (32-68)</td><td>47 (30-65)</td><td>98.1 (97.1-98.9)</td><td>99.3 (98.6-99.7)</td></tr></table> |
57bf2709bf2fc765d2ad6bad04a14948cc3b78b3baf24c8177b471d02a7f7120.png | simple | <table><tr><td></td><td>Mean</td><td>Median</td><td>Inter-quartile range</td><td>Direct cost as % of total cost of illness</td></tr><tr><td>Total CNCD sample (<i>n</i> = 475)</td><td>1040.82</td><td>40</td><td>(1000, 0)</td><td>56.8 %</td></tr><tr><td>Chronic pain conditions (<i>n</i> = 126)</td><td>926.92</td><td>200</td><td>(1268, 0)</td><td>51.6 %</td></tr><tr><td>Chronic respiratory conditions (<i>n</i> = 98)</td><td>623.60</td><td>0</td><td>(900, 0)</td><td>60.8 %</td></tr><tr><td>Chronic cardiovascular conditions (<i>n</i> = 95)</td><td>1723.99</td><td>200</td><td>(1600, 0)</td><td>54.0 %</td></tr><tr><td>Chronic sense organ conditions (<i>n</i> = 65)</td><td>465.35</td><td>0</td><td>(357, 0)</td><td>66.4 %</td></tr><tr><td>Chronic neuropsychiatric conditions (<i>n</i> = 47)</td><td>1465.64</td><td>50</td><td>(951, 0)</td><td>65.2 %</td></tr><tr><td>Chronic digestive conditions (<i>n</i> = 42)</td><td>929.05</td><td>70</td><td>(1268, 0)</td><td>53.3 %</td></tr></table> |
851da1954da5962a31c9b13d12c8ef62eac94c64ce426ca0912160f0395a788e.png | complex | <table><tr><td>GenBank accession no.</td><td>Gene name</td><td>Gene symbol</td><td>Fold change (HN2/control)a</td><td>Summary function</td></tr><tr><td colspan="5">Highest response to HN2</td></tr><tr><td> BG080773</td><td>AMP deaminase 3</td><td><i>Ampd3</i></td><td>4.10</td><td>Purine metabolism</td></tr><tr><td> BG066562</td><td>proteasome (prosome, macropain) 26S subunit, non-ATPase, 7</td><td><i>Psmd7</i></td><td>3.86</td><td>Protein degradation</td></tr><tr><td> C87546</td><td>serine/threonine kinase 11</td><td><i>Stk11</i></td><td>3.83</td><td>Cell cycle and polarity</td></tr><tr><td> BG086264</td><td>polymerase (RNA) II, DNA directed</td><td><i>Polr2</i></td><td>–3.27</td><td>RNA synthesis</td></tr><tr><td colspan="5">Neuronal function</td></tr><tr><td> AI850277</td><td>neuromedin</td><td><i>Nmu</i></td><td>2.03</td><td>Locomotor and stress response</td></tr><tr><td> A1848307</td><td>staufen homolog 2</td><td><i>Stauf2</i></td><td>–2.14</td><td>RNA transport</td></tr><tr><td> AI847890</td><td>proteolipid protein</td><td><i>Plp</i></td><td>–2.16</td><td>Myelination</td></tr><tr><td colspan="5">Development</td></tr><tr><td> BG088163</td><td>split hand/foot deleted gene 1</td><td><i>Shfdg1</i></td><td>3.08</td><td>DNA repair</td></tr><tr><td> AU021923</td><td>jagged 1</td><td><i>Jag1</i></td><td>2.61</td><td>Oligodendrocyte development</td></tr><tr><td> BG063365</td><td>chemokine (C-X-C motif) receptor 4</td><td><i>Cxcr4</i></td><td>2.39</td><td>Neural progenitors</td></tr><tr><td> AI847007</td><td>NCK-associated protein 1</td><td><i>Nckap1</i></td><td>–2.02</td><td>Cell motility</td></tr><tr><td> AI843136</td><td>N-myc downstream regulated 2</td><td><i>Ndr2</i></td><td>–2.23</td><td>Neural differentiation</td></tr><tr><td colspan="5">Apoptosis control</td></tr><tr><td> C85471</td><td>programmed cell death 8</td><td><i>Pdcd8</i></td><td>2.69</td><td>Apoptosis control</td></tr><tr><td> BG086831</td><td>programmed cell death 4</td><td><i>Pdcd4</i></td><td>2.13</td><td>Apoptosis control</td></tr><tr><td> AI853558</td><td>tumor necrosis factor receptor superfamily, member 12a</td><td><i>Tnfrsf12a</i></td><td>–2.11</td><td>Nuclear factor-kappaB activation</td></tr><tr><td colspan="5">Ubiquitin-proteasome pathway</td></tr><tr><td> BG085363</td><td>proteasome (prosome, macropain) 26S subunit, non-ATPase, 11</td><td><i>Psmd11</i></td><td>2.71</td><td>Proteasome (19S Lid)</td></tr><tr><td> AI843127</td><td>huntingtin interacting protein 2</td><td><i>Hip2</i></td><td>2.11</td><td>Ubiqutiin-conjugating enzyme</td></tr><tr><td> AU020960</td><td>proteaseome (prosome, macropain) 28 subunit, 3</td><td><i>Psme3</i></td><td>–2.41</td><td>Proteasome (20S alpha subunit)</td></tr><tr><td colspan="5">Growth and cell cycle control</td></tr><tr><td> C86021</td><td>growth differentiation factor 9</td><td><i>Gdf9</i></td><td>3.61</td><td>Cell growth</td></tr><tr><td> AI853288</td><td>ras homolog gene family, member U</td><td><i>Arhu</i></td><td>2.33</td><td>Signal transduction</td></tr><tr><td> BG072244</td><td>calmodulin 1</td><td><i>Calm1</i></td><td>2.13</td><td>Cell cycle</td></tr><tr><td> AI843756</td><td>calmodulin 2</td><td><i>Calm2</i></td><td>–2.16</td><td>Cell cycle</td></tr><tr><td colspan="5">Miscellaneous genes of interest</td></tr><tr><td> AI851097</td><td>H1 histone family, member 2</td><td><i>H1f2</i></td><td>–2.36</td><td>Chromatin compaction</td></tr><tr><td> AI849019</td><td>myelin-associated oligodendrocytic basic protein</td><td><i>Mobp</i></td><td>–2.71</td><td>Stuctural components of myelin</td></tr></table> |
2c948e8063cb063ae777640b964f694a489e833c04d95fc971a6875a731341ff.png | complex | <table><tr><td></td><td colspan="3">icddr,b service area</td><td colspan="3">Government service area</td></tr><tr><td>Cause of death</td><td>Male</td><td>Female</td><td>Total</td><td>Male</td><td>Female</td><td>Total</td></tr><tr><td>Communicable diseases (CDs)</td><td>20.5</td><td>16.8*</td><td>18.8</td><td>24.3</td><td>21.3*</td><td>22.9*</td></tr><tr><td> ARI/pneumonia</td><td>8.3</td><td>8.3</td><td>8.3</td><td>10.6</td><td>10.8</td><td>10.7*</td></tr><tr><td> Pulmonary tuberculosis</td><td>10.0</td><td>5.8*</td><td>8.1</td><td>11.0</td><td>6.8*</td><td>9.1$</td></tr><tr><td> Other CDs</td><td>2.3</td><td>2.7</td><td>2.5</td><td>2.7</td><td>3.6$</td><td>3.1$</td></tr><tr><td>Non-communicable diseases (NCDs)</td><td>55.9</td><td>60.9*</td><td>58.2</td><td>49.6</td><td>52.1$</td><td>50.7*</td></tr><tr><td> Stroke</td><td>15.9</td><td>24.6*</td><td>19.9</td><td>13.9</td><td>17.6*</td><td>15.6*</td></tr><tr><td> Cardiac disease</td><td>9.8</td><td>6.2*</td><td>8.1</td><td>7.6</td><td>4.4*</td><td>6.1*</td></tr><tr><td> COPD and asthma</td><td>6.1</td><td>6.1</td><td>6.1</td><td>5.3</td><td>5.0</td><td>5.1*</td></tr><tr><td>Malignant neoplasm</td><td>16.2</td><td>11.8*</td><td>14.2</td><td>15.9</td><td>14.6</td><td>15.3</td></tr><tr><td> Digestive system</td><td>6.1</td><td>4.7*</td><td>5.5</td><td>6.3</td><td>5.7</td><td>6.0</td></tr><tr><td> Respiratory system</td><td>5.8</td><td>2.2*</td><td>4.1</td><td>6.1</td><td>4.2*</td><td>5.2*</td></tr><tr><td> Other neoplasm</td><td>4.3</td><td>4.9</td><td>4.6</td><td>3.5</td><td>4.7$</td><td>4.1</td></tr><tr><td> Acute abdomen</td><td>2.8</td><td>4.0*</td><td>3.4</td><td>2.7</td><td>3.3</td><td>3.0</td></tr><tr><td> Liver cirrhosis</td><td>0.5</td><td>0.4</td><td>0.5</td><td>0.6</td><td>0.8</td><td>0.7</td></tr><tr><td> Diabetes mellitus</td><td>1.6</td><td>2.6*</td><td>2.0</td><td>1.2</td><td>2.0$</td><td>1.5$</td></tr><tr><td> Anaemia/malnutrition</td><td>1.1</td><td>2.4*</td><td>1.7</td><td>1.2</td><td>2.4*</td><td>1.8</td></tr><tr><td> Other NCD</td><td>1.2</td><td>1.7</td><td>1.4</td><td>0.7</td><td>0.9</td><td>0.8*</td></tr><tr><td>Perinatal and neonatal causes</td><td>6.8</td><td>5.0*</td><td>6.0</td><td>7.5</td><td>7.3</td><td>7.4*</td></tr><tr><td> ARI, pneumonia, sepsis</td><td>3.2</td><td>2.1*</td><td>2.7</td><td>3.7</td><td>2.8$</td><td>3.3$</td></tr><tr><td> Birth asphyxia</td><td>0.9</td><td>0.7</td><td>0.8</td><td>1.4</td><td>1.4</td><td>1.4*</td></tr><tr><td> Prematurity</td><td>1.9</td><td>1.6</td><td>1.8</td><td>1.3</td><td>2.1</td><td>1.7</td></tr><tr><td> Other neonatal cause</td><td>0.9</td><td>0.6</td><td>0.8</td><td>1.1</td><td>0.9</td><td>1.0</td></tr><tr><td>Cause related to pregnancy</td><td>NA</td><td>0.7</td><td>0.3</td><td>Na</td><td>1.0</td><td>0.5</td></tr><tr><td>Injury and other external cause</td><td>5.4</td><td>5.5</td><td>5.4</td><td>6.1</td><td>5.4</td><td>5.8</td></tr><tr><td> Accidental drowning</td><td>2.8</td><td>2.7</td><td>2.8</td><td>2.8</td><td>2.3</td><td>2.6</td></tr><tr><td> Road traffic accident</td><td>0.7</td><td>0.3*</td><td>0.5</td><td>0.9</td><td>0.2*</td><td>0.6</td></tr><tr><td> International self-harm</td><td>0.4</td><td>1.2*</td><td>0.7</td><td>0.5</td><td>1.5*</td><td>1.0</td></tr><tr><td> Assault</td><td>0.3</td><td>0.5</td><td>0.4</td><td>0.4</td><td>0.5</td><td>0.5</td></tr><tr><td> Other cause</td><td>1.1</td><td>0.8</td><td>1.0</td><td>1.4</td><td>1.0</td><td>1.2</td></tr><tr><td>Indeterminate</td><td>11.4</td><td>11.0</td><td>11.2</td><td>12.4</td><td>12.8</td><td>12.6$</td></tr><tr><td> # VA with disease symptoma</td><td>3217</td><td>2729</td><td>5,946</td><td>3,348</td><td>2,819</td><td>6,167</td></tr></table> |
fbc17b082264adc8e4340d63c3389dc170df5351ac4746bea3495cf07d771cbf.png | complex | <table><tr><td rowspan="2">Element</td><td>Certified value</td><td>Amino acids</td><td>Glucose</td><td>Lipids</td></tr><tr><td colspan="4">[<i>μ</i>g/kg]</td></tr><tr><td>As</td><td>26.67 ± 0.41</td><td>26.2 ± 1.3</td><td>27.2 ± 1.2</td><td>26.9 ± 1.2</td></tr><tr><td>Cd</td><td>22.79 ± 0.96</td><td>22.8 ± 1.2</td><td>23.1 ± 1.1</td><td>22.9 ± 0.8</td></tr><tr><td>Pb</td><td>27.89 ± 0.14</td><td>27.0 ± 1.4</td><td>27.7 ± 1.3</td><td>27.8 ± 1.2</td></tr><tr><td>Hg*</td><td>1.590 ± 0.018</td><td>1.57 ± 0.07</td><td>1.56 ± 0.06</td><td>1.61 ± 0.08</td></tr><tr><td>Cr</td><td>38.6 ± 1.6</td><td>37.5 ± 1.9</td><td>38.2 ± 1.6</td><td>37.9 ± 1.3</td></tr><tr><td>Cu</td><td>85.2 ± 1.2</td><td>87.5 ± 3.9</td><td>86.2 ± 4.2</td><td>84.3 ± 4.1</td></tr><tr><td>Mn</td><td>121.5 ± 1.1</td><td>120 ± 5.1</td><td>120 ± 6.0</td><td>123 ± 5.8</td></tr><tr><td>Mo</td><td>46.75 ± 0.26</td><td>46.8 ± 2.2</td><td>46.0 ± 2.2</td><td>47.4 ± 2.3</td></tr><tr><td>Ni</td><td>27.40 ± 0.80</td><td>27.0 ± 1.3</td><td>26.7 ± 1.3</td><td>27.3 ± 1.1</td></tr><tr><td>V</td><td>12.99 ± 0.37</td><td>12.9 ± 0.6</td><td>13.2 ± 0.6</td><td>12.9 ± 0.5</td></tr></table> |
115467db76b3ba5828b9cdda8ce0475ff8b598a89b71bef6ebd3808e244caea8.png | simple | <table><tr><td>Type</td><td>Number of reads</td><td>Percentage (%)</td></tr><tr><td>Total unique reads</td><td>9,664,154</td><td>100</td></tr><tr><td>Reads mapping to the transcripts</td><td>9,193,054</td><td>95.13</td></tr><tr><td>Reads mapping to target site</td><td>6,916</td><td>0.072</td></tr><tr><td>Total Number of input cDNAs</td><td>77,024</td><td>100</td></tr><tr><td>Number of covered cDNAs</td><td>43,648</td><td>56.65</td></tr></table> |
de42513fc337cf05e8416296323e1efdff89f898357d4e9690fc6e3acbc7a481.png | complex | <table><tr><td> </td><td>Trial</td><td><i>N</i>, inclusion criteria</td><td>Dose (dose per fraction)</td><td>Outcome</td></tr><tr><td rowspan="2">Early hypofractionation trials</td><td>Lukka et al. [44]</td><td>936GS 6–10</td><td>52.5 Gy (2.625 Gy)66 Gy (2 Gy)</td><td>40% versus 43% 5-year freedom from biochemical failure</td></tr><tr><td>Yeoh et al. [45]</td><td>217</td><td>55 Gy (2.75 Gy)64 Gy (2 Gy)</td><td>53% versus 34% 7-year freedom from biochemical failure</td></tr><tr><td rowspan="3">Modern superiority trials</td><td>Hoffman et al. [47]</td><td>20499% low-intermediate risk</td><td>72 Gy (2.4 Gy)75.6 Gy (1.8 Gy)</td><td>96% versus 92% 5-year freedom from biochemical failure</td></tr><tr><td>Pollack et al. [49]</td><td>303GS 6+</td><td>70.2 Gy (2.7 Gy)78 Gy (2.17 Gy)</td><td>23% versus 21% 5-year biochemical or clinical disease failure</td></tr><tr><td>Arcangeli et al. [48]</td><td>168GS 7+</td><td>62 Gy (3.1 Gy)80 Gy (2 Gy)</td><td>85% versus 79% 5-year freedom from biochemical failure</td></tr><tr><td rowspan="4">Modern noninferiority trials</td><td>Dearnaley et al. [46]</td><td>457</td><td>57 Gy (3 Gy)60 Gy (3 Gy)74 Gy (2 Gy)</td><td>Similar GU and GI toxicity ≥ grade 2 (<5%)</td></tr><tr><td>Incrocci [52]</td><td>820Intermediate-high risk</td><td>64.6 Gy (3.4 Gy)78 Gy (2 Gy)</td><td>Worse GI toxicity ≥ grade 2, similar GU toxicity</td></tr><tr><td>RTOG 0415 [51]</td><td>1101Low risk</td><td>70 Gy (2.5 Gy)73.8 Gy (1.8 Gy)</td><td>Noninferior biochemical recurrence and overall survival, similar toxicity</td></tr><tr><td>PROFIT [53]</td><td>Intermediate risk</td><td>60 Gy (3 Gy)78 Gy (2 Gy)</td><td>Pending</td></tr></table> |
8ad82cffa8204bea32b9eec31bb9d54708a6b4433107e5eabd8519e3d1349981.png | complex | <table><tr><td>Implicit review process measure</td><td colspan="2">Acceptable care*</td><td colspan="2">Extremely appropriate care**</td></tr><tr><td></td><td><i>Reviewer 1</i></td><td><i>Reviewer 2</i></td><td><i>Reviewer 1</i></td><td><i>Reviewer 2</i></td></tr><tr><td>Initial data gathering by physician about acute problems</td><td>163 (91.6)</td><td>151 (84.8)</td><td>12 (6.7)</td><td>25 (14.0)</td></tr><tr><td>Physician integration of information and development of appropriate diagnoses</td><td>147 (82.6)</td><td>159 (89.3)</td><td>10 (5.6)</td><td>41 (23.0)</td></tr><tr><td>Physician initial treatment plan and orders</td><td>117 (65.7)</td><td>126 (70.8)</td><td>10 (5.6)</td><td>26 (14.6)</td></tr><tr><td>Physician plan for disposition and follow-up</td><td>146 (82.0)</td><td>167 (93.8)</td><td>10 (5.6)</td><td>64 (36.0)</td></tr><tr><td>Overall quality of care</td><td>136 (76.4)</td><td>141 (79.2)</td><td>10 (5.6)</td><td>22 (12.4)</td></tr></table> |
ab6b475265f04e1687b49be4f50dac3deacc3fc8d7ad8dc7ae9a8c2275b6087b.png | complex | <table><tr><td>Score for sorting</td><td colspan="4">KSEARCH</td><td colspan="2">SANS</td><td>BLAST</td></tr><tr><td></td><td><i>k</i> = 5</td><td><i>k</i> = 6</td><td><i>k</i> = 7</td><td><i>k</i> = 8</td><td><i>w</i> = 1000</td><td><i>w</i> = 2000</td><td></td></tr><tr><td>Native</td><td>0.51</td><td>0.55</td><td>0.49</td><td>0.44</td><td>0.56</td><td>0.54</td><td></td></tr><tr><td>Alignment</td><td>0.52</td><td>0.56</td><td>0.49</td><td>0.44</td><td>0.60</td><td>0.62</td><td>0.95</td></tr></table> |
d71aecdf807598c81ef1199517251a87ef72d751b4ec2f34cce1641e7457ee6a.png | complex | <table><tr><td></td><td></td><td colspan="3">Mean accuracy</td><td colspan="4">Mean reaction time (ms)</td></tr><tr><td>Task</td><td>Group</td><td>RT</td><td>ST</td><td>NT</td><td>RT</td><td>ST</td><td>NT</td><td>RG</td></tr><tr><td>CS</td><td>High</td><td>1.00</td><td>0.97</td><td>0.88</td><td>346.72</td><td>390.01</td><td>454.67</td><td>43.29</td></tr><tr><td></td><td>Low</td><td>1.00</td><td>0.98</td><td>0.89</td><td>369.78</td><td>418.83</td><td>491.96</td><td>49.05</td></tr><tr><td>DD</td><td>High</td><td>0.99</td><td>0.98</td><td>0.93</td><td>400.13</td><td>420.46</td><td>574.43</td><td>20.33</td></tr><tr><td></td><td>Low</td><td>0.99</td><td>0.98</td><td>0.93</td><td>417.35</td><td>440.78</td><td>595.11</td><td>23.43</td></tr><tr><td>VA</td><td>High</td><td>1.00</td><td>0.97</td><td>0.93</td><td>323.27</td><td>382.87</td><td>539.70</td><td>59.60</td></tr><tr><td></td><td>Low</td><td>1.00</td><td>0.97</td><td>0.91</td><td>329.31</td><td>391.29</td><td>556.98</td><td>61.99</td></tr></table> |
8275d9ec26fb86648d6b4ce076c5652d895791fd69f141b3d2f23515433f8cb8.png | simple | <table><tr><td>Category #</td><td>Job title</td><td># of participantsinterviewed</td></tr><tr><td>1</td><td>Laboratory Manager</td><td>3</td></tr><tr><td>2</td><td>Transfusion Safety Officer</td><td>2</td></tr><tr><td>3</td><td>Lab Technologist (Blood Bank)</td><td>9</td></tr><tr><td>4</td><td>Physicians - Blood Bank</td><td>4</td></tr><tr><td>5</td><td>Physicians - who use blood products</td><td>7</td></tr><tr><td>6</td><td>Hospital Administration</td><td>4</td></tr><tr><td>7</td><td>Hospital PR</td><td>1</td></tr><tr><td>8</td><td>Hospital Risk Management</td><td>2</td></tr><tr><td>9</td><td>Blood Suppliers (CBS, Hema-Quebec)</td><td>9</td></tr><tr><td>11</td><td>MoH (Provincial)</td><td>2</td></tr><tr><td>13</td><td>Recipients of blood products</td><td>2</td></tr><tr><td>11</td><td>Total</td><td>45</td></tr></table> |
a1ff08ecd3b1e3aef6504348b44719be914693afbdad6d6e6f55fed70533105d.png | complex | <table><tr><td> </td><td>N</td><td><i>Whole sample</i></td><td><i>Boys</i></td><td><i>Girls</i></td><td>F</td><td>R<sup>2</sup></td></tr><tr><td colspan="7"><i>Age 11</i></td></tr><tr><td colspan="7"> Self-report</td></tr><tr><td>Behavior problems</td><td>5057</td><td>8.79 (5.30)</td><td>9.37 (5.36)</td><td>8.28 (5.20)</td><td>53.62**a</td><td>0.01</td></tr><tr><td>Moods and feelings</td><td>5077</td><td>3.29 (3.85)</td><td>3.43 (3.73)</td><td>3.16 (3.95)</td><td>6.11*</td><td><0.01</td></tr><tr><td>Victimisation</td><td>5623</td><td>7.80 (7.39)</td><td>8.68 (7.83)</td><td>7.01 (6.87)</td><td>69.66** a</td><td>0.01</td></tr><tr><td>Pubertal development</td><td>5066</td><td>1.72 (0.58)</td><td>1.54 (0.47)</td><td>1.88 (0.62)</td><td>536.44**a</td><td>0.09</td></tr><tr><td colspan="7"> Parent report</td></tr><tr><td>Behavior problems</td><td>5056</td><td>6.82 (4.92)</td><td>7.51 (5.06)</td><td>6.22 (4.67)</td><td>86.52**a</td><td>0.02</td></tr><tr><td>Moods and feelings</td><td>5065</td><td>1.73 (2.75)</td><td>1.83 (2.67)</td><td>1.65 (2.82)</td><td>5.54*</td><td><0.01</td></tr><tr><td>Antisocial personality</td><td>5078</td><td>7.12 (4.32)</td><td>7.93 (4.51)</td><td>6.43 (4.02)</td><td>154.04**a</td><td>0.03</td></tr><tr><td>Autism</td><td>5245</td><td>4.69 (3.15)</td><td>5.22 (3.31)</td><td>4.23 (2.95)</td><td>129.61**a</td><td>0.02</td></tr><tr><td>ADHD</td><td>5070</td><td>13.27 (7.80)</td><td>11.13 (8.73)</td><td>7.87 (7.19)</td><td>206.84**a</td><td>0.04</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="7"><i>Age 14</i></td></tr><tr><td colspan="7"> Self-report</td></tr><tr><td>Victimisation</td><td>3173</td><td>7.64 (7.21)</td><td>8.51 (7.78)</td><td>6.93 (6.63)</td><td>41.93**a</td><td>0.01</td></tr><tr><td>ADHD</td><td>3054</td><td>13.28 (7.80)</td><td>14.00 (8.33)</td><td>12.68 (7.67)</td><td>21.15**</td><td><0.01</td></tr><tr><td>Pubertal development</td><td>2905</td><td>2.75 (0.61)</td><td>2.46 (0.57)</td><td>3.00 (0.53)</td><td>815.16**a</td><td>0.22</td></tr><tr><td colspan="7"> Parent report</td></tr><tr><td>Victimisation</td><td>2845</td><td>6.50 (7.65)</td><td>6.81 (7.99)</td><td>6.25 (7.34)</td><td>4.49*a</td><td><0.01</td></tr><tr><td>Autism</td><td>3039</td><td>36.94 (21.18)</td><td>38.31 (12.74)</td><td>35.75 (11.55)</td><td>33.84**a</td><td>0.01</td></tr><tr><td>Antisocial personality</td><td>3065</td><td>7.78 (5.05)</td><td>8.67 (5.22)</td><td>76.01 (4.78)</td><td>84.53**a</td><td>0.03</td></tr><tr><td>ADHD</td><td>3087</td><td>8.28 (7.96)</td><td>9.95 (8.77)</td><td>6.83 (6.85)</td><td>121.10**a</td><td>0.04</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="7"><i>Age 16</i></td></tr><tr><td colspan="7"> Self-report</td></tr><tr><td>Behavior problems</td><td>4815</td><td>9.49 (5.12)</td><td>8.89 (4.93)</td><td>9.96 (5.22)</td><td>53.36**a</td><td>0.01</td></tr><tr><td>Anxiety</td><td>4820</td><td>7.97 (5.87)</td><td>6.10 (4.75)</td><td>9.49 (6.22)</td><td>481.33**a</td><td>0.09</td></tr><tr><td>Moods and feelings</td><td>4821</td><td>3.60 (4.42)</td><td>2.64 (3.49)</td><td>4.38 (4.91)</td><td>202.78**a</td><td>0.04</td></tr><tr><td>ADHD</td><td>1073</td><td>4.74 (0.86)</td><td>4.72 (0.85)</td><td>4.76 (0.87)</td><td>0.60</td><td><0.01</td></tr><tr><td>Callous unemotional traits</td><td>1070</td><td>19.61 (7.58)</td><td>22.30 (7.88)</td><td>17.96 6.91)</td><td>80.93**a</td><td>0.07</td></tr><tr><td>Autism</td><td>4818</td><td>11.88 (5.77)</td><td>12.19 (5.70)</td><td>11.63 (5.81)</td><td>11.20**</td><td><0.01</td></tr><tr><td>Paranoid checklist</td><td>4813</td><td>12.17 (10.63)</td><td>11.76 (10.42)</td><td>12.50 (10.78)</td><td>5.73*</td><td><0.01</td></tr><tr><td>Anomalous perceptions</td><td>4821</td><td>4.66 (6.01)</td><td>4.28 (5.73)</td><td>4.97 (6.21)</td><td>16.07**a</td><td><0.01</td></tr><tr><td>Grandiosity and delusion</td><td>4817</td><td>5.32 (4.43)</td><td>5.84 (4.59)</td><td>4.91 (4.25)</td><td>53.26**a</td><td>0.01</td></tr><tr><td>Cognitive disorganization</td><td>4815</td><td>3.96 (2.85)</td><td>3.40 (2.72)</td><td>4.41 (2.87)</td><td>155.21**a</td><td>0.03</td></tr><tr><td>Hedonia</td><td>4817</td><td>33.68 (7.93)</td><td>31.52 (7.98)</td><td>35.42 (7.44)</td><td>299.96**a</td><td>0.06</td></tr><tr><td>Introvertive anhedonia</td><td>4814</td><td>1.30 (1.32)</td><td>1.47 (1.31)</td><td>1.16 (1.31)</td><td>61.13**a</td><td>0.01</td></tr><tr><td>Eating problems</td><td>1067</td><td>3.18 (1.96)</td><td>2.14 (1.40)</td><td>3.84 (1.97)</td><td>272.03**a</td><td>0.18</td></tr><tr><td>Peer victimisation</td><td>2502</td><td>3.50 (3.22)</td><td>4.09 (2.23)</td><td>3.06 (3.14)</td><td>63.92**</td><td>0.03</td></tr><tr><td>Sleep</td><td>3747</td><td>7.87 (4.72)</td><td>7.25 (4.33)</td><td>8.41 (4.97)</td><td>57.63**a</td><td>0.02</td></tr><tr><td>Substance use</td><td>3747</td><td>2.58 (2.73)</td><td>2.62 (2.82)</td><td>2.55 (2.66)</td><td>0.96</td><td><0.01</td></tr><tr><td>Delinquency</td><td>1074</td><td>5.34 (7.24)</td><td>6.50 (7.87)</td><td>4.61 (6.72)</td><td>16.50**a</td><td>0.02</td></tr><tr><td>Pubertal development</td><td>2234</td><td>3.36 (0.42)</td><td>3.2 (0.41)</td><td>3.49 (0.37)</td><td>385.73**</td><td>0.15</td></tr><tr><td colspan="7"> Parent report</td></tr><tr><td>Behavior problems</td><td>4836</td><td>3.80 (3.18)</td><td>4.28 (3.36)</td><td>3.41 (2.98)</td><td>86.01**a</td><td>0.02</td></tr><tr><td>Anxiety</td><td>4837</td><td>3.56 (4.20)</td><td>2.71 (3.57)</td><td>4.24 (4.53)</td><td>176.97**a</td><td>0.03</td></tr><tr><td>Moods and feelings</td><td>4834</td><td>0.97 (2.27)</td><td>0.74 (1.83)</td><td>1.16 (2.56)</td><td>43.33**a</td><td><0.01</td></tr><tr><td>ADHD</td><td>4832</td><td>6.73 (7.45)</td><td>8.05 (8.25)</td><td>5.66 (6.55)</td><td>116.51**a</td><td>0.03</td></tr><tr><td>Negative symptoms</td><td>4832</td><td>2.81 (3.87)</td><td>3.17 (4.08)</td><td>2.51 (3.67)</td><td>33.45**a</td><td><0.01</td></tr><tr><td>Callous unemotional traits</td><td>4835</td><td>17.55 (9.16)</td><td>19.74 (9.39)</td><td>15.77 (8.57)</td><td>229.85**a</td><td>0.05</td></tr><tr><td>Autism</td><td>4835</td><td>24.05 (10.63)</td><td>25.97 (10.98)</td><td>22.49 (10.07)</td><td>126.94***a</td><td>0.03</td></tr><tr><td colspan="7"> Self-report</td></tr><tr><td>Age of menarche</td><td>1864</td><td>12.75 (1.22)</td><td> </td><td> </td><td> </td><td> </td></tr></table> |
327649e73db0fc33ee42dd4cd197227b696fe18e920cf8c3faa36fb5ff4eb2d1.png | simple | <table><tr><td></td><td>Preoperatively</td><td>1-Week</td><td>1-Month</td></tr><tr><td>cSystolic</td><td>145</td><td>113</td><td>120</td></tr><tr><td>cDiastolic</td><td>99</td><td>68</td><td>78</td></tr><tr><td>cPP</td><td>46</td><td>45</td><td>42</td></tr><tr><td>PWV</td><td>11.6</td><td>10.6</td><td>10.9</td></tr><tr><td>AI@75</td><td>28</td><td>14</td><td>7</td></tr><tr><td>RM</td><td>68</td><td>76</td><td>52</td></tr><tr><td>AP</td><td>15</td><td>6</td><td>4</td></tr><tr><td>CI</td><td>2.9</td><td>3.1</td><td>4.3</td></tr><tr><td>PR</td><td>1.41</td><td>0.99</td><td>0.85</td></tr></table> |
d1c62979547577da449abce6bc47d0a691a54f35fa801030450a2aae0c2f9008.png | simple | <table><tr><td>Description</td><td>Selected study</td></tr><tr><td>Critical endpoint</td><td>Acute irritation of the eyes and upper airways</td></tr><tr><td></td><td>A few (4 out of 27) individuals reacted with additional cough and slight airway obstruction</td></tr><tr><td>Source</td><td>The Health Council of the Netherlands (2007) (Wieslander <i>et al.</i>, 2001)</td></tr><tr><td>Species</td><td>Healthy human subjects (27)</td></tr><tr><td>Exposure regimen</td><td>Propylene glycol in aviation emergency training. Exposure to artificial mist generator in short-term inhalation exposure (~1 min)</td></tr><tr><td>Concentrations tested (mg/m<sup>3</sup>)</td><td>0, 176-851</td></tr><tr><td>Duration of exposure</td><td>Average rating on 10 questions before and after 1 min propylene glycol exposure every 30 min for 4 hours</td></tr><tr><td>NOAEL (mg/m<sup>3</sup>)</td><td>-</td></tr><tr><td>If no NOAEL, then value for LOAEL</td><td>Min = 176</td></tr><tr><td></td><td>Max = 851</td></tr><tr><td></td><td>Mean = 309</td></tr><tr><td><i>C</i><sub><i>alv;max</i></sub> (mg/m<sup>3</sup>)</td><td>430-603</td></tr><tr><td>Source of <i>C</i><sub><i>alv;max</i></sub> (mg/m<sup>3</sup>)</td><td>1 puff (50 mL [5], 70 mL [6])</td></tr><tr><td>MOE<sub>1-puff shisha-pen/100% transfer rate</sub></td><td><i>Min range = 0.3-0.4 (~2.5-3x higher than in human study)</i></td></tr><tr><td></td><td><i>Max range = 1.4-2</i></td></tr><tr><td></td><td><i>Mean range = 0.5-0.7 (~1.4-2x higher than in human study)</i></td></tr></table> |
728c175a562a6f5b946b08f28540fb6b6a34e457ee2721d7609e11202f090aa4.png | complex | <table><tr><td colspan="2">Variables</td><td><i>n</i> (%)</td></tr><tr><td rowspan="4">Marital status</td><td>single</td><td>47 (13.6)</td></tr><tr><td>married</td><td>259 (75.1)</td></tr><tr><td>divorced</td><td>37 (10.7)</td></tr><tr><td>widow</td><td>2 (0.6)</td></tr><tr><td rowspan="4">Education</td><td>primary</td><td>1 (0.3)</td></tr><tr><td>vocational</td><td>7 (2.0)</td></tr><tr><td>secondary</td><td>78 (22.6)</td></tr><tr><td>higher</td><td>259 (75.1)</td></tr><tr><td rowspan="4">Place of residence</td><td>village</td><td>41 (11.9)</td></tr><tr><td>town of up to 10,000 residents</td><td>10 (2.9)</td></tr><tr><td>town of up to 100,000 residents</td><td>44 (12.7)</td></tr><tr><td>city with more than 100,000 residents</td><td>250 (72.5)</td></tr><tr><td rowspan="2">Employment status</td><td>employed</td><td>331 (96.5)</td></tr><tr><td>unemployed</td><td>12 (3.5)</td></tr><tr><td rowspan="3">Number of pregnancies</td><td>0</td><td>42 (12.2)</td></tr><tr><td>1</td><td>92 (26.8)</td></tr><tr><td>>1</td><td>210 (61.0)</td></tr></table> |
6dc6bf92a2e86fe4eb05cc05e077485440b0e5f26ce284e6b3124d76eb36ec71.png | simple | <table><tr><td>Outcomes</td><td>Standard Therapy (n = 32)</td><td>Acupuncture (n = 34)</td><td>p*</td></tr><tr><td><i>Primary outcomes </i></td><td></td><td></td><td></td></tr><tr><td><i>VAS</i></td><td></td><td></td><td></td></tr><tr><td>Mean VAS score at baseline (SD)</td><td>8.02 (1.69)</td><td>7.81 (1.48)</td><td>0.6</td></tr><tr><td>Mean VAS score after therapy (SD)</td><td>3.89 (2.38)</td><td>2.96 (1.84)</td><td>0.08</td></tr><tr><td>Mean change in VAS score (SD)</td><td>4.12 (2.29)</td><td>4.85 (1.87)</td><td>0.12</td></tr><tr><td>Response rate (>=2 VAS units decrease), %</td><td>81.6</td><td>89.2</td><td>0.8</td></tr><tr><td><i>Secondary outcomes</i></td><td></td><td></td><td></td></tr><tr><td><i>McGill score</i></td><td></td><td></td><td></td></tr><tr><td>Mean McGill score at baseline (SD)</td><td>2.32 (1.05)</td><td>2.38 (1.12)</td><td>0.8</td></tr><tr><td>Mean McGill score after therapy (SD)</td><td>0.99 (0.69)</td><td>0.99 (0.73)</td><td>0.9</td></tr><tr><td>Mean change in McGill score (SD)</td><td>1.32 (0.85)</td><td>1.33 (0.88)</td><td>0.9</td></tr><tr><td>Post-herpetic neuralgia at 3 months, %</td><td>48.4</td><td>46.8</td><td>0.9</td></tr><tr><td>Post-herpetic neuralgia at 6 months, %</td><td>33.3</td><td>29.0</td><td>0.7</td></tr><tr><td>Post-herpetic neuralgia at 12 months, %</td><td>10.3</td><td>3.6</td><td>0.3</td></tr><tr><td>Mean AUC during follow-up (SD)</td><td>199(136)</td><td>173(141)</td><td>0.5</td></tr></table> |
7f75bd917ce831bfdd93cad6479381eefc7d7f0fa5b96543800ad6c100299f87.png | complex | <table><tr><td>Predictor</td><td>Odds Ratio</td><td colspan="2">95% Confidence Interval</td></tr><tr><td>Age</td><td>0.97</td><td>0.95</td><td>1.00*</td></tr><tr><td>Education</td><td>0.93</td><td>0.87</td><td>1.01</td></tr><tr><td>Services</td><td>0.98</td><td>0.84</td><td>1.14</td></tr><tr><td>Partner support</td><td>0.88</td><td>0.80</td><td>0.97**</td></tr><tr><td>Mother support</td><td>0.95</td><td>0.89</td><td>1.01</td></tr><tr><td>Father support</td><td>0.95</td><td>0.88</td><td>1.02</td></tr><tr><td>Weeks pregnant</td><td>1.01</td><td>0.99</td><td>1.02</td></tr><tr><td>Single vs. married/living together</td><td>0.93</td><td>0.68</td><td>1.28</td></tr><tr><td>Informal housing vs. formal</td><td>1.04</td><td>0.72</td><td>1.49</td></tr><tr><td>Unemployed vs. employed</td><td>1.09</td><td>0.76</td><td>1.56</td></tr><tr><td>HH income < R2000 p/m</td><td>1.52</td><td>1.15</td><td>2.01**</td></tr><tr><td>No income baby father</td><td>1.20</td><td>0.78</td><td>1.83</td></tr><tr><td>Tobacco use</td><td>1.33</td><td>0.67</td><td>2.65</td></tr><tr><td>Alcohol use</td><td>1.22</td><td>0.89</td><td>1.66</td></tr><tr><td>Relationship violence</td><td>1.49</td><td>1.13</td><td>1.96**</td></tr></table> |
121f8c0d991b1bef1f41cf1f06fc46ef871efdfe6e9b8a47b31386cae707683a.png | simple | <table><tr><td>Surgical procedure</td><td>Vault prolapse</td><td>POP-Q III</td><td>POP-Q IV</td></tr><tr><td> Sacrospinous fixation </td><td> 4 </td><td> 5 </td><td> 23 </td></tr><tr><td> Anterior colporrhaphy </td><td> 2 </td><td> 5 </td><td> 23 </td></tr><tr><td> Enterocele repair </td><td> 3 </td><td> 1 </td><td> 20 </td></tr><tr><td> Bladder neck suspension </td><td> 1 </td><td> - </td><td> 4 </td></tr></table> |
b9696579b6e66dde557cdbadbfb67f4781decced124419e6015095ceb47a6e89.png | simple | <table><tr><td>Class</td><td>TP rate</td><td>FP rate</td><td>Precision</td><td>Recall</td><td><i>f</i>-measure</td><td>ROC area</td><td>Accuracy</td></tr><tr><td>Migraine</td><td>1</td><td>1</td><td>0.716</td><td>1</td><td>0.835</td><td>0.5</td><td>100.00%</td></tr><tr><td>Cluster</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.5</td><td>0.00%</td></tr><tr><td>Tension</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.5</td><td>0.00%</td></tr><tr><td>No headache</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0.5</td><td>0.00%</td></tr><tr><td>Weighted avg</td><td>0.716</td><td>0.716</td><td>0.513</td><td>0.716</td><td>0.598</td><td>0.5</td><td>71.60%</td></tr></table> |
81ac90db584ee86f4672404fa64cab5496da24335afbe75fbc5de4964290256c.png | simple | <table><tr><td> </td><td>Number of respondents</td><td>Percentage (95% CI)</td></tr><tr><td>Equipment cost</td><td>177</td><td>89.4% (85.7-93.1)</td></tr><tr><td>Training costs</td><td>146</td><td>73.7% (68.4-79)</td></tr><tr><td>Challenges in training</td><td>106</td><td>53.5% (47.5-59.5)</td></tr><tr><td>Transport times</td><td>95</td><td>48% (42-54)</td></tr><tr><td>Concerns about delaying time to definitive care</td><td>90</td><td>45.5% (39.5-51.5)</td></tr><tr><td>Ultrasound is beyond the scope of practice of providers</td><td>76</td><td>38.4% (32.6-44.2)</td></tr><tr><td>Lack of evidence</td><td>76</td><td>38.4% (32.6-44.2)</td></tr><tr><td>Approval by EMS administration</td><td>25</td><td>12.6% (8.6-16.6)</td></tr><tr><td>Buy-in by other EMS medical directors</td><td>21</td><td>10.6% (6.9-14.3)</td></tr><tr><td>Regulatory factors</td><td>29</td><td>14.6% (10.4-18.8)</td></tr></table> |
8f192f843addfe83bffae0a5ecc3ea3652029443983c029a16975aa3ced4beb8.png | simple | <table><tr><td>Variable</td><td>PPR</td><td>SE</td><td><i>p</i>-Value</td><td>(95% CI)</td></tr><tr><td>L<sub>Night</sub></td><td>0.969</td><td>0.031</td><td>0.32</td><td>(0.91, 1.031)</td></tr><tr><td>Sensitivity</td><td></td><td></td><td></td><td></td></tr><tr><td>Not sensitive</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Sensitive</td><td>0.009</td><td>0.020</td><td>0.03</td><td>(0, 0.691)</td></tr><tr><td>Lnight × Sensitive interaction</td><td>1.105</td><td>0.043</td><td>0.01</td><td>(1.024, 1.192)</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td></tr><tr><td>18–29</td><td>1</td><td></td><td></td><td></td></tr><tr><td>30–39</td><td>1.554</td><td>0.611</td><td>0.26</td><td>(0.719, 3.359)</td></tr><tr><td>40–49</td><td>1.484</td><td>0.556</td><td>0.29</td><td>(0.712, 3.094)</td></tr><tr><td>50–59</td><td>1.825</td><td>0.674</td><td>0.10</td><td>(0.885, 3.763)</td></tr><tr><td>60–69</td><td>1.687</td><td>0.660</td><td>0.18</td><td>(0.783, 3.634)</td></tr><tr><td>70–79</td><td>1.042</td><td>0.489</td><td>0.93</td><td>(0.415, 2.612)</td></tr><tr><td>≥80</td><td>1.505</td><td>0.833</td><td>0.46</td><td>(0.508, 4.457)</td></tr><tr><td>Education</td><td></td><td></td><td></td><td></td></tr><tr><td>No diploma</td><td>1</td><td></td><td></td><td></td></tr><tr><td>High school</td><td>0.614</td><td>0.225</td><td>0.18</td><td>(0.299, 1.261)</td></tr><tr><td>CEGEP</td><td>0.837</td><td>0.295</td><td>0.61</td><td>(0.419, 1.671)</td></tr><tr><td>University degree</td><td>0.721</td><td>0.239</td><td>0.33</td><td>(0.376, 1.383)</td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td></tr><tr><td>Men</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Women</td><td>1.175</td><td>0.180</td><td>0.29</td><td>(0.87, 1.586)</td></tr><tr><td>Constant</td><td>0.162</td><td>0.311</td><td>0.34</td><td>(0.004, 6.979)</td></tr></table> |
084a154a5984c363a5d5a1742fdf83d365a33fd97a319224a1a4934c7cb0e64b.png | simple | <table><tr><td>Hematological parameter</td><td><i>N</i></td><td>Median</td><td>Mean</td><td>SE</td><td>Min–Max</td></tr><tr><td>PCV (%)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Adult</td><td>19</td><td>19.0</td><td>19.42</td><td>1.38</td><td>5–27</td></tr><tr><td> Juvenile</td><td>6</td><td>18.5</td><td>19.17</td><td>1.87</td><td>15–27</td></tr><tr><td>Total solids* (mg/dl)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Adult</td><td>19</td><td>5.2</td><td>5.25</td><td>0.33</td><td>1.2–7.6</td></tr><tr><td> Juvenile</td><td>6</td><td>3.3</td><td>3.52</td><td>0.30</td><td>2.8–4.9</td></tr><tr><td>WBC (×10<sup>9</sup>/l)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Adult</td><td>19</td><td>3150</td><td>3617.86</td><td>428.90</td><td>1400–7800</td></tr><tr><td> Juvenile</td><td>8</td><td>3850</td><td>4375.00</td><td>684.20</td><td>2800–8400</td></tr><tr><td>Heterophils (%)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Adult</td><td>21</td><td>45.0</td><td>46.19</td><td>1.66</td><td>35–64</td></tr><tr><td> Juvenile</td><td>8</td><td>42.5</td><td>41.88</td><td>3.19</td><td>25–54</td></tr><tr><td>Lymphocytes (%)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Adult</td><td>21</td><td>30</td><td>30.90</td><td>1.34</td><td>23–43</td></tr><tr><td> Juvenile</td><td>8</td><td>35</td><td>34.75</td><td>3.17</td><td>22–50</td></tr><tr><td>Monocytes (%)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Adult</td><td>21</td><td>19</td><td>17.57</td><td>1.14</td><td>8–28</td></tr><tr><td> Juvenile</td><td>8</td><td>14</td><td>15.38</td><td>3.18</td><td>3–32</td></tr><tr><td>Eosinophils (%)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Adult</td><td>21</td><td>1.0</td><td>1.57</td><td>0.32</td><td>0–6</td></tr><tr><td> Juvenile</td><td>8</td><td>1.5</td><td>2.00</td><td>0.65</td><td>0–5</td></tr><tr><td>Basophils (%)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Adult</td><td>21</td><td>3.0</td><td>3.90</td><td>0.50</td><td>0–9</td></tr><tr><td> Juvenile</td><td>8</td><td>5.5</td><td>6.00</td><td>1.12</td><td>2–12</td></tr></table> |
cb94733f8ef88d6354cfe2b1267d454a7611de234fd041f63f8836887661d20c.png | simple | <table><tr><td>Average hours per month</td><td>Programs Reported Resident UseNo. (%)</td></tr><tr><td>< 1 h</td><td>17 (38)</td></tr><tr><td>1–2 h</td><td>14 (31)</td></tr><tr><td>3–5 h</td><td>2 (4)</td></tr><tr><td>6–10 h</td><td>1 (2)</td></tr><tr><td>> 10 h</td><td>1 (2)</td></tr><tr><td>No response</td><td>10 (22)</td></tr></table> |
0db0e1ced3b61c946b9fdd2fa07b947215f9910c7f488b623cbe829af1541ee0.png | complex | <table><tr><td rowspan="3">Antibiotics</td><td colspan="3">Cattle (3 isolates)</td><td colspan="3">Buffalo (1 isolates)</td><td colspan="3">Pig (6 isolates)</td><td colspan="3">Total isolates (10)</td></tr><tr><td>R</td><td>MS</td><td>S</td><td>R</td><td>MS</td><td>S</td><td>R</td><td>MS</td><td>S</td><td>R (%)</td><td>MS (%)</td><td>S (%)</td></tr><tr><td>A</td><td>00</td><td>02</td><td>01</td><td>00</td><td>01</td><td>00</td><td>02</td><td>01</td><td>03</td><td>02 (20)</td><td>04 (40)</td><td>04 (40)</td></tr><tr><td>G</td><td>00</td><td>01</td><td>02</td><td>00</td><td>00</td><td>00</td><td>00</td><td>01</td><td>06</td><td>00</td><td>02 (20)</td><td>08 (80)</td></tr><tr><td>K</td><td>00</td><td>03</td><td>00</td><td>00</td><td>01</td><td>00</td><td>00</td><td>05</td><td>01</td><td>00</td><td>09 (90)</td><td>01 (10)</td></tr><tr><td>Ak</td><td>00</td><td>03</td><td>00</td><td>00</td><td>00</td><td>01</td><td>00</td><td>04</td><td>02</td><td>00</td><td>07 (70)</td><td>03 (30)</td></tr><tr><td>Tr</td><td>02</td><td>00</td><td>01</td><td>00</td><td>01</td><td>00</td><td>03</td><td>00</td><td>03</td><td>05 (50)</td><td>01 (10)</td><td>04 (40)</td></tr></table> |
24d0d076693ae018e04e577cd2f700d98b2cf41e0301d6646c42037f0ea87c24.png | complex | <table><tr><td rowspan="2">Economic Quantiles</td><td colspan="3">Tobacco Use Prevalence (TP)</td><td colspan="3">Tobacco Use Quantities (TQ)</td></tr><tr><td>Men</td><td>Women</td><td>All</td><td>Men</td><td>Women</td><td>All</td></tr><tr><td>Poorest</td><td>26.0</td><td>4.1</td><td>14.0</td><td>12.6</td><td>8.4</td><td>11.9</td></tr><tr><td>Poorer</td><td>29.0</td><td>3.0</td><td>15.5</td><td>14.2</td><td>12.3</td><td>14.0</td></tr><tr><td>Middle</td><td>30.9</td><td>4.0</td><td>17.0</td><td>14.8</td><td>11.1</td><td>14.4</td></tr><tr><td>Richer</td><td>28.8</td><td>3.0</td><td>15.6</td><td>15.8</td><td>10.1</td><td>15.2</td></tr><tr><td>Richest</td><td>32.7</td><td>3.4</td><td>17.7</td><td>16.5</td><td>11.8</td><td>16.0</td></tr><tr><td><i>p</i>-value</td><td><0.001</td><td>0.179</td><td><0.001</td><td><0.001</td><td>0.081</td><td><0.001</td></tr></table> |
a47e73c7dfd87e4abd52660388bda8e2e0492500f6784c03cbf4afea90684431.png | simple | <table><tr><td>rs4880 T > C</td><td>Cases, <i>n</i> (%)</td><td>Controls, <i>n</i> (%)</td><td>OR (95% CI) <sup>a</sup></td><td><i>p</i><sup>a</sup></td></tr><tr><td>TT</td><td>319 (69.35%)</td><td>426 (80.37%)</td><td>Reference</td><td>-</td></tr><tr><td>TC</td><td>111 (24.13%)</td><td>99 (18.68%)</td><td>1.35 (0.79–2.81)</td><td>0.195</td></tr><tr><td>CC</td><td>30 (6.52%)</td><td>5 (0.94%)</td><td>3.81 (1.22–5.67)</td><td>0.013</td></tr><tr><td>TC + CC</td><td>141 (30.65%)</td><td>104 (19.62%)</td><td>2.75 (1.23–3.98)</td><td>0.010</td></tr><tr><td><i>p</i> trend</td><td></td><td></td><td></td><td>0.023</td></tr></table> |
72fca98642a343d94c6192a466e0bab9aa682c4ff76ff5c0facf899fc13d4bf2.png | complex | <table><tr><td></td><td colspan="4">Reference SSC-I (cos 0.98)</td></tr><tr><td>SSC-II</td><td>DISO</td><td>SPE</td><td>PRGE</td><td>CHED</td></tr><tr><td>Rec</td><td>89.0%</td><td>94.5%</td><td>59.7%</td><td>49.6%</td></tr><tr><td>Prec</td><td>71.6%</td><td>90.0%</td><td>96.8%</td><td>49.4%</td></tr><tr><td>F-meas</td><td>79.3%</td><td>92.2%</td><td>73.8%</td><td>49.5%</td></tr></table> |
e245282a8658cf0d4fbc66080dc289d3dd7daea99557c047ede41264417bc72e.png | complex | <table><tr><td>Outcomes</td><td>Instrument</td><td>t0</td><td>t1</td><td>t2</td><td>t3</td><td>t4</td><td>t5</td><td>t6</td></tr><tr><td colspan="9">Primary endpoint</td></tr><tr><td>Overall 2-year survival</td><td>Medical log (ongoing assessment)</td><td colspan="7"></td></tr><tr><td colspan="9">Secondary endpoints</td></tr><tr><td>2-year non-relapse mortality, median (disease-free) survival</td><td>Medical log (ongoing assessment)</td><td colspan="7"></td></tr><tr><td>Quality of life</td><td>EORTC QLQ30 / HDC-29 module</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Fatigue</td><td>Multidimensional Fatigue Inventory (MFI)</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td rowspan="2">Muscle strength</td><td>Isometric and isokinetic strength of representative muscle groups for upper and lower extremity measured at the IsoMed2000®</td><td>X</td><td></td><td></td><td>X</td><td></td><td>X</td><td>X</td></tr><tr><td>Hand-Held-Dynamometer (isometric)</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Cardiorespiratory fitness</td><td>CPET (VO<sub>2</sub>peak)</td><td>X</td><td></td><td></td><td>X</td><td></td><td>X</td><td>X</td></tr><tr><td></td><td>6-min Walk Test</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Body composition</td><td>bioelectrical impedance analysis, weight, height</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Physical Activity</td><td>Accelerometry</td><td>X</td><td></td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Depression</td><td>CES-D</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Distress</td><td>NCCN-Distress</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Locus of control</td><td>KKG (German)</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Cognitive function</td><td>Trail-making-test</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Common side-effects</td><td>VAS, every week, later every 3 weeks</td><td colspan="7"></td></tr><tr><td>Biomarker</td><td>Various methods (ELISA)</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Oxidative stress marker</td><td>Analysed in urine samples</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td colspan="9">Others</td></tr><tr><td>Socio-demographic factors</td><td>Recording of date of birth, education, occupation, familial situation, smoking, alcohol consumption</td><td>X</td><td></td><td></td><td></td><td></td><td>X</td><td>X</td></tr><tr><td>Medical history</td><td>Recording of pre-existing diseases, therapies</td><td>X</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Treatment data</td><td>Conditioning, complications</td><td></td><td>X</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Karnofsky Performance Score</td><td>Physician rating</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Medication (immunosuppression, corticosteroids, analgesics)</td><td>Recorded at each visit/phone call on a medication log form</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Physical activity history</td><td>Physical activity in adolescence, pre-diagnosis, during, and after intervention is recorded, including walking, cycling, and sports activities</td><td>X</td><td></td><td></td><td>X</td><td></td><td>X</td><td>X</td></tr></table> |
519e23787e680fa0ddb77ee6074e45ae2f0c5489c03b1b1a22cda753b5151b2b.png | complex | <table><tr><td><i>Individual components of global assessment of inflammation</i></td><td colspan="2"><i>Patients with grade 0,</i> n <i>(%)</i></td></tr><tr><td> </td><td><i>Difluprednate 0.05% (</i>n=<i>39)</i></td><td><i>Prednisolone acetate 1% (</i>n=<i>40)</i></td></tr><tr><td>Anterior chamber cell</td><td>30 (78.9)</td><td>31 (77.5)</td></tr><tr><td>Anterior chamber flare</td><td>29 (74.4)</td><td>28 (70.0)</td></tr><tr><td>Corneal clarity</td><td>37 (94.9)</td><td>36 (90.0)</td></tr><tr><td>Conjunctival injection</td><td>35 (89.7)</td><td>37 (92.5)</td></tr><tr><td>Ciliary/limbal injection</td><td>39 (100.0)</td><td>40 (100.0)</td></tr><tr><td>Chemosis</td><td>39 (100.0)</td><td>39 (97.5)</td></tr><tr><td>Hypopyon</td><td>39 (100.0)</td><td>40 (100.0)</td></tr><tr><td>Vitritis</td><td>39 (100.0)</td><td>39 (97.5)</td></tr><tr><td>Wound integrity</td><td>39 (100.0)</td><td>40 (100.0)</td></tr><tr><td>Photophobia</td><td>38 (97.4)</td><td>38 (95.0)</td></tr><tr><td>Lacrimation</td><td>39 (100.0)</td><td>38 (95.0)</td></tr></table> |
83357e5932eef05d0eb3b87b1cb42c844d8ee3114f83821f08eab6835dbd8cb1.png | simple | <table><tr><td></td><td></td><td>Decreased dose</td><td>Stable dose</td><td>Increased dose</td><td>Total</td></tr><tr><td>DAS</td><td>Remission: < 1.6, N (%)</td><td>257 (13)</td><td>1149 (56)</td><td>629 (31)</td><td>2035 (100)</td></tr><tr><td></td><td><sup>a</sup>LDA: 1.6–2.4, N (%)</td><td>179 (12)</td><td>852 (55)</td><td>511 (33)</td><td>1542 (100)</td></tr><tr><td></td><td><sup>a</sup>MDA: 2.4–3.7, N (%)</td><td>125 (9)</td><td>770 (56)</td><td>479 (35)</td><td>1374 (100)</td></tr><tr><td></td><td><sup>a</sup>HDA: > 3.7, N (%)</td><td>23 (11)</td><td>110 (53)</td><td>73 (35)</td><td>206 (100)</td></tr></table> |
63274e0b02012dc136962e7e37542f520a6171ef3f88a8027c255cc98f6fd8b2.png | simple | <table><tr><td>Material Scan Rate Cathodic Threshold Potential</td><td><i>i</i><sub>corr</sub><i><sup>f</sup></i><sup>w</sup> (A/cm2)</td><td>CR<i><sup>f</sup></i><sup>w</sup> (mm/year)</td><td><i>E</i><sub>corr</sub><i><sup>f</sup></i><sup>w</sup> (V<i>vs.</i> SCE)</td><td><i>i</i><sub>corr</sub><i><sup>b</sup></i><sup>w</sup> (A/cm2)</td><td>CR<i><sup>b</sup></i><sup>w</sup> (mm/year)</td><td><i>E</i><sub>corr</sub><i><sup>b</sup></i><sup>w</sup> (V <i>vs.</i> SCE)</td><td><i>R</i><sub>p</sub> (Ω cm2)</td></tr><tr><td>WE43 10 mV/s E<sub>T</sub> = −1 V<i>vs.</i> OCP</td><td>3.92 × 10<sup>−5</sup></td><td>5.68 × 10<sup>−1</sup></td><td>−1.51214</td><td>6.67 × 10<sup>−5</sup></td><td>9.66 × 10<sup>−1</sup></td><td>−1.5432</td><td>276</td></tr><tr><td>SD</td><td>7.71 × 10<sup>−6</sup></td><td>1.12 × 10<sup>−1</sup></td><td>0.01187468</td><td>6.47 × 10<sup>−5</sup></td><td>9.37 × 10<sup>−1</sup></td><td>0.05866018</td><td></td></tr><tr><td>WE43 100 mV/s E<sub>T</sub> = −0.5 V<i>vs.</i> OCP</td><td>2.75 × 10<sup>−5</sup></td><td>3.98 × 10<sup>−1</sup></td><td>−1.51482</td><td>2.48 × 10<sup>−5</sup></td><td>3.59 × 10<sup>−1</sup></td><td>−1.5146</td><td>393</td></tr><tr><td>SD</td><td>1.07 × 10<sup>−6</sup></td><td>1.55 × 10<sup>−2</sup></td><td>0.00584739</td><td>1.52 × 10<sup>−6</sup></td><td>2.20 × 10<sup>−2</sup></td><td>0.00335857</td><td></td></tr><tr><td>WE43 100 mV/s E<sub>T</sub> = −1 V<i>vs.</i> OCP</td><td>3.03 × 10<sup>−5</sup></td><td>4.38 × 10<sup>−1</sup></td><td>−1.54254</td><td>2.91 × 10<sup>−5</sup></td><td>4.22 × 10<sup>−1</sup></td><td>−1.5400</td><td></td></tr><tr><td>SD</td><td>4.77 × 10<sup>−6</sup></td><td>6.92 × 10<sup>−2</sup></td><td>0.00609286</td><td>2.95 × 10<sup>−6</sup></td><td>4.28 × 10<sup>−2</sup></td><td>0.00758571</td><td></td></tr><tr><td>Mg 10 mV/s E<sub>T</sub> = −1 V<i>vs.</i> OCP</td><td>1.48 × 10<sup>−4</sup></td><td>2.14</td><td>−1.4752</td><td>2.08 × 10<sup>−4</sup></td><td>3.01</td><td>−1.6444</td><td>59</td></tr><tr><td>SD</td><td>9.34 × 10<sup>−5</sup></td><td>1.35</td><td>0.0671203</td><td>8.39 × 10<sup>−6</sup></td><td>1.22 × 10<sup>−1</sup></td><td>0.01472678</td><td></td></tr><tr><td>Mg 100 mV/s E<sub>T</sub> = −0.5 V<i>vs.</i> OCP</td><td>1.68 × 10<sup>−4</sup></td><td>2.44</td><td>−1.61504</td><td>1.72 × 10<sup>−4</sup></td><td>2.49</td><td>−1.6475</td><td>68</td></tr><tr><td>SD</td><td>1.24 × 10<sup>−5</sup></td><td>1.80 × 10<sup>−1</sup></td><td>0.01142817</td><td>3.56 × 10<sup>−6</sup></td><td>5.16 × 10<sup>−2</sup></td><td>0.00302476</td><td></td></tr><tr><td>Mg 100 mV/s E<sub>T</sub> = −1 V<i>vs.</i> OCP</td><td>5.40 × 10<sup>−5</sup></td><td>7.82 × 10<sup>−1</sup></td><td>−1.5261</td><td>5.00 × 10<sup>−5</sup></td><td>7.24 × 10<sup>−1</sup></td><td>−1.5457</td><td></td></tr><tr><td>SD</td><td>2.51 × 10<sup>−6</sup></td><td>3.64 × 10<sup>−2</sup></td><td>0.00435603</td><td>2.28 × 10<sup>−6</sup></td><td>3.31 × 10<sup>−2</sup></td><td>0.00314754</td><td></td></tr></table> |
4a73f716af05e5138f95044d9c92051ff04916767341baef25cf8db6d37a7c64.png | simple | <table><tr><td><i>Ingredients</i></td><td><i>% of DM</i></td></tr><tr><td><i>Mix Silage</i></td><td>39.00</td></tr><tr><td><i>Mix Hay</i></td><td>5.00</td></tr><tr><td><i>Barley</i></td><td>18.09</td></tr><tr><td><i>Oats</i></td><td>15.12</td></tr><tr><td><i>Rape Seed Cake</i></td><td>6.48</td></tr><tr><td><i>Rape Seed Meal</i></td><td>2.16</td></tr><tr><td><i>Brewers Grain</i></td><td>2.16</td></tr><tr><td><i>Soybean Meal</i></td><td>3.78</td></tr><tr><td><i>Dried Sugar Beet Pulp</i></td><td>5.40</td></tr><tr><td><i>Wheat Bran</i></td><td>0.81</td></tr><tr><td><i>Mineral Mix</i><sup>1</sup></td><td>2.00</td></tr><tr><td><i>Nutrients analysis</i></td><td>% of DM</td></tr><tr><td><i>DM (%)</i></td><td>52.50</td></tr><tr><td><i>CP</i></td><td>17.20</td></tr><tr><td><i>NDF</i></td><td>35.94</td></tr><tr><td><i>Ether extract</i></td><td>3.72</td></tr><tr><td><i>Ash</i></td><td>9.01</td></tr><tr><td><i>Ca</i></td><td>0.89</td></tr><tr><td><i>P</i></td><td>0.46</td></tr><tr><td><i>NE<sub>L </sub>MJ/kg of DM</i></td><td>6.95</td></tr></table> |
ee35c86af1c0d672a0464dd652ba166c9cf938cb72106bbf3f991933c89cf795.png | simple | <table><tr><td>Isolate</td><td>Source</td><td>BioSample ID</td><td>SRA Run</td><td>GenBank accession number</td><td>PubMLST ID</td><td><i>rpoB</i> allelic type (AT)</td><td>MLST ST<sup>a</sup></td><td>Novel MLST AT or ST<sup>b</sup></td></tr><tr><td>FSL H7-0926</td><td>Pasteurized 2 % milk</td><td>SAMN03800014</td><td>SRR2541537</td><td>LOBD00000000</td><td>1774</td><td>90</td><td>667</td><td></td></tr><tr><td>FSL H8-0482</td><td>Soil from areas adjacent to barns</td><td>SAMN03800015</td><td>SRR2541601</td><td>LOAZ00000000</td><td>1764</td><td>129</td><td>223</td><td></td></tr><tr><td>FSL H8-0488</td><td>Water from hose in milking area</td><td>SAMN03800016</td><td>SRR2541602</td><td>LOBA00000000</td><td>1765</td><td>129</td><td>111</td><td></td></tr><tr><td>FSL K6-0040</td><td>Raw milk</td><td>SAMN03800017</td><td>SRR2541603</td><td>LOBE00000000</td><td>1775</td><td>362</td><td>1101</td><td><i>ilv</i> 245, ST-1101</td></tr><tr><td>FSL K6-0043</td><td>Raw milk</td><td>SAMN03800018</td><td>SRR2541604</td><td>LOMW00000000</td><td>1763</td><td>363</td><td>1087</td><td><i>pta</i> 235, ST-1087</td></tr><tr><td>FSL K6-0067</td><td>Raw milk</td><td>SAMN03800019</td><td>SRR2541605</td><td>LOMN00000000</td><td>1762</td><td>365</td><td>1086</td><td><i>gmk</i> 138, <i>pur</i> 218, ST-1086</td></tr><tr><td>FSL K6-0069</td><td>Raw milk</td><td>SAMN03800020</td><td>SRR2541606</td><td>LOBB00000000</td><td>1756</td><td>194</td><td>1080</td><td><i>glp</i> 224, <i>gmk</i> 135, <i>ilv</i> 237, <i>pta</i> 233, ST-1080</td></tr><tr><td>FSL K6-0073</td><td>Raw milk</td><td>SAMN03800021</td><td>SRR2541607</td><td>LOMO00000000</td><td>1773</td><td>366</td><td>33</td><td></td></tr><tr><td>FSL K6-0267</td><td>Raw milk</td><td>SAMN03800022</td><td>SRR2541613</td><td>LOMP00000000</td><td>1755</td><td>90</td><td>1090</td><td>ST-1090</td></tr><tr><td>FSL M8-0117</td><td>Raw milk</td><td>SAMN03800023</td><td>SRR2541639</td><td>LONG00000000</td><td>1761</td><td>308</td><td>1085</td><td><i>gmk</i> 137, <i>pyc</i> 186, ST-1085</td></tr><tr><td>FSL W8-0003</td><td>Ricotta/mozzarella whey</td><td>SAMN03800024</td><td>SRR2541640</td><td>LOMQ00000000</td><td>1760</td><td>125</td><td>1084</td><td><i>ilv</i> 239, ST-1084</td></tr><tr><td>FSL W8-0050</td><td>Condensed product from evaporator</td><td>SAMN03800025</td><td>SRR2541641</td><td>LOMR00000000</td><td>1772</td><td>380</td><td>32</td><td></td></tr><tr><td>FSL W8-0169</td><td>Raw milk</td><td>SAMN03800026</td><td>SRR2541651</td><td>LOBC00000000</td><td>1757</td><td>61</td><td>1081</td><td><i>gmk</i> 136, <i>pta</i> 234, ST-1081</td></tr><tr><td>FSL W8-0268</td><td>Evaporator - liquid</td><td>SAMN03800027</td><td>SRR2541662</td><td>LOMS00000000</td><td>1759</td><td>92</td><td>1083</td><td><i>tpi</i> 185, ST-1083</td></tr><tr><td>FSL W8-0275</td><td>Liquid milk whey permeate</td><td>SAMN03800028</td><td>SRR2541668</td><td>LOMT00000000</td><td>1771</td><td>463</td><td>1050</td><td></td></tr><tr><td>FSL W8-0483</td><td>Liquid raw milk from silo</td><td>SAMN03800029</td><td>SRR2541674</td><td>LOMU00000000</td><td>1758</td><td>120</td><td>1082</td><td><i>ilv</i> 238, ST-1082</td></tr><tr><td>FSL W8-0520</td><td>Processed liquid milk</td><td>SAMN03800030</td><td>SRR2541680</td><td>LONH00000000</td><td>1770</td><td>481</td><td>1032</td><td></td></tr><tr><td>FSL W8-0523</td><td>Liquid from blended whey silo</td><td>SAMN03800031</td><td>SRR2541686</td><td>LOMV00000000</td><td>1769</td><td>481</td><td>1032</td><td></td></tr><tr><td>FSL W8-0640</td><td>Processed skim milk</td><td>SAMN03800032</td><td>SRR2541688</td><td>LOQA00000000</td><td>1754</td><td>154</td><td>1089</td><td>ST-1089</td></tr><tr><td>FSL W8-0824</td><td>Finished dairy product</td><td>SAMN03800033</td><td>SRR2541693</td><td>LOQB00000000</td><td>1767</td><td>92</td><td>24</td><td></td></tr><tr><td>FSL W8-0932</td><td>Processed skim milk</td><td>SAMN03800034</td><td>SRR2541715</td><td>LOQC00000000</td><td>1766</td><td>120</td><td>365</td><td></td></tr><tr><td>FSL W8-0767</td><td>Milk powder</td><td>SAMN03800035</td><td>SRR2541718</td><td>LOQD00000000</td><td>1768</td><td>154</td><td>787</td><td></td></tr></table> |
15b67cee1f21cc1dda659be106a5cc9c538fbec3b1165f54935a3589ee72b38f.png | simple | <table><tr><td>Main nutrients </td><td>Rice porridge</td><td>Rice cereal *</td><td>Hard-boiled egg yolk</td></tr><tr><td>Energy, including dietary fibre (kJ)</td><td>158</td><td>1537</td><td>1450</td></tr><tr><td>Protein (g)</td><td>0.7</td><td>6.8</td><td>16.1</td></tr><tr><td>Fat (g)</td><td>0.1</td><td>1.1</td><td>31.7</td></tr><tr><td>Calcium (mg)</td><td>2</td><td>6</td><td>115</td></tr><tr><td>Iodine (ug)</td><td>0.8</td><td>3.7</td><td>127.7</td></tr><tr><td>Iron (mg)</td><td>0.08</td><td>15.5</td><td>4.8</td></tr><tr><td>Zinc (mg)</td><td>0.12</td><td>7.8</td><td>2.7</td></tr><tr><td>Riboflavin (B2) (mg)</td><td>0.002</td><td>1.9</td><td>0.42</td></tr><tr><td>Pyridoxine (B6) (mg)</td><td>0.01</td><td>0</td><td>0.33</td></tr><tr><td>Vitamin C (mg)</td><td>0</td><td>33</td><td>0</td></tr><tr><td>Folate, natural (μg)</td><td>1</td><td>70</td><td>177</td></tr></table> |
eb64c5b2908d0deec3d641acba5b89bd8897127a521da1b8a9b5038714bf6980.png | simple | <table><tr><td>Variable</td><td>Laser</td><td>Steel</td><td>Total</td><td>p-value</td></tr><tr><td>Age</td><td> </td><td> </td><td> </td><td>0.548</td></tr><tr><td><i>Mean</i></td><td>65.2</td><td>67.4</td><td>66.3</td><td> </td></tr><tr><td><i>Range</i></td><td>-</td><td>-</td><td>34-87</td><td> </td></tr><tr><td><i>SD</i></td><td>11.5</td><td>12.7</td><td>12.0</td><td> </td></tr><tr><td>Gender</td><td> </td><td> </td><td> </td><td>1.0</td></tr><tr><td><i>Male</i></td><td>20</td><td>19</td><td>39</td><td> </td></tr><tr><td><i>Female</i></td><td>3</td><td>3</td><td>6</td><td> </td></tr><tr><td>Diagnosis</td><td> </td><td> </td><td> </td><td>0.463</td></tr><tr><td>a) Premalignant</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><i>Moderate dysplasia</i></td><td>0</td><td>2</td><td>2</td><td> </td></tr><tr><td><i>Severe dysplasia/CIS</i></td><td>6</td><td>3</td><td>9</td><td> </td></tr><tr><td>b) Invasive SCC</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><i>Well differentiated</i></td><td>2</td><td>2</td><td>4</td><td> </td></tr><tr><td><i>Moderately differentiated</i></td><td>12</td><td>14</td><td>26</td><td> </td></tr><tr><td><i>Poorly differentiated</i></td><td>3</td><td>1</td><td>4</td><td> </td></tr></table> |
4c2854d228e35fda8e4d4cbc7ad28be0363640e31aec8c7fc8d178c3d8fa241e.png | complex | <table><tr><td> </td><td colspan="7">1991-1996</td><td colspan="7">1997-2001</td><td colspan="7">1991-2001</td></tr><tr><td> </td><td>Deaths</td><td colspan="3">Controlling for age</td><td colspan="3">Controlling for all variables (1)</td><td>Deaths</td><td colspan="3">Controlling for age</td><td colspan="3">Controlling for all variables (1)</td><td>Deaths</td><td colspan="3">Controlling for age</td><td colspan="3">Controlling for all variables (1)</td></tr><tr><td> </td><td> </td><td>HR</td><td colspan="2">95% CI</td><td>HR</td><td colspan="2">95% CI</td><td> </td><td>HR</td><td colspan="2">95% CI</td><td>HR</td><td colspan="2">95% CI</td><td> </td><td>HR</td><td colspan="2">95% CI</td><td>HR</td><td colspan="2">95% CI</td></tr><tr><td>All causes of death</td><td>17,923</td><td>1.36</td><td>1.29</td><td>−1.43</td><td>1.22</td><td>1.15</td><td>−1.28</td><td>23,757</td><td>1.37</td><td>1.31</td><td>−1.43</td><td>1.22</td><td>1.17</td><td>−1.28</td><td>41,680</td><td>1.37</td><td>1.32</td><td>−1.41</td><td>1.22</td><td>1.18</td><td>−1.26</td></tr><tr><td>Malignant neoplasms</td><td>7071</td><td>1.19</td><td>1.09</td><td>−1.30</td><td>1.10</td><td>1.01</td><td>−1.21</td><td>10,079</td><td>1.28</td><td>1.19</td><td>−1.37</td><td>1.17</td><td>1.09</td><td>−1.26</td><td>17,150</td><td>1.24</td><td>1.18</td><td>−1.31</td><td>1.14</td><td>1.08</td><td>−1.21</td></tr><tr><td>Stomach cancer</td><td>529</td><td>1.54</td><td>1.16</td><td>−2.05</td><td>1.45</td><td>1.08</td><td>−1.94</td><td>732</td><td>1.17</td><td>0.89</td><td>−1.54</td><td>1.06</td><td>0.80</td><td>−1.40</td><td>1,261</td><td>1.33</td><td>1.09</td><td>−1.61</td><td>1.22</td><td>1.00</td><td>−1.49</td></tr><tr><td>Lung cancer</td><td>2,248</td><td>1.18</td><td>1.01</td><td>−1.38</td><td>1.01</td><td>0.86</td><td>−1.18</td><td>3,091</td><td>1.44</td><td>1.28</td><td>−1.63</td><td>1.19</td><td>1.05</td><td>−1.35</td><td>5,339</td><td>1.33</td><td>1.21</td><td>−1.46</td><td>1.11</td><td>1.01</td><td>−1.23</td></tr><tr><td>Cancer of intestine and rectum</td><td>908</td><td>0.92</td><td>0.70</td><td>−1.21</td><td>0.91</td><td>0.69</td><td>−1.20</td><td>1,302</td><td>1.22</td><td>1.00</td><td>−1.50</td><td>1.18</td><td>0.96</td><td>−1.45</td><td>2,210</td><td>1.10</td><td>0.93</td><td>−1.29</td><td>1.07</td><td>0.91</td><td>−1.26</td></tr><tr><td>Other cancers</td><td>3,386</td><td>1.21</td><td>1.07</td><td>−1.37</td><td>1.18</td><td>1.04</td><td>−1.33</td><td>4,954</td><td>1.21</td><td>1.09</td><td>−1.34</td><td>1.17</td><td>1.05</td><td>−1.30</td><td>8,340</td><td>1.21</td><td>1.12</td><td>−1.31</td><td>1.17</td><td>1.08</td><td>−1.27</td></tr><tr><td>Circulatory diseases</td><td>5,474</td><td>1.19</td><td>1.08</td><td>−1.32</td><td>1.09</td><td>0.98</td><td>−1.20</td><td>7,208</td><td>1.24</td><td>1.14</td><td>−1.35</td><td>1.13</td><td>1.03</td><td>−1.23</td><td>12,682</td><td>1.22</td><td>1.14</td><td>−1.30</td><td>1.11</td><td>1.04</td><td>−1.18</td></tr><tr><td>Acute myocardial infarction</td><td>2,405</td><td>1.11</td><td>0.95</td><td>−1.29</td><td>1.02</td><td>0.87</td><td>−1.19</td><td>2,716</td><td>1.21</td><td>1.05</td><td>−1.40</td><td>1.11</td><td>0.96</td><td>−1.28</td><td>5,121</td><td>1.16</td><td>1.05</td><td>−1.29</td><td>1.07</td><td>0.96</td><td>−1.18</td></tr><tr><td>Other ischaemic heart disease</td><td>1,538</td><td>1.13</td><td>0.93</td><td>−1.37</td><td>1.03</td><td>0.85</td><td>−1.25</td><td>2,154</td><td>1.31</td><td>1.12</td><td>−1.52</td><td>1.17</td><td>1.00</td><td>−1.36</td><td>3,692</td><td>1.23</td><td>1.09</td><td>−1.39</td><td>1.11</td><td>0.98</td><td>−1.25</td></tr><tr><td>Cerebro-vascular disease</td><td>553</td><td>1.35</td><td>1.00</td><td>−1.81</td><td>1.17</td><td>0.86</td><td>−1.58</td><td>863</td><td>1.29</td><td>1.01</td><td>−1.64</td><td>1.19</td><td>0.93</td><td>−1.52</td><td>1,416</td><td>1.31</td><td>1.09</td><td>−1.58</td><td>1.18</td><td>0.98</td><td>−1.43</td></tr><tr><td>Other circulatory diseases</td><td>978</td><td>1.42</td><td>1.14</td><td>−1.76</td><td>1.31</td><td>1.05</td><td>−1.63</td><td>1,475</td><td>1.17</td><td>0.97</td><td>−1.42</td><td>1.06</td><td>0.88</td><td>−1.29</td><td>2,453</td><td>1.27</td><td>1.10</td><td>−1.46</td><td>1.16</td><td>1.00</td><td>−1.34</td></tr><tr><td>Respiratory diseases</td><td>406</td><td>1.50</td><td>1.07</td><td>−2.08</td><td>1.34</td><td>0.95</td><td>−1.87</td><td>974</td><td>1.44</td><td>1.16</td><td>−1.78</td><td>1.22</td><td>0.98</td><td>−1.52</td><td>1,380</td><td>1.45</td><td>1.21</td><td>−1.74</td><td>1.25</td><td>1.04</td><td>−1.51</td></tr><tr><td>Alcohol-related diseases</td><td>400</td><td>2.14</td><td>1.60</td><td>−2.85</td><td>1.54</td><td>1.15</td><td>−2.07</td><td>526</td><td>2.33</td><td>1.82</td><td>−2.98</td><td>1.84</td><td>1.43</td><td>−2.37</td><td>926</td><td>2.25</td><td>1.86</td><td>−2.71</td><td>1.70</td><td>1.40</td><td>−2.06</td></tr><tr><td>Accidents and violence</td><td>2,382</td><td>2.01</td><td>1.78</td><td>−2.26</td><td>1.59</td><td>1.40</td><td>−1.80</td><td>2,114</td><td>1.88</td><td>1.65</td><td>−2.14</td><td>1.51</td><td>1.32</td><td>−1.72</td><td>4,496</td><td>1.94</td><td>1.78</td><td>−2.12</td><td>1.55</td><td>1.42</td><td>−1.70</td></tr><tr><td>Suicide</td><td>943</td><td>1.94</td><td>1.60</td><td>−2.35</td><td>1.58</td><td>1.30</td><td>−1.93</td><td>879</td><td>1.81</td><td>1.47</td><td>−2.22</td><td>1.44</td><td>1.17</td><td>−1.78</td><td>1822</td><td>1.87</td><td>1.63</td><td>−2.16</td><td>1.51</td><td>1.31</td><td>−1.75</td></tr><tr><td>Homicide</td><td>87</td><td>2.78</td><td>1.59</td><td>−4.85</td><td>2.10</td><td>1.18</td><td>−3.73</td><td>50</td><td>2.17</td><td>0.98</td><td>−4.83</td><td>1.44</td><td>0.63</td><td>−3.29</td><td>137</td><td>2.55</td><td>1.62</td><td>−4.03</td><td>1.83</td><td>1.15</td><td>−1.94</td></tr><tr><td>Traffic accidents</td><td>611</td><td>1.67</td><td>1.29</td><td>−2.14</td><td>1.35</td><td>1.04</td><td>−1.75</td><td>454</td><td>1.51</td><td>1.11</td><td>−2.05</td><td>1.26</td><td>0.92</td><td>−1.73</td><td>1065</td><td>1.60</td><td>1.32</td><td>−1.94</td><td>1.31</td><td>1.07</td><td>−1.60</td></tr><tr><td>Falls</td><td>104</td><td>3.68</td><td>2.29</td><td>−5.89</td><td>2.80</td><td>1.71</td><td>−4.58</td><td>163</td><td>1.73</td><td>1.06</td><td>−2.83</td><td>1.49</td><td>0.90</td><td>−2.47</td><td>267</td><td>2.44</td><td>1.75</td><td>−3.42</td><td>2.00</td><td>1.41</td><td>−2.83</td></tr><tr><td>Other accidents and violence</td><td>637</td><td>2.10</td><td>1.67</td><td>−2.63</td><td>1.58</td><td>1.25</td><td>−2.00</td><td>568</td><td>2.31</td><td>1.82</td><td>−2.91</td><td>1.81</td><td>1.42</td><td>−2.30</td><td>1205</td><td>2.20</td><td>1.86</td><td>−2.58</td><td>1.69</td><td>1.42</td><td>−1.99</td></tr><tr><td>All other causes</td><td>2,590</td><td>1.60</td><td>1.41</td><td>−1.82</td><td>1.33</td><td>1.17</td><td>−1.51</td><td>3,382</td><td>1.58</td><td>1.41</td><td>−1.77</td><td>1.36</td><td>1.22</td><td>−1.53</td><td>5,972</td><td>1.59</td><td>1.46</td><td>−1.73</td><td>1.35</td><td>1.24</td><td>−1.47</td></tr></table> |
75ae05db73ad7a4163cdda927712abd939838b4ddfc9ae779926a61c6620fc26.png | simple | <table><tr><td>Cluster description</td><td>Codon</td><td>Size</td><td>Example organism (locus)</td></tr><tr><td>Selenocysteine</td><td></td><td></td><td></td></tr><tr><td>Formate dehydrogenase α subunit</td><td>TGA</td><td>45</td><td>Escherichia coli (b1474)</td></tr><tr><td>Selenide water dikinase</td><td>TGA</td><td>12</td><td>Haemophilus influenzae (HI0200m)</td></tr><tr><td>Glycine reductase complex selenoprotein A</td><td>TGA</td><td>6</td><td>Treponema denticola (TDE0745)</td></tr><tr><td>Glycine reductase complex selenoprotein B</td><td>TGA</td><td>6</td><td>Treponema denticola (TDE0078)</td></tr><tr><td>Heterodisulfide reductase subunit A</td><td>TGA</td><td>6</td><td>Methanococcus jannaschii (MJ1190m)</td></tr><tr><td>Coenzyme F420-reducing hydrogenase δ subunit</td><td>TGA</td><td>5</td><td>Methanococcus jannaschii (MJ1190a)</td></tr><tr><td>Formylmethanofuran dehydrogenase subunit B</td><td>TGA</td><td>4</td><td>Methanococcus jannaschii (MJ1194m)</td></tr><tr><td>Glutaredoxin-like</td><td>TGA</td><td>3</td><td>Carboxydothermus hydrogenoformans (CHY_0740)</td></tr><tr><td>Thioredoxin</td><td>TGA</td><td>3</td><td>Geobacter sulfurreducens (GSU3446)</td></tr><tr><td>Coenzyme F420-reducing hydrogenase α subunit</td><td>TGA</td><td>3</td><td>Methanococcus jannaschii (MJ0029)</td></tr><tr><td>HesB family</td><td>TGA</td><td>3</td><td>Desulfovibrio vulgaris (DVU_1382)</td></tr><tr><td>HesB family</td><td>TGA</td><td>2</td><td>Methanococcus maripaludis (MMP0252 + upstream)</td></tr><tr><td>Fe-S oxidoreductase</td><td>TGA</td><td>2</td><td>Desulfotalea psychrophila (DP1009)</td></tr><tr><td>DsbA-like</td><td>TGA</td><td>2</td><td>Desulfovibrio desulfuricans (Dde_1263 + upstream)</td></tr><tr><td>Periplasmic [NiFeSe] hydrogenase large subunit</td><td>TGA</td><td>2</td><td>Desulfovibrio vulgaris (DVU_1918)</td></tr><tr><td>Pyrrolysine</td><td></td><td></td><td></td></tr><tr><td>Monomethylamine methyltransferase</td><td>TAG</td><td>7</td><td>Methanosarcina acetivorans (MA0144)</td></tr><tr><td>Dimethylamine methyltransferase</td><td>TAG</td><td>7</td><td>Methanosarcina acetivorans (MA0532)</td></tr><tr><td>Trimethylamine methyltransferase</td><td>TAG</td><td>6</td><td>Methanosarcina acetivorans (MA0528)</td></tr><tr><td>Transcriptional regulator, TetR family</td><td>TAG</td><td>2</td><td>Methanosarcina acetivorans (MA2902)</td></tr><tr><td>Unknown</td><td></td><td></td><td></td></tr><tr><td>Cytochrome c family protein</td><td>TGA</td><td>2</td><td>Geobacter sulfurreducens (GSU2937 + GSU2936)</td></tr><tr><td>Hypothetical protein</td><td>TAG</td><td>2</td><td>Geobacter sulfurreducens (GSU2293 + downstream)</td></tr></table> |
6a8e16da199b55d219454c5507ad53121a023e8b67ca718b8750b613e2af5fc8.png | complex | <table><tr><td></td><td colspan="3">Intention-to-treat analysis</td><td colspan="3">Per protocol analysis</td></tr><tr><td></td><td>1 Hz (<i>n</i> = 22)</td><td>25 Hz (<i>n</i> = 24)</td><td>Group comparison</td><td>1 Hz (<i>n</i> = 17)</td><td>25 Hz (<i>n</i> = 23)</td><td>Group comparison</td></tr><tr><td>Treatment period (days)</td><td>77.9 ± 25.8</td><td>85.7 ± 11.4</td><td><i>p</i> = 0.22</td><td>89.0 ± 8.4</td><td>87.5 ± 7.5</td><td><i>p</i> = 0.67</td></tr><tr><td>Average number of stimulated hours per day</td><td>3.42 ± 0.59</td><td>3.44 ± 0.61</td><td><i>p</i> = 0.69</td><td>3.34 ± 0.62</td><td>3.44 ± 0.62</td><td><i>p</i> = 0.51</td></tr></table> |
4646c5af634a932915f27b85dd61d97b1600e3a3bfcd1155f520508ed67a4ff0.png | complex | <table><tr><td>Variables</td><td></td><td colspan="2">Patients</td><td>KRAS</td><td>NRAS</td><td>BRAF</td></tr><tr><td></td><td></td><td><i>n</i></td><td>%</td><td><i>n</i></td><td><i>n</i></td><td><i>n</i></td></tr><tr><td>Age</td><td>≤ 55</td><td>14</td><td>64</td><td>4</td><td>1</td><td>3</td></tr><tr><td></td><td>> 55</td><td>8</td><td>44</td><td>2</td><td>0</td><td>1</td></tr><tr><td>Gender</td><td>male</td><td>16</td><td>73</td><td>2</td><td>1</td><td>4</td></tr><tr><td></td><td>female</td><td>6</td><td>27</td><td>4</td><td>0</td><td>0</td></tr><tr><td>Histology</td><td>ADC with SRC</td><td>3</td><td>14</td><td>0</td><td>0</td><td>1</td></tr><tr><td></td><td>ADC without SRC</td><td>19</td><td>86</td><td>6</td><td>1</td><td>3</td></tr><tr><td>Calcification</td><td>present</td><td>3</td><td>14</td><td>1</td><td>0</td><td>0</td></tr><tr><td></td><td>absent</td><td>19</td><td>86</td><td>5</td><td>1</td><td>4</td></tr><tr><td>Sheldon Stage</td><td>I-II</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td></td><td>IIIA</td><td>10</td><td>45</td><td>2</td><td>1</td><td>2</td></tr><tr><td></td><td>IIIB</td><td>7</td><td>32</td><td>4</td><td>0</td><td>1</td></tr><tr><td></td><td>IIIC</td><td>1</td><td>5</td><td>0</td><td>0</td><td>0</td></tr><tr><td></td><td>IVA</td><td>2</td><td>9</td><td>0</td><td>0</td><td>0</td></tr><tr><td></td><td>IVB</td><td>2</td><td>9</td><td>0</td><td>0</td><td>1</td></tr><tr><td></td><td>IVC</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Mayo stage</td><td>I</td><td>4</td><td>19</td><td>1</td><td>0</td><td>0</td></tr><tr><td></td><td>II</td><td>10</td><td>48</td><td>3</td><td>1</td><td>3</td></tr><tr><td></td><td>III</td><td>5</td><td>24</td><td>2</td><td>0</td><td>0</td></tr><tr><td></td><td>IV</td><td>2</td><td>9</td><td>0</td><td>0</td><td>1</td></tr><tr><td></td><td>missing</td><td>1</td><td></td><td></td><td></td><td></td></tr><tr><td>LN or distant meta at diagn.</td><td>N0/M0</td><td>18</td><td>82</td><td>6</td><td>1</td><td>3</td></tr><tr><td></td><td>N + / M+</td><td>4</td><td>18</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Initial surgical treatment</td><td>partial CE</td><td>15</td><td>68</td><td>5</td><td>0</td><td>3</td></tr><tr><td></td><td>radical CE</td><td>5</td><td>23</td><td>1</td><td>0</td><td>0</td></tr><tr><td></td><td>TURB</td><td>2</td><td>9</td><td>0</td><td>1</td><td>1</td></tr><tr><td>Umbilectomy</td><td>yes</td><td>11</td><td>50</td><td>4</td><td>0</td><td>2</td></tr><tr><td></td><td>no</td><td>11</td><td>50</td><td>2</td><td>1</td><td>2</td></tr><tr><td>LND</td><td>yes</td><td>13</td><td>59</td><td>3</td><td>0</td><td>2</td></tr><tr><td></td><td>no</td><td>9</td><td>41</td><td>3</td><td>1</td><td>2</td></tr><tr><td>Chemotherapy</td><td>yes</td><td>6</td><td>27</td><td>1</td><td>1</td><td>2</td></tr><tr><td></td><td>no</td><td>16</td><td>73</td><td>5</td><td>0</td><td>2</td></tr><tr><td>Progression</td><td>local recurrence</td><td>2</td><td>9</td><td>1</td><td>1</td><td>1</td></tr><tr><td></td><td>distant met</td><td>2</td><td>9</td><td>1</td><td>0</td><td>0</td></tr><tr><td></td><td>both</td><td>5</td><td>23</td><td>2</td><td>0</td><td>1</td></tr><tr><td></td><td>no progression</td><td>13</td><td>59</td><td>3</td><td>0</td><td>2</td></tr></table> |
54276a86973717f5b1e0961041056a5682b8d462f252c6a2fcfc5181a601e7bc.png | complex | <table><tr><td></td><td colspan="4">Alcohol intake (g/day)</td></tr><tr><td></td><td>0</td><td>0.1–5</td><td>5.1–15</td><td>>15</td></tr><tr><td>No. of participans</td><td>10,153</td><td>22,249</td><td>11,734</td><td>1,097</td></tr><tr><td>Age at enrollment (mean)</td><td>39.8</td><td>39.7</td><td>40.5</td><td>41.4</td></tr><tr><td>Educational attainment >11 years, (%)</td><td>46.3</td><td>56.3</td><td>61.4</td><td>61.7</td></tr><tr><td>History of breast cancer in mother and/or sister (%)</td><td>4.2</td><td>4.2</td><td>5.3</td><td>5.9</td></tr><tr><td>Smoking habits (%)</td><td></td><td></td><td></td><td></td></tr><tr><td> Never</td><td>50.5</td><td>43.0</td><td>32.0</td><td>18.1</td></tr><tr><td> Former</td><td>28.2</td><td>35.3</td><td>40.7</td><td>40.7</td></tr><tr><td> Current</td><td>21.3</td><td>21.7</td><td>27.3</td><td>41.2</td></tr><tr><td>Age at menarche (mean)</td><td>12.9</td><td>13.0</td><td>13.0</td><td>13.1</td></tr><tr><td>Women with more than 3 children (%)</td><td>32.5</td><td>27.2</td><td>24.0</td><td>23.4</td></tr><tr><td>Age at first child birth among parous women (mean)</td><td>23.5</td><td>24.0</td><td>24.1</td><td>23.8</td></tr><tr><td>Total duration of breast feeding (months)</td><td>30.9</td><td>30.8</td><td>30.2</td><td>30.3</td></tr><tr><td>Ever oral contraceptive use (%)</td><td>75.1</td><td>85.0</td><td>88.2</td><td>89.7</td></tr><tr><td>Post-menopause (%)</td><td>4.4</td><td>3.8</td><td>4.3</td><td>3.7</td></tr><tr><td>Body mass index (>25 kg/m<sup>2</sup>, %)</td><td>31.9</td><td>24.1</td><td>21.1</td><td>24.6</td></tr></table> |
36bdabae3fa9efc1c66488814861c65dfe357581268e666270072e94d3b69a0e.png | complex | <table><tr><td> </td><td colspan="2">Location</td><td rowspan="2">Group</td><td colspan="5">IHC grade<sup>#</sup></td><td rowspan="2"><i>P</i> value*</td></tr><tr><td> </td><td>Stroma</td><td>Cancer nest</td><td>−</td><td>+</td><td>++</td><td>+++</td><td>++++</td></tr><tr><td rowspan="2"><i>α</i>-SMA</td><td rowspan="2">Positive<sup>$</sup></td><td rowspan="2">ND</td><td>Chronic nasopharyngitis (21)</td><td>11</td><td>7</td><td>2</td><td>1</td><td>0</td><td rowspan="2">0.000</td></tr><tr><td>NPC (18)</td><td>0</td><td>4</td><td>0</td><td>7</td><td>7</td></tr><tr><td rowspan="2">CD133</td><td rowspan="2">Positive</td><td rowspan="2">ND</td><td>Chronic nasopharyngitis (10)</td><td>9</td><td>1</td><td>0</td><td>0</td><td>0</td><td rowspan="2">0.006</td></tr><tr><td>NPC (30)</td><td>8</td><td>9</td><td>9</td><td>4</td><td>0</td></tr><tr><td rowspan="2">VEGFR-2</td><td rowspan="2">Positive</td><td rowspan="2">ND</td><td>Chronic nasopharyngitis (8)</td><td>7</td><td>1</td><td>0</td><td>0</td><td>0</td><td rowspan="2">0.04</td></tr><tr><td>NPC (10)</td><td>2</td><td>5</td><td>1</td><td>2</td><td>0</td></tr><tr><td rowspan="2">CD34</td><td rowspan="2">Positive</td><td rowspan="2">ND</td><td>Chronic nasopharyngitis (14)</td><td>0</td><td>8</td><td>6</td><td>0</td><td>0</td><td rowspan="2">0.000</td></tr><tr><td>NPC (24)</td><td>0</td><td>0</td><td>3</td><td>7</td><td>14</td></tr><tr><td rowspan="2">CXCR4</td><td rowspan="2">Positive</td><td rowspan="2">Positive</td><td>Chronic nasopharyngitis (6)</td><td>0</td><td>3</td><td>1</td><td>2</td><td>0</td><td rowspan="2">0.041</td></tr><tr><td>NPC (11)</td><td>0</td><td>0</td><td>2</td><td>4</td><td>5</td></tr><tr><td rowspan="2">VEGF-A</td><td rowspan="2">Positive</td><td rowspan="2">Positive</td><td>Chronic nasopharyngitis (10)</td><td>0</td><td>1</td><td>5</td><td>4</td><td>0</td><td rowspan="2">0.015</td></tr><tr><td>NPC (19)</td><td>0</td><td>0</td><td>2</td><td>9</td><td>8</td></tr><tr><td rowspan="2">SDF-1</td><td rowspan="2">ND</td><td rowspan="2">Positive</td><td>Chronic nasopharyngitis (22)</td><td>5</td><td>9</td><td>5</td><td>2</td><td>1</td><td rowspan="2">0.008</td></tr><tr><td>NPC (20)</td><td>3</td><td>0</td><td>7</td><td>5</td><td>5</td></tr></table> |
ca322fb97810764fbba3a7b83b46eb975ccc07962cd586a9f402c3385ffd68a8.png | simple | <table><tr><td> </td><td>Japanese (<i>n</i>22)</td><td>Thai (<i>n</i>27)</td></tr><tr><td> </td><td>Mean ± SD (range)</td><td>Mean ± SD (range)</td></tr><tr><td>Age (years)</td><td>21.5 ± 0.7 (21–24)</td><td>21.2 ± 2.2 (18–25)</td></tr><tr><td>Height (cm)</td><td>159.9 ± 5.9 (151.7-170.5)</td><td>160.6 ± 6.0 (146.0-170.0)</td></tr><tr><td>Body fat (%)</td><td>23.0 ± 5.3<sup>a</sup> (12.2-35.4)</td><td>26.7 ± 5.6<sup>a</sup> (15.8-36.1)</td></tr><tr><td>Weight (kg)</td><td>49.5 ± 4.2 (43.6-58.3)</td><td>51.2 ± 5.9 (41.4-64.6)</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>19.4 ± 1.5 (16.5-22.1)</td><td>19.8 ± 2.0 (16.6-23.0)</td></tr></table> |
368653111d46c06feaddcc99be5500cf0a27ad1b3f21b902e2375d9b05729f3c.png | complex | <table><tr><td rowspan="2"> </td><td colspan="3">Culture-Gram-PCR result<sup>b</sup></td></tr><tr><td>All tests negative</td><td>Isolated RT-PCR positive</td><td>All tests positive</td></tr><tr><td> </td><td>(n=329)</td><td>(n=20)</td><td>(n=75)</td></tr><tr><td>Age in years (median, range)</td><td>9 (0–64)</td><td>11 (0–63)</td><td>15 (0–78)</td></tr><tr><td>Altered mental status (%)</td><td>66 (22.6)</td><td>6 (40.0)</td><td>47 (66.2)</td></tr><tr><td>Deaths (%)</td><td>27 (9.1)</td><td>2 (10.5)</td><td>10 (14.3)</td></tr><tr><td>Median WBC (x10<sup>6</sup> cells/L, range)<sup>c</sup></td><td>430 (100–10,000)</td><td>10,000 (32–10,000)</td><td>8,600 (0–10,000)</td></tr><tr><td>>50% PMN cells (%)</td><td>186 (56.7)</td><td>18 (90.0)</td><td>72 (96.0)</td></tr><tr><td>Median protein (g/L, range)<sup>d</sup></td><td>0.50 (0.20-5.00)</td><td>2.90 (0.32-5.00)</td><td>3.50 (0.28-5.00)</td></tr><tr><td>Median glucose (mmol/L, range)</td><td>2.9 (1.1-3.9)</td><td>1.6 (0.6-3.1)</td><td>1.1 (1.1-3.2)</td></tr><tr><td>LAT positive (% of total LAT performed)</td><td>1 (2.0)</td><td>5 (38.5)</td><td>25 (80.6)</td></tr><tr><td>Positive LAT concordant with RT-PCR (%)<sup>e</sup></td><td>n/a</td><td>5 (100.0)</td><td>25 (100.0)</td></tr><tr><td>Antibiotic bioassay positive (%)</td><td>28 (8.8)</td><td>12 (63.2)</td><td>41 (55.4)</td></tr></table> |
af5777833e2fc8d220e8d35d5a417bacaf8c185971a089b0042620bba9067560.png | complex | <table><tr><td rowspan="2"></td><td colspan="4">Male</td><td colspan="4">Female</td><td colspan="4">Total</td></tr><tr><td>Cases</td><td>n</td><td>p-y</td><td>Rate</td><td>Cases</td><td>n</td><td>p-y</td><td>Rate</td><td>Cases</td><td>n</td><td>p-y</td><td>Rate</td></tr><tr><td>18–20 years</td><td>175</td><td>61,333</td><td>70,412.87</td><td>2.49</td><td>101</td><td>61,303</td><td>68,905.12</td><td>1.47</td><td>276</td><td>122,636</td><td>139,317.98</td><td>1.98</td></tr><tr><td>20–25 years</td><td>433</td><td>79,410</td><td>196,125.36</td><td>2.21</td><td>329</td><td>89,087</td><td>204,046.95</td><td>1.61</td><td>762</td><td>168,497</td><td>400,172.31</td><td>1.90</td></tr><tr><td>25–30 years</td><td>566</td><td>111,187</td><td>260,050.38</td><td>2.18</td><td>458</td><td>122,885</td><td>275,279.73</td><td>1.66</td><td>1024</td><td>234,072</td><td>535,330.11</td><td>1.91</td></tr><tr><td>30–35 years</td><td>818</td><td>134,560</td><td>332,654.60</td><td>2.46</td><td>796</td><td>140,318</td><td>343,610.41</td><td>2.32</td><td>1614</td><td>274,878</td><td>676,265.01</td><td>2.39</td></tr><tr><td>35–40 years</td><td>1070</td><td>123,355</td><td>336,083.56</td><td>3.18</td><td>1157</td><td>125,302</td><td>341,845.69</td><td>3.38</td><td>2227</td><td>248,657</td><td>677,929.25</td><td>3.29</td></tr><tr><td>40–45 years</td><td>1074</td><td>108,836</td><td>306,130.49</td><td>3.51</td><td>1060</td><td>110,765</td><td>309,832.41</td><td>3.42</td><td>2134</td><td>219,601</td><td>615,962.90</td><td>3.46</td></tr><tr><td>45–50 years</td><td>823</td><td>93,700</td><td>272,812.94</td><td>3.02</td><td>833</td><td>98,233</td><td>280,717.22</td><td>2.97</td><td>1656</td><td>191,933</td><td>553,530.15</td><td>2.99</td></tr><tr><td>50–55 years</td><td>874</td><td>81,114</td><td>239,243.53</td><td>3.65</td><td>903</td><td>88,311</td><td>256,471.30</td><td>3.52</td><td>1777</td><td>169,425</td><td>495,714.83</td><td>3.58</td></tr><tr><td>55–60 years</td><td>917</td><td>71,745</td><td>207,713.86</td><td>4.41</td><td>937</td><td>77,261</td><td>222,700.73</td><td>4.21</td><td>1854</td><td>149,006</td><td>430,414.59</td><td>4.31</td></tr><tr><td>60–65 years</td><td>1097</td><td>64,835</td><td>190,729.33</td><td>5.75</td><td>1080</td><td>71,241</td><td>207,353.03</td><td>5.21</td><td>2177</td><td>136,076</td><td>398,082.36</td><td>5.47</td></tr><tr><td>65–70 years</td><td>1098</td><td>48,791</td><td>155,627.10</td><td>7.06</td><td>935</td><td>54,759</td><td>172,088.42</td><td>5.43</td><td>2033</td><td>103,550</td><td>327,715.52</td><td>6.20</td></tr><tr><td>70–75 years</td><td>1214</td><td>41,283</td><td>116,993.45</td><td>10.38</td><td>890</td><td>51,806</td><td>143,029.88</td><td>6.22</td><td>2104</td><td>93,089</td><td>260,023.33</td><td>8.09</td></tr><tr><td>75–80 years</td><td>1604</td><td>36,855</td><td>109,640.33</td><td>14.63</td><td>1115</td><td>52,422</td><td>149,267.10</td><td>7.47</td><td>2719</td><td>89,277</td><td>258,907.43</td><td>10.50</td></tr><tr><td>80–85 years</td><td>1472</td><td>25,189</td><td>75,766.96</td><td>19.43</td><td>1204</td><td>43,904</td><td>125,031.08</td><td>9.63</td><td>2676</td><td>69,093</td><td>200,798.03</td><td>13.33</td></tr><tr><td>85–90 years</td><td>978</td><td>12,965</td><td>39,021.71</td><td>25.06</td><td>1081</td><td>28,978</td><td>83,030.03</td><td>13.02</td><td>2059</td><td>41,943</td><td>122,051.74</td><td>16.87</td></tr><tr><td>90–110 years</td><td>514</td><td>4952</td><td>13,917.42</td><td>36.93</td><td>873</td><td>15,937</td><td>44,495.90</td><td>19.62</td><td>1387</td><td>20,889</td><td>58,413.33</td><td>23.74</td></tr><tr><td>Total</td><td>14,727</td><td>1,100,110</td><td>2,922,923.88</td><td>5.04</td><td>13.752</td><td>1,232,512</td><td>3,227,704.99</td><td>4.26</td><td>28,479</td><td>2,332,622</td><td>6,150,628.88</td><td>4.63</td></tr></table> |
bc758f6c8de05dd430a2bf4e8f071a10566ff58d8d372ed30d6e999233d7ebf5.png | complex | <table><tr><td>Specific primer</td><td>Primer sequences (5′–3′)</td></tr><tr><td rowspan="2">N type <i>DlRans</i></td><td>Forward: AAGGACAGCTCTCATGGCTTTGC</td></tr><tr><td>Reverse: TGCCTCCATCACCGACGATGAC</td></tr><tr><td rowspan="2">D type <i>DlRans</i></td><td>Forward: TAGTGATCGTCGGCGATGGTGG</td></tr><tr><td>Reverse: TGCAGTGTCCCAGCAATAGAAGCG</td></tr><tr><td rowspan="2"><i>Fe</i>-<i>SOD</i></td><td>Forward: GGTCAGATGGTGAAGCCGTAGAG</td></tr><tr><td>Reverse: GTCTATGCCACCGATACAACAAACCC</td></tr><tr><td rowspan="2"><i>EF</i>-<i>1a</i></td><td>Forward: GATGATTCCCACCAAGCCCAT</td></tr><tr><td>Reverse: GGGTCCTTCTTCTCAACACTCT</td></tr></table> |
1e33d01e678a9cfd3b05a30d5d9de5f3584d580ac11c08aad8e986d28eac1b4f.png | complex | <table><tr><td></td><td colspan="3">Increasing ANNV (> 4)</td><td colspan="3">Stable ANNV (-4 to 4)</td><td colspan="3">Decreasing ANNV (< -4)</td></tr><tr><td>Parameter</td><td>PCa (n = 22)</td><td>BPH (n = 16)</td><td>p-value</td><td>PCa (n = 17)</td><td>BPH (n = 124)</td><td>p-value</td><td>PCa (n = 10)</td><td>BPH (n = 10)</td><td>p-value</td></tr><tr><td>Age (years)</td><td>65*</td><td>68.5</td><td>0.61</td><td>70</td><td>68</td><td>0.7</td><td>62</td><td>64</td><td>0.29</td></tr><tr><td>tPSA (ng/mL)</td><td>8.3</td><td>6.8</td><td>0.17</td><td>10.2</td><td>5.3</td><td>0.002</td><td>5.5</td><td>4.35</td><td>0.5</td></tr><tr><td>%fPSA (%)</td><td>8.0<sup>*$</sup></td><td>13.15</td><td>0.017</td><td>15.15</td><td>17.4</td><td>0.85</td><td>11.2</td><td>13.8</td><td>0.1</td></tr><tr><td>Volume (mL)</td><td>33.5*</td><td>36.5*</td><td>0.34</td><td>50</td><td>53.5<sup>$</sup></td><td>0.87</td><td>30.5*</td><td>34*</td><td>0.26</td></tr></table> |
fcf10846c7ff7be69365b55c971c8e4e604ea5e48b8eca1d58d62f0f26d2eff7.png | simple | <table><tr><td>Group</td><td>Swell degree (mg)</td><td>Inhibition rate (%)</td></tr><tr><td>Fenli</td><td>5.13 ± 0.68</td><td>69.15</td></tr><tr><td>DE MDTS</td><td>5.86 ± 1.76</td><td>64.76</td></tr><tr><td>Control</td><td>16.63 ± 1.57</td><td> </td></tr></table> |
169fd98530a563c3089ae1d756afbdd0aceca336399f54c6147290f7c16e87dd.png | simple | <table><tr><td>Workflow</td><td>Sequential</td><td>Parallel</td></tr><tr><td>Preprocess (clipOverlap)</td><td>2.82</td><td>2.91</td></tr><tr><td>SNV: mutationSeq</td><td>5.68</td><td>5.99</td></tr><tr><td>SNV: Strelka</td><td>2.60</td><td>4.49</td></tr><tr><td>CNV: Titan</td><td>29.34</td><td>36.31</td></tr><tr><td>CNV: Sequenza</td><td>8.24</td><td>9.40</td></tr></table> |
431141e08b808b23474824f4c64b3711ef677890c066e7a1d5b2a9e12f1924a1.png | complex | <table><tr><td>Gene Name</td><td>Primers</td></tr><tr><td rowspan="2"><i>Rbcl</i> (ribulose-1,5-bisphosphate carboxylase/oxygenase: Genbank-KR914695.1)</td><td><i>Rbcl1</i>: ACGAATGTTTACGCGGTGGTCT</td></tr><tr><td><i>Rbcl2</i>: GGTACACCCAACTCCTTAGCA</td></tr><tr><td rowspan="2"><i>CrtZ</i> (carotenoid hydroxylase: Genbank-KP866868.1)</td><td><i>CrtZ1</i>: ATCTTCGCCACCTACCTGAG</td></tr><tr><td><i>CrtZ2</i>: CGGGCAGTCCATTGATGATT</td></tr><tr><td rowspan="2"><i>LcyB</i> (lycopene beta cyclase: Genbank-AY182008.1)</td><td><i>LcyB1</i>: CTTTGACCCAGCACGACTTG</td></tr><tr><td><i>LcyB2:</i> TTAGGAACTTCTCGCCCTCT</td></tr><tr><td rowspan="2"><i>CrtISO</i> (carotenoid isomerase: Genbank-KP780062.1)</td><td><i>CrtISO1</i>: GCACCACTAACCTCATCACA</td></tr><tr><td><i>CrtISO2</i>: CCTTCCAGCAGTCGTCATAA</td></tr><tr><td rowspan="2"><i>ZEP</i> (zeaxanthin epoxidase: Genbank-KP780061.1)</td><td><i>ZEP1</i>: TACCTCAACCCTGCTCCTGA</td></tr><tr><td><i>ZEP2</i>: TTCGCCCTTCTCAAGCCTGT</td></tr></table> |
7a8a221070adffee699fedac0fda4adef5d1d057feecc5c274c287997f209bd4.png | complex | <table><tr><td> </td><td> </td><td> </td><td colspan="3"><i>WALK</i></td><td> </td><td colspan="3"><i>JOG</i></td><td> </td></tr><tr><td>Phase</td><td>Joint</td><td>Plane</td><td>Barefoot</td><td>Thong</td><td><i>p;<0.05</i></td><td>95% CI</td><td>Barefoot</td><td>Thong</td><td><i>p;<0.05</i></td><td>95% CI</td></tr><tr><td rowspan="7">Contact</td><td rowspan="3">Ankle</td><td>Sagittal</td><td>1.1(8.3)</td><td>12.0(12.2)</td><td>0.005*</td><td>−17.8, -4.04</td><td>13.0(7.6)</td><td>21.1(10.4)</td><td>0.005*</td><td>−13.2, -2.98</td></tr><tr><td>Frontal</td><td>−7.5(3.6)</td><td>−10.0(5.8)</td><td>0.694</td><td>−3.23, 2.25,</td><td>−4.7(4.3)</td><td>−3.6(4.7)</td><td>0.31</td><td>−3.30, 1.14</td></tr><tr><td>Transverse</td><td>1.6(4.7)</td><td>1.7(3.2)</td><td>0.957</td><td>−3.15, 3.00</td><td>3.6(5.0)</td><td>1.4(5.8)</td><td>0.194</td><td>−1.30, 5.77</td></tr><tr><td rowspan="3">Midfoot</td><td>Sagittal</td><td>−3.8(6.5)</td><td>−9.2(12.2)</td><td>0.090</td><td>−1.00, 11.9</td><td>−3.5(6.5)</td><td>−6.6(11.9)</td><td>0.203</td><td>−1.92, 8.13</td></tr><tr><td>Frontal</td><td>2.0 (2.9)</td><td>0.6 (5.0)</td><td>0.181</td><td>−0.750, 3.55</td><td>1.2(3.6)</td><td>−2.6(6.5</td><td>0.042*</td><td>0.15, 7.40</td></tr><tr><td>Transverse</td><td>−3.6(3.6)</td><td>1.0(4.0)</td><td>0.441</td><td>−5.21, 2.42</td><td>−0.8(4.3)</td><td>2.2(4.3)</td><td>0.075</td><td>−6.30, 0.35</td></tr><tr><td>Hallux</td><td>Sagittal</td><td>6.2(4.3)</td><td>3.7(5.4)</td><td>0.203</td><td>−1.57, 6.65</td><td>4.3(4.7)</td><td>3.3(6.5)</td><td>0.694</td><td>−4.41, 6.41</td></tr><tr><td rowspan="7">Midstance</td><td rowspan="3">Ankle</td><td>Sagittal</td><td>7.6(5.8)</td><td>12.6(10.4)</td><td>0.124</td><td>−11.44, 1.56</td><td>20.3(5.4)</td><td>24.4(9.0)</td><td>0.099</td><td>−9.02, 0.88</td></tr><tr><td>Frontal</td><td>−3.8(3.6)</td><td>−4.2(4.7)</td><td>0.672</td><td>−1.47, 2.20</td><td>0.3(4.7)</td><td>1.0(4.7)</td><td>0.492</td><td>−2.94, 1.50</td></tr><tr><td>Transverse</td><td>4.1(4.3)</td><td>2.5(4.0)</td><td>0.315</td><td>−1.74, 4.96</td><td>6.4(5.8)</td><td>3.4(5.8)</td><td>0.069</td><td>−0.28, 6.40</td></tr><tr><td rowspan="3">Midfoot</td><td>Sagittal</td><td>−0.8(6.1)</td><td>−7.4(12.6)</td><td>0.052</td><td>−0.065, 13.3</td><td>2.9(7.2)</td><td>−2.2(12.6)</td><td>0.037*</td><td>0.370, 9.73</td></tr><tr><td>Frontal</td><td>3.6 (1.8)</td><td>2.2 (5.0)</td><td>0.231</td><td>−1.02, 3.83</td><td>2.0(4.3)</td><td>−0.5(6.1)</td><td>0.140</td><td>−0.908, 5.71</td></tr><tr><td>Transverse</td><td>0.5(3.2)</td><td>1.9(4.7)</td><td>0.421</td><td>−5.21, 2.33</td><td>0.1(4.7)</td><td>2.8(4.0)</td><td>0.085</td><td>−5.82, 0.435</td></tr><tr><td>Hallux</td><td>Sagittal</td><td>1.1(2.9)</td><td>1.2(4.7)</td><td>0.926</td><td>−2.99, 2.74</td><td>−0.3(3.2)</td><td>0.4(4.7)</td><td>0.664</td><td>−4.26, 2.81</td></tr><tr><td rowspan="7">Propulsive</td><td rowspan="3">Ankle</td><td>Sagittal</td><td>12.4(8.3)</td><td>16.4(11.5)</td><td>0.282</td><td>−3.74, 11.8</td><td>18.0(6.5)</td><td>21.0(10.4)</td><td>0.242</td><td>−8.12, 2.27</td></tr><tr><td>Frontal</td><td>−6.8(5.0)</td><td>−6.8(5.0)</td><td>0.552</td><td>−1.44, 2.56</td><td>−3.6(4.3)</td><td>−3.0(4.7)</td><td>0.536</td><td>−2.68, 1.47</td></tr><tr><td>Transverse</td><td>0.1(5.4)</td><td>−1.3(4.3)</td><td>0.383</td><td>−1.97, 4.78</td><td>3.6(5.8)</td><td>0.8(6.1)</td><td>0.098</td><td>−0.591, 6.09</td></tr><tr><td rowspan="3">Midfoot</td><td>Sagittal</td><td>−3.4(7.2)</td><td>−10.1(12.6)</td><td>0.044*</td><td>0.205, 13.3</td><td>−2.1(7.9)</td><td>−7.5(11.9)</td><td>0.020*</td><td>−9.84, -1.01</td></tr><tr><td>Frontal</td><td>2.5(1.8)</td><td>1.9(4.7)</td><td>0.645</td><td>−2.07, 3.18</td><td>1.8(4.0)</td><td>−0.3(5.4)</td><td>0.153</td><td>−0.908, 5.13</td></tr><tr><td>Transverse</td><td>−0.7(3.2)</td><td>0.5(4.7)</td><td>0.524</td><td>−5.00, 2.69</td><td>−0.7(4.3)</td><td>1.7(3.6)</td><td>0.107</td><td>−5.37, 0.594</td></tr><tr><td>Hallux</td><td>Sagittal</td><td>7.0(4.3)</td><td>6.0(6.8)</td><td>0.675</td><td>−3.89, 5.81</td><td>7.6(5.4)</td><td>5.4(4.3)</td><td>0.249</td><td>−1.77, 6.30</td></tr><tr><td rowspan="6">Stance</td><td rowspan="3">Ankle</td><td>Sagittal</td><td>9.1(6.8)</td><td>14.4(8.3)</td><td>0.122</td><td>−12.32, 1.66</td><td>17.6(6.1)</td><td>22.0(9.7)</td><td>0.070</td><td>−9.23, 0.416</td></tr><tr><td>Frontal</td><td>−5.5(4.0)</td><td>−5.8(5.0)</td><td>0.775</td><td>−1.68, 2.19</td><td>−2.8(4.3)</td><td>−2.0(4.3)</td><td>0.426</td><td>−2.86, 1.29</td></tr><tr><td>Transverse</td><td>1.9(4.7)</td><td>0.7(4.0)</td><td>0.444</td><td>−2.11, 4.52</td><td>4.3(5.8)</td><td>1.7(5.8)</td><td>0.120</td><td>−0.798, 6.06</td></tr><tr><td rowspan="3">Midfoot</td><td>Sagittal</td><td>−2.5(6.5)</td><td>−9.0 (13.0)</td><td>0.055</td><td>−0.156, 13.3</td><td>−1.1(7.2)</td><td>−5.6(11.9)</td><td>0.051</td><td>−0.31, 9.17</td></tr><tr><td>Frontal</td><td>2.8(2.2)</td><td>1.7(4.7)</td><td>0.362</td><td>−1.37, 3.48</td><td>1.7(4.0)</td><td>−0.9(5.8)</td><td>0.102</td><td>−0.596, 5.78</td></tr><tr><td>Transverse</td><td>−0.2(3.2)</td><td>1.2(4.3)</td><td>0.435</td><td>−5.20, 2.39</td><td>−0.5(3.6)</td><td>2.2(4.0)</td><td>0.084</td><td>−5.65, 0.409</td></tr><tr><td> </td><td>Hallux</td><td>Sagittal</td><td>1.1(2.9)</td><td>1.2(4.3)</td><td>0.926</td><td>−2.99, 2.74</td><td>4.9(4.3)</td><td>3.5(3.2)</td><td>0.384</td><td>−2.08, 5.08</td></tr></table> |
8c1317f4a3d67c736565237a9577e55a7533a0f2e9359587e6ce46d43b5115df.png | complex | <table><tr><td rowspan="3">Factors</td><td colspan="6">The effects of selection criteria fulfillment and AFP on recurrence-free survival adjusted for</td></tr><tr><td colspan="2">Microvascular invasion</td><td colspan="2">Poor tumor differentiation</td><td colspan="2">Recipient age</td></tr><tr><td>HR (95 % CI)</td><td><i>P</i></td><td>HR (95 % CI)</td><td><i>P</i></td><td>HR (95 % CI)</td><td><i>P</i></td></tr><tr><td colspan="7">Milan criteria and AFP</td></tr><tr><td> Within Milan criteria</td><td>0.20 (0.08–0.50)</td><td><0.001</td><td>0.19 (0.08–0.48)</td><td><0.001</td><td>0.18 (0.07–0.44)</td><td><0.001</td></tr><tr><td> AFP >100 ng/ml</td><td>3.98 (1.87–8.47)</td><td><0.001</td><td>3.56 (1.69–7.52)</td><td><0.001</td><td>3.46 (1.62–7.41)</td><td>0.001</td></tr><tr><td colspan="7">UCSF criteria and AFP</td></tr><tr><td> Within UCSF criteria</td><td>0.26 (0.12–0.57)</td><td><0.001</td><td>0.25 (0.11–0.54)</td><td><0.001</td><td>0.23 (0.10–0.50)</td><td><.001</td></tr><tr><td> AFP >100 ng/ml</td><td>3.83 (1.81–8.12)</td><td><0.001</td><td>3.31 (1.55–7.08)</td><td>0.002</td><td>3.38 (1.58–7.22)</td><td>.002</td></tr><tr><td colspan="7">Up-to-7 criteria and AFP</td></tr><tr><td> Within up-to-7 criteria</td><td>0.19 (0.08–0.42)</td><td><0.001</td><td>0.17 (0.08–0.37)</td><td><0.001</td><td>0.18 (0.08–0.38)</td><td><.001</td></tr><tr><td> AFP >100 ng/ml</td><td>3.60 (1.69–7.64)</td><td><0.001</td><td>3.18 (1.50–6.75)</td><td>0.003</td><td>3.27 (1.53–6.99)</td><td>.002</td></tr></table> |
ce546fde18c0b03f4131a59cd8bf8583f0f44ec57e746d6c686bebc71e4cb1a1.png | simple | <table><tr><td>Test</td><td>Method</td></tr><tr><td>Blood testsAs listed in table 1, plus:</td><td></td></tr><tr><td> Collagen C-telopeptide (CTX)Osteocalcin (OC)</td><td>Roche Elecsys beta cross-lapsRoche Elecsys 2010Canterbury District Health Board Laboratory</td></tr><tr><td>Weight at baseline and 6 months</td><td>Tanita electronic scales</td></tr></table> |
4e40215eb5f5bc2052eb3d441b34aa7ad15f5777ea9ad40947d74d2b88a27e65.png | simple | <table><tr><td></td><td>Rule role</td><td>Rule example</td><td>Location term</td></tr><tr><td><i>Ex. 1</i></td><td>Type disambiguation</td><td>IF <i>dead, decaying </i>in term THEN type =Env</td><td><i>dead animal </i>(Host) becomes <i>dead animal </i>(Env)</td></tr><tr><td><i>Ex. 2</i></td><td>Boundary extension</td><td>IF nationality before term (Env) THEN include nationality</td><td><i>oil field </i>(Env) becomes <i>German oil field </i>(Env)</td></tr><tr><td><i>Ex. 3</i></td><td>Boundary reduction</td><td>IF irrelevant modifier in term THEN delete modifier</td><td><i>infected rodent </i>(Host) becomes <i>rodent </i>(Host)</td></tr></table> |
209a0e4cbf539d2eaebe72c1e1c2a4c4668720bd4d58e2328b653c7d691ac646.png | complex | <table><tr><td rowspan="2">Rabbit antibody</td><td colspan="4">Neutralization titers</td><td rowspan="2">Dog Sera A/P<sup>a</sup></td><td colspan="2">Serological prevalence</td></tr><tr><td>3–68</td><td>W191R</td><td>L198 T</td><td>A128T</td><td>Arrival<sup>a</sup></td><td>Post<sup>a</sup></td></tr><tr><td>3–68</td><td>>1024</td><td>16</td><td><4</td><td><4</td><td>< 4 / 32</td><td>14/21<sup>c</sup></td><td>14/21</td></tr><tr><td>W191R</td><td><16</td><td>16,384</td><td><16</td><td><16</td><td>< 4 / 64</td><td>6/30</td><td>5/30</td></tr><tr><td>L198 T</td><td><4</td><td><16</td><td>256</td><td>4</td><td>4 / na<sup>b</sup></td><td>8/29</td><td>8/29</td></tr><tr><td>A128T</td><td><4</td><td><16</td><td><4</td><td>256</td><td>< 4 / 16</td><td>20/31</td><td>21/31<sup>d</sup></td></tr></table> |
31e68bc36485073925aa4960a8d4edfa617154da02904be02948ab415bd2c259.png | complex | <table><tr><td colspan="2"></td><td>Clients & informal caregivers (n = 28)</td><td>Health care providers (n = 20)</td></tr><tr><td rowspan="2">Urban (n = 16)</td><td>Male</td><td>4</td><td>0</td></tr><tr><td>Female</td><td>8</td><td>4</td></tr><tr><td rowspan="2">Rural (n = 32)</td><td>Male</td><td>1</td><td>1</td></tr><tr><td>Female</td><td>15</td><td>15</td></tr></table> |
e30bda0d69523a0cb8ac1458c056b76f522b8e4d8400ce2cf26d25d105e1d295.png | complex | <table><tr><td></td><td colspan="6">Median duration of stay (days) for SARI cases</td><td colspan="6">Median duration in ICU (days) for SARI cases with ICU treatment</td><td colspan="6">Median duration of ventilation (hours) for ventilated SARI cases</td></tr><tr><td>Case definition</td><td>< 5</td><td>5–14</td><td>15–34</td><td>35–59</td><td>60+</td><td>all</td><td>< 5</td><td>5–14</td><td>15–34</td><td>35–59</td><td>60+</td><td>all</td><td>< 5</td><td>5–14</td><td>15–34</td><td>35–59</td><td>60+</td><td>all</td></tr><tr><td>BCD</td><td>4</td><td>4</td><td>4</td><td>6</td><td>8</td><td>6</td><td>3</td><td>4</td><td>3</td><td>3</td><td>3</td><td>3</td><td>100</td><td>140.5</td><td>78</td><td>74</td><td>61</td><td>69</td></tr><tr><td>SCD</td><td>4</td><td>4</td><td>5</td><td>8</td><td>10</td><td>8</td><td>3</td><td>4</td><td>4</td><td>5</td><td>4</td><td>4</td><td>118</td><td>143</td><td>128.5</td><td>142</td><td>95</td><td>104</td></tr><tr><td>TCD</td><td>4</td><td>4</td><td>3</td><td>4</td><td>5</td><td>4</td><td>2</td><td>3</td><td>1</td><td>1</td><td>1</td><td>2</td><td>44</td><td>117</td><td>47</td><td>41.5</td><td>32</td><td>37</td></tr></table> |
29fc23580f14c1fba10d72e9f016b0d89c39f0f339358f71a452d4eaaab073a4.png | simple | <table><tr><td>Gene id</td><td>Contiguous<i>E. histolytica </i>DNA region ID</td><td>Length (bp)</td><td>Location of SNP(s) (bp)</td></tr><tr><td>EHI_080100</td><td>DS571720</td><td>5179</td><td>2725-2730</td></tr><tr><td>EHI_065250</td><td>DS571302</td><td>38246</td><td>10296-10318</td></tr></table> |
bc15280aa1a9647bad90edfee908f3a2a4a85f7653d23dac49b4ef35c8411373.png | simple | <table><tr><td>Antimicrobial agents</td><td>MIC range</td><td>MIC<sub>50</sub></td><td>MIC<sub>90</sub></td><td>Resistance (%)</td><td>Susceptible (%)</td></tr><tr><td>Cefoperazone–sulbactam</td><td>16–256</td><td>64</td><td>128</td><td>85.4</td><td>4.2</td></tr><tr><td>Ampicillin–sulbactam</td><td>16–128</td><td>64</td><td>128</td><td>93.8</td><td>0</td></tr><tr><td>Piperacillin–tazobactam</td><td>128 to >256</td><td>>256</td><td>>256</td><td>100</td><td>0</td></tr><tr><td>Ceftazidime</td><td>32–64</td><td>64</td><td>64</td><td>100</td><td>0</td></tr><tr><td>Cefepime</td><td>32–64</td><td>64</td><td>64</td><td>100</td><td>0</td></tr><tr><td>Imipenem</td><td>1–32</td><td>32</td><td>32</td><td>95.8</td><td>2.1</td></tr><tr><td>Meropenem</td><td>2–32</td><td>32</td><td>32</td><td>95.8</td><td>2.1</td></tr><tr><td>Amikacin</td><td>8 to >128</td><td>>128</td><td>>128</td><td>83.3</td><td>16.7</td></tr><tr><td>Gentamicin</td><td>2–64</td><td>64</td><td>64</td><td>95.8</td><td>4.2</td></tr><tr><td>Ciprofloxacin</td><td>16</td><td>16</td><td>16</td><td>100</td><td>0</td></tr><tr><td>Levofloxacin</td><td>4–32</td><td>8</td><td>32</td><td>91.7</td><td>0</td></tr><tr><td>Trimethoprim–sulfamethoxazole</td><td>1–16</td><td>16</td><td>16</td><td>97.9</td><td>2.1</td></tr><tr><td>Colistin</td><td>1–32</td><td>1</td><td>2</td><td>4.2</td><td>93.8</td></tr><tr><td>Tigecycline</td><td>0.25–2</td><td>0.5</td><td>1</td><td>0</td><td>100</td></tr></table> |
225ddd16bc59a0d213b56f683e211788bb750b909a0d00f651cdcd1156fa6c4c.png | simple | <table><tr><td>Group</td><td>Sequence</td><td>Repeat times</td></tr><tr><td>A1</td><td>DYDRYSSALIAA</td><td>5</td></tr><tr><td>A3</td><td>YWTPGYTPSQTE</td><td>1</td></tr><tr><td>A7</td><td>NNSRDTALRWFV</td><td>1</td></tr><tr><td>A13</td><td>GQPKTFLSVSEL</td><td>5</td></tr></table> |
0409626d7667049f261c8163bfd55e0e56386abe5c1f88ef1f2c3a67c1b57d1e.png | complex | <table><tr><td rowspan="2"></td><td>PCOS</td><td>Controls</td><td rowspan="2"><i>p</i>-value</td></tr><tr><td>(<i>N</i> = 8048)</td><td>(<i>N</i> = 32192)</td></tr><tr><td></td><td><i>n</i> (%)</td><td><i>n</i> (%)</td><td></td></tr><tr><td>Age, years</td><td></td><td></td><td></td></tr><tr><td> Mean (SD)</td><td>28.11 (6.89)</td><td>28.11 (6.90)</td><td>0.96<sup>a</sup></td></tr><tr><td> 15–29</td><td>5026 (62.5)</td><td>20159 (62.6)</td><td>0.95</td></tr><tr><td> 30–39</td><td>2534 (31.5)</td><td>10072 (31.3)</td><td></td></tr><tr><td> 40–49</td><td>488 (6.06)</td><td>1961 (6.09)</td><td></td></tr><tr><td>Follow-up duration, years</td><td></td><td></td><td></td></tr><tr><td> Mean (SD)</td><td>5.90 (3.98)</td><td>5.84 (3.96)</td><td>0.24<sup>a</sup></td></tr><tr><td>Disease entity</td><td></td><td></td><td></td></tr><tr><td> Obesity</td><td>320 (3.98)</td><td>303 (0.94)</td><td>< 0.001</td></tr><tr><td> Hirsutism</td><td>64 (0.80)</td><td>17 (0.05)</td><td>< 0.001</td></tr><tr><td> Irregular menstruation</td><td>5346 (66.4)</td><td>9303 (28.9)</td><td>< 0.001</td></tr><tr><td> Infertility</td><td>1643 (20.4)</td><td>1119 (3.48)</td><td>< 0.001</td></tr><tr><td>Comorbidity</td><td></td><td></td><td></td></tr><tr><td> Diabetes</td><td>51 (0.63)</td><td>99 (0.31)</td><td>< 0.001</td></tr><tr><td> Hypertension</td><td>237 (2.94)</td><td>470 (1.46)</td><td>< 0.001</td></tr><tr><td> Hyperlipidemia</td><td>462 (5.74)</td><td>757 (2.35)</td><td>< 0.001</td></tr><tr><td> Atrial fibrillation</td><td>5 (0.06)</td><td>9 (0.03)</td><td>0.14</td></tr><tr><td> Chronic Kidney disease</td><td>34 (0.42)</td><td>73 (0.23)</td><td>0.002</td></tr><tr><td> Atherosclerosis</td><td>10 (0.12)</td><td>19 (0.06)</td><td>0.05</td></tr></table> |
f45c48402cdd9fc81d3bafe70519a239f398da06db58fd9f3c2f09d4f8626a98.png | simple | <table><tr><td>No.</td><td>Primer’s name</td><td>Forward sequence</td><td>Reverse sequence</td><td>Annealing time and temperature</td></tr><tr><td>1</td><td><i>otud4</i></td><td>CCACCTCCTGCAGAACAAAAG</td><td>GGGTCTTGGTAAAGGCTCATT</td><td>15 s/60 °C</td></tr><tr><td>2</td><td><i>cx43</i> (<i>gja1</i>)</td><td>TGCTGCGAACCTACATCATC</td><td>CGATGACGTTCAAGGCAAGA</td><td>15 s/60 °C</td></tr><tr><td>3</td><td><i>sod2</i></td><td>GTCACCGAGGAGAAGTACCA</td><td>CTGGTTAGGACAGGCAACAA</td><td>15 s/60 °C</td></tr><tr><td>4</td><td><i>sod1</i></td><td>GATTCCACGTCCACGAGTTT</td><td>CCCGAGAGTGAGATCACAGA</td><td>15 s/60 °C</td></tr><tr><td>5</td><td><i>tgfb2</i></td><td>AGTACTACGCCAAGGAGGTT</td><td>TAGGCGGGATGGCATTTTCC</td><td>15 s/60 °C</td></tr><tr><td>6</td><td><i>myf5</i></td><td>GGAGACGCCTGAAGAAAGTC</td><td>CCGGCAGGCTGTAGTAATTC</td><td>15 s/60 °C</td></tr><tr><td>7</td><td><i>bdnf</i></td><td>CCCCATGAAAGAAGCAAACG</td><td>TACAAGTCCGCGTCCTTACT</td><td>15 s/60 °C</td></tr><tr><td>8</td><td><i>gapdh</i></td><td>GTTTGTGATGGGCGTGAACC</td><td>GTCTTCTGGGTGGCAGTGAT</td><td>15 s/60 °C</td></tr></table> |
0e3b755903a7cc6905df5c9b192c7b70595361a7a4b0c4138d4b746ae8f42ab7.png | simple | <table><tr><td>Subjects</td><td>/a/</td><td>/e/</td><td>/i/</td><td>/o/</td><td>/u/</td><td>Total</td></tr><tr><td>Viet. hyponasality</td><td>19.0</td><td>7.0</td><td>9.0</td><td>6.0</td><td>7.0</td><td>9.6</td></tr><tr><td>Viet. hypernasality</td><td>22.5</td><td>54.5</td><td>45.5</td><td>28</td><td>23</td><td>34.7</td></tr><tr><td>Kor. hypernasality</td><td>31.4</td><td>43.7</td><td>76.9</td><td>55.4</td><td>57.9</td><td>53.0</td></tr><tr><td>Viet. control group</td><td>19.0</td><td>8.0</td><td>12.0</td><td>11.0</td><td>8.0</td><td>11.6</td></tr><tr><td>Kor. control group</td><td>8.6</td><td>8.7</td><td>22.3</td><td>8.4</td><td>10.0</td><td>11.6</td></tr></table> |
f1a59d077b5995418b5b676797df4318c2bd3390189af8472ccceafce1874d68.png | complex | <table><tr><td>Type</td><td>Div</td><td>Cov</td><td colspan="5">Caller</td></tr><tr><td></td><td>(%)</td><td></td><td>GATK UG</td><td>Platypus</td><td>SAMtools</td><td>GATK HC</td><td>FreeBayes</td></tr><tr><td>SNP</td><td>0.05–1.00</td><td>10</td><td>87.3–89.8 (A)</td><td>77.6–83.0 (C)</td><td>85.9–88.4 (B)</td><td>85.4–87.3 (B)</td><td>84.1–88.1 (B)</td></tr><tr><td>SNP</td><td>0.05–1.00</td><td>40–100</td><td>96.0–98.5 (A)</td><td>87.6–96.0 (D)</td><td>95.3–98.2 (B)</td><td>95.3–97.4 (C)</td><td>93.3–98.6 (C)</td></tr><tr><td>SNP</td><td>5.00–10.00</td><td>10</td><td>82.2–88.0 (A)</td><td>43.7–59.4 (E)</td><td>80.7–85.5 (B)</td><td>73.6–84.0 (C)</td><td>61.3–74.3 (D)</td></tr><tr><td>SNP</td><td>5.00–10.00</td><td>40–100</td><td>91.3–97.4 (A)</td><td>42.0–64.1 (E)</td><td>90.8–95.1 (B)</td><td>85.7–95.3 (C)</td><td>65.6–81.6 (D)</td></tr><tr><td>INDEL</td><td>0.05–1.00</td><td>10</td><td>42.0–53.5 (D)</td><td>69.1–74.9 (A)</td><td>63.2–73.1 (C)</td><td>69.7–74.5 (A)</td><td>67.5–75.3 (B)</td></tr><tr><td>INDEL</td><td>0.05–1.00</td><td>40–100</td><td>74.2–82.9 (C)</td><td>77.8–85.5 (A)</td><td>72.6–82.9 (C)</td><td>77.9–83.3 (B)</td><td>76.0–84.0 (B)</td></tr><tr><td>INDEL</td><td>5.00–10.00</td><td>10</td><td>37.4–47.4 (D)</td><td>64.1–70.9 (A)</td><td>13.3–47.7 (E)</td><td>58.4–69.0 (B)</td><td>55.5–65.5 (C)</td></tr><tr><td>INDEL</td><td>5.00–10.00</td><td>40–100</td><td>70.5–79.7 (B)</td><td>72.8–81.7 (A)</td><td>23.6–64.1 (D)</td><td>70.8–78.6 (B)</td><td>62.4–73.7 (C)</td></tr></table> |
4d40bebcd3bc07d8175d952f703dcdf040d35dcfb00302068ecad47d8b1902fe.png | simple | <table><tr><td>Organism</td><td>Inpatient</td><td>Outpatient</td><td>Pediatrics</td><td>Missing</td><td>Total</td></tr><tr><td>Streptococcus species</td><td>162</td><td>16</td><td>19</td><td>9</td><td>206</td></tr><tr><td>Neisseria species</td><td>94</td><td>11</td><td>2</td><td>0</td><td>107</td></tr><tr><td>Haemophilus species</td><td>47</td><td>2</td><td>9</td><td>1</td><td>59</td></tr><tr><td>Staphylococcus aureus</td><td>34</td><td>1</td><td>1</td><td>0</td><td>36</td></tr><tr><td>Escherichia coli</td><td>13</td><td>7</td><td>1</td><td>1</td><td>22</td></tr><tr><td>Other Gram negative</td><td>20</td><td>2</td><td>0</td><td>0</td><td>22</td></tr><tr><td>Other Gram positive</td><td>12</td><td>0</td><td>1</td><td>0</td><td>13</td></tr><tr><td>Enterococcus species</td><td>8</td><td>0</td><td>1</td><td>0</td><td>9</td></tr><tr><td>Acinetobacter species</td><td>6</td><td>0</td><td>2</td><td>0</td><td>8</td></tr><tr><td>ESBL’s Klebsiella pneumoniae</td><td>6</td><td>1</td><td>0</td><td>0</td><td>7</td></tr><tr><td>Klebsiella</td><td>7</td><td>0</td><td>0</td><td>0</td><td>7</td></tr><tr><td>Pseudomonas species</td><td>0</td><td>0</td><td>7</td><td>0</td><td>7</td></tr><tr><td>Total</td><td>409 (81.3%)</td><td>40 (8.0%)</td><td>43 (8.5%)</td><td>11 (2.2%)</td><td>503 (100%)</td></tr></table> |
82be55fed07e318433a4907e4cfd27116b92dc2972d41f6af26c54dff9f74407.png | complex | <table><tr><td colspan="6">Mesencephalon</td></tr><tr><td>Most Discriminative Texture Parameters on Patients</td><td>p-values (patients)</td><td>p-values (controls)</td><td>Most Discriminative Texture Parameters on Controls</td><td>p-values (controls)</td><td>p-values (patients)</td></tr><tr><td>Teta4</td><td><0.001*</td><td>0.105</td><td>S(4,-4)DifVarnc</td><td>0.002*</td><td>0.519</td></tr><tr><td>Teta3</td><td><0.001*</td><td>0.020*</td><td>S(5,-5DifVarnc</td><td>0.004*</td><td>0.465</td></tr><tr><td>S(5,5)Entropy</td><td><0.001*</td><td>0.105</td><td>Teta3</td><td>0.020*</td><td><0.001*</td></tr><tr><td>S(5,5)AngScMom</td><td><0.001*</td><td>0.020*</td><td>S(5,-5)DifEntrp</td><td>0.004*</td><td>0.413</td></tr><tr><td>S(4,4)AngScMom</td><td><0.001*</td><td>0.432</td><td>Teta2</td><td>0.014*</td><td><0.001*</td></tr><tr><td>S(4,4)Entropy</td><td><0.001*</td><td>0.322</td><td>S(4,-4)DifEnrtp</td><td>0.002*</td><td>0.372</td></tr><tr><td>Teta2</td><td><0.001*</td><td>0.014*</td><td>S(3,-3)DifVarnc</td><td>0.002*</td><td>0.160</td></tr><tr><td>S(1,-1)DifVarnc</td><td><0.001*</td><td>0.375</td><td>WavEnLL_s-2</td><td>0.027*</td><td>0,472</td></tr><tr><td>S(1,1)DifVarnc</td><td><0.001*</td><td>0.375</td><td>S(5,-5)Contrast</td><td>0.002*</td><td>0.833</td></tr><tr><td>S(3,3)AngScMom</td><td><0.001*</td><td>0.492</td><td>S(4,-4)Contrast</td><td>0.002*</td><td>0.432</td></tr></table> |
c819609bb392443cd5699aaa135e53be4677c799bad6d7b8bb3b141c8ca58306.png | complex | <table><tr><td> </td><td>Administration</td><td>Clearance</td><td colspan="2">Side effects</td></tr><tr><td>GLP-1R agonist</td><td>Subctaneous</td><td> </td><td>Weight loss</td><td>Gastrointestinal tract (GIT)</td></tr><tr><td>Exenatide</td><td>Twice a day, once a week</td><td>Renal</td><td>+</td><td>++/±*</td></tr><tr><td>Liraglutide</td><td>Once a day</td><td>Extrarenal</td><td>+</td><td>+</td></tr><tr><td>DPP-4 inhibitor</td><td>Oral</td><td> </td><td>→</td><td>→</td></tr><tr><td>Sitagliptin</td><td>Once a day</td><td>Renal</td><td>→</td><td>→</td></tr><tr><td>Vildagliptin</td><td>Twice a day</td><td>Renal</td><td>→</td><td>→</td></tr><tr><td>Saxagliptin</td><td>Once a day</td><td>Renal</td><td>→</td><td>→</td></tr><tr><td>Linagliptin</td><td>Once a day</td><td>Extrarenal</td><td>→</td><td>→</td></tr><tr><td>Anagliptin</td><td>Twice a day</td><td>Renal</td><td>→</td><td>→</td></tr><tr><td>Teneligliptin</td><td>Once a day</td><td>Extrarenal > renal</td><td>→</td><td>→</td></tr><tr><td>Alogliptin</td><td>Once a day</td><td>Renal</td><td>→</td><td>→</td></tr></table> |
075c51de07a2366c7287590ec51a8a09319b9bffdf63f2551c81a493243a44bf.png | simple | <table><tr><td>MIGS ID</td><td>Property</td><td>Term</td><td>Evidence code<sup>a</sup></td></tr><tr><td></td><td>Classification</td><td>Domain <i>Bacteria</i></td><td>TAS [37]</td></tr><tr><td></td><td></td><td>Phylum <i>Bacteroidaeota</i></td><td>TAS [3]</td></tr><tr><td></td><td></td><td>Class <i>Flavobacteriia</i></td><td>TAS [38]</td></tr><tr><td></td><td></td><td>Order <i>Flavobacteriales</i></td><td>TAS [39]</td></tr><tr><td></td><td></td><td>Family <i>Flavobacteriaceae</i></td><td>TAS [40]</td></tr><tr><td></td><td></td><td>Genus <i>Elizabethkingia</i></td><td>TAS [2]</td></tr><tr><td></td><td></td><td>Species <i>Elizabethkingia meningoseptica</i></td><td>TAS [2]</td></tr><tr><td></td><td></td><td>Strain Em3</td><td>TAS [2]</td></tr><tr><td></td><td>Gram stain</td><td>Negative</td><td>IDA</td></tr><tr><td></td><td>Cell shape</td><td>Rod</td><td>IDA</td></tr><tr><td></td><td>Motility</td><td>Non motile</td><td>IDA</td></tr><tr><td></td><td>Sporulation</td><td>Non-spore-forming</td><td>NAS</td></tr><tr><td></td><td>Temperature range</td><td>4–40 °C</td><td>IDA</td></tr><tr><td></td><td>Optimum temperature</td><td>37 °C</td><td>IDA</td></tr><tr><td></td><td>pH range; Optimum</td><td>4–10; 8</td><td>IDA</td></tr><tr><td></td><td>Carbon source</td><td>Heterotroph</td><td>IDA</td></tr><tr><td></td><td>Energy source</td><td>Varied; including glucose and mannitol</td><td>IDA</td></tr><tr><td>MIGS-6</td><td>Habitat</td><td>Human</td><td>NAS</td></tr><tr><td>MIGS-6.3</td><td>Salinity</td><td>Not determined</td><td></td></tr><tr><td>MIGS-22</td><td>Oxygen requirement</td><td>Aerobic</td><td>NAS</td></tr><tr><td>MIGS-15</td><td>Biotic relationship</td><td>Free-living</td><td>NAS</td></tr><tr><td>MIGS-14</td><td>Pathogenicity</td><td>Pathogen</td><td>NAS</td></tr><tr><td>MIGS-4</td><td>Geographic location</td><td>Michigan, USA</td><td>NAS</td></tr><tr><td>MIGS-5</td><td>Sample collection time</td><td>February, 6, 2016</td><td>NAS</td></tr><tr><td>MIGS-4.1</td><td>Latitude</td><td>42° 43′ 57′′ N</td><td>NAS</td></tr><tr><td>MIGS-4.2</td><td>Longitude</td><td>84° 33′ 20′′ W</td><td>NAS</td></tr><tr><td>MIGS-4.4</td><td>Altitude</td><td>Not reported</td><td>NAS</td></tr></table> |
c1164584091236746439307ffbff4d2093c3a58ad2f7b60946936b525175d9b0.png | complex | <table><tr><td>Included trials</td><td colspan="2">Selective head cooling</td><td colspan="3">Whole body cooling</td></tr><tr><td></td><td>Gunn 1998</td><td>Gluckman 2005</td><td>Shankaran 2002</td><td>Shankaran 2005</td><td>Eicher 2005</td></tr><tr><td>Design</td><td>RCT</td><td>RCTMulticenter</td><td>RCTMulticenter</td><td>RCTMulticenter</td><td>RCTMulticenter</td></tr><tr><td>Number of participants</td><td>26</td><td>234</td><td>19</td><td>208</td><td>65</td></tr><tr><td>Gestation</td><td>≥ 37 wks</td><td>≥ 37 wks</td><td>≥ 36 wks</td><td>≥ 37 wks</td><td>≥ 35 wks</td></tr><tr><td>Inclusion criteria (details see Table 2)</td><td>Asphyxia and moderate to severe HIE</td><td>Asphyxia and moderate to severe HIE</td><td>Asphyxia and moderate to severe HIE</td><td>Asphyxia and moderate to severe HIE</td><td>Asphyxia and HIE</td></tr><tr><td>Target temperature treatment group (°C)</td><td>34.5–35.5 (n = 6)34.0–35.0 (n = 7)Not analyzed:36.0–36.5 (n = 6)35.5–35.9 (n = 6)</td><td>34.0–35.0</td><td>34.5</td><td>33.5</td><td>32.5–33.5</td></tr><tr><td>Target temperature control group (°C)</td><td>36.8–37.2</td><td>36.5–37.5</td><td>36.5</td><td>36.5–37.0</td><td>36.5–37.5</td></tr><tr><td>Site of temperature probe</td><td>Rectal</td><td>Rectal</td><td>Esophageal</td><td>Esophageal</td><td>Rectal</td></tr><tr><td>Average age at start of cooling (min)</td><td>294</td><td>330</td><td>318</td><td>302</td><td>120</td></tr><tr><td>Duration of cooling (h)</td><td>48–72</td><td>72</td><td>72</td><td>72</td><td>48</td></tr><tr><td>Cooling device</td><td>Servo-controlled cooling cap</td><td>Servo-controlled cooling cap</td><td>Two servo-controlled cooling blankets</td><td>Two servo-controlled cooling blankets</td><td>Ice bags followed by one servo-controlled cooling blanket</td></tr><tr><td>Primary outcome</td><td>Adverse events</td><td>Composite of death/severe disability</td><td>Adverse events</td><td>Composite of death/moderate or severe disability</td><td>Adverse events</td></tr><tr><td>Latest follow-up (months)</td><td>18</td><td>18</td><td>Follow-up not reported</td><td>18–22</td><td>12</td></tr><tr><td>Follow-up tools</td><td>Bayley II</td><td>Bayley IIGMF</td><td>-</td><td>Bayley IIGMF</td><td>Bayley IIVineland</td></tr></table> |
372f586139094f33a33153ed6a51bdae6b87740604390e2b3d71fa25a1be5cc7.png | simple | <table><tr><td>Chromosome</td><td>Number of SNPs in EU regions</td><td>Sequence length of EU regions (Mb)</td><td>SNP density in EU regions (Kb/SNP)</td><td>Number of SNPs in HET regions</td><td>Sequence length of HET regions (Mb)</td><td>SNP density in HET regions (Kb/SNP)</td><td>Number of SNPs</td><td>Sequence length (Mb)</td><td>SNP density (Kb/SNP)</td></tr><tr><td>Chr.01</td><td>1012</td><td>14.8</td><td>14.6</td><td>425</td><td>41.1</td><td>96.6</td><td>1437</td><td>55.9</td><td>39.2</td></tr><tr><td>Chr.02</td><td>1853</td><td>26.2</td><td>14.1</td><td>261</td><td>25.3</td><td>97.1</td><td>2114</td><td>51.6</td><td>24.3</td></tr><tr><td>Chr.03</td><td>1160</td><td>18.8</td><td>16.2</td><td>212</td><td>28.9</td><td>136.1</td><td>1372</td><td>47.7</td><td>34.8</td></tr><tr><td>Chr.04</td><td>1249</td><td>18.8</td><td>15.0</td><td>390</td><td>30.1</td><td>77.3</td><td>1639</td><td>49.2</td><td>30.0</td></tr><tr><td>Chr.05</td><td>1425</td><td>21.8</td><td>15.3</td><td>83</td><td>18.8</td><td>227.1</td><td>1508</td><td>41.9</td><td>27.8</td></tr><tr><td>Chr.06</td><td>1326</td><td>22.0</td><td>16.6</td><td>315</td><td>28.6</td><td>90.8</td><td>1641</td><td>50.6</td><td>30.9</td></tr><tr><td>Chr.07</td><td>1630</td><td>27.5</td><td>16.9</td><td>168</td><td>17.0</td><td>101.4</td><td>1798</td><td>44.7</td><td>24.8</td></tr><tr><td>Chr.08</td><td>1960</td><td>30.5</td><td>15.6</td><td>182</td><td>15.8</td><td>86.5</td><td>2142</td><td>46.9</td><td>21.9</td></tr><tr><td>Chr.09</td><td>1262</td><td>17.4</td><td>13.8</td><td>369</td><td>29.2</td><td>79.0</td><td>1631</td><td>46.8</td><td>28.7</td></tr><tr><td>Chr.10</td><td>1536</td><td>24.1</td><td>15.7</td><td>337</td><td>26.7</td><td>79.2</td><td>1873</td><td>50.9</td><td>27.2</td></tr><tr><td>Chr.11</td><td>1241</td><td>24.3</td><td>19.6</td><td>111</td><td>14.7</td><td>132.2</td><td>1352</td><td>39.2</td><td>29.0</td></tr><tr><td>Chr.12</td><td>1140</td><td>17.0</td><td>14.9</td><td>135</td><td>22.6</td><td>167.2</td><td>1275</td><td>40.1</td><td>31.5</td></tr><tr><td>Chr.13</td><td>2086</td><td>29.5</td><td>14.1</td><td>171</td><td>14.7</td><td>86.2</td><td>2257</td><td>44.3</td><td>19.6</td></tr><tr><td>Chr.14</td><td>1345</td><td>20.3</td><td>15.1</td><td>307</td><td>29.3</td><td>95.3</td><td>1652</td><td>49.7</td><td>30.1</td></tr><tr><td>Chr.15</td><td>1779</td><td>22.9</td><td>12.9</td><td>309</td><td>27.5</td><td>89.1</td><td>2088</td><td>50.9</td><td>24.4</td></tr><tr><td>Chr.16</td><td>1246</td><td>17.6</td><td>14.1</td><td>225</td><td>19.6</td><td>87.3</td><td>1471</td><td>37.3</td><td>25.4</td></tr><tr><td>Chr.17</td><td>1422</td><td>20.1</td><td>14.2</td><td>289</td><td>21.6</td><td>74.7</td><td>1711</td><td>41.9</td><td>24.5</td></tr><tr><td>Chr.18</td><td>2480</td><td>36.6</td><td>14.7</td><td>309</td><td>25.5</td><td>82.6</td><td>2789</td><td>62.3</td><td>22.3</td></tr><tr><td>Chr.19</td><td>1660</td><td>27.4</td><td>16.5</td><td>331</td><td>23.2</td><td>70.0</td><td>1991</td><td>50.6</td><td>25.4</td></tr><tr><td>Chr.20</td><td>1007</td><td>17.6</td><td>17.5</td><td>261</td><td>26.6</td><td>101.9</td><td>1268</td><td>46.8</td><td>36.9</td></tr><tr><td>Average</td><td>1491</td><td>22.8</td><td>15.4</td><td>260</td><td>24.3</td><td>102.9</td><td>1750</td><td>47.5</td><td>27.9</td></tr></table> |
6368514eb6f4bd597afafb233896c9ac788e035b8d03fdfac30e2f40acb1ad63.png | simple | <table><tr><td>Candidate Biomarker</td><td>Comparison</td><td>Difference</td><td>Lower CI</td><td>Upper CI</td><td>Q-value</td></tr><tr><td>CEA</td><td>Malignant/Non-malignant</td><td>1.97</td><td>1.08</td><td>2.85</td><td>0</td></tr><tr><td>CEA</td><td>Malignant/Healthy</td><td>2.11</td><td>1.02</td><td>3.19</td><td>0</td></tr><tr><td>IL.8</td><td>Malignant/Healthy</td><td>1.22</td><td>0.14</td><td>2.31</td><td>0</td></tr><tr><td>Prolactin</td><td>Non-malignant/Healthy</td><td>1.1</td><td>0.02</td><td>2.19</td><td>0.04</td></tr></table> |
db3c741a41749febcdee935b3814b7f976304f7a920fc657e155574ee64b1175.png | complex | <table><tr><td colspan="2">Health professional/service</td><td>Communications sent out</td><td>Communications received</td></tr><tr><td>6</td><td>Oncologist</td><td>0</td><td>1</td></tr><tr><td>7</td><td>Psychologist</td><td>0</td><td>1</td></tr><tr><td>9</td><td>Neurosurgeon</td><td>5</td><td>1</td></tr><tr><td>16</td><td>Primary nurse, Oncology</td><td>0</td><td>0</td></tr><tr><td>23</td><td>Family Physician</td><td>0</td><td>1</td></tr><tr><td>30</td><td>Pediatrician/Palliative Care</td><td>0</td><td>0</td></tr><tr><td>36</td><td>Oncologist</td><td>0</td><td>1</td></tr><tr><td>38</td><td>Oncologist</td><td>0</td><td>2</td></tr><tr><td>42</td><td>Pediatrician/Palliative Care</td><td>0</td><td>1</td></tr><tr><td>44</td><td>Neurosurgeon</td><td>0</td><td>3</td></tr><tr><td>47</td><td>Neurosurgeon</td><td>3</td><td>0</td></tr><tr><td>78</td><td>Canuck Place</td><td>3</td><td>0</td></tr><tr><td></td><td><i>Mean</i></td><td><i>0.92</i></td><td><i>0.92</i></td></tr></table> |
3d2e8b9eec991a72861bfc7ea4bc237f5e5ec91b6a782febfe0571e0900de929.png | complex | <table><tr><td rowspan="2"> </td><td colspan="2">Free attention (FA)</td><td rowspan="2"> </td><td colspan="2">Attention to the right (AR)</td><td rowspan="2"> </td><td colspan="2">Attention to the left (AL)</td></tr><tr><td>P</td><td>G</td><td>P</td><td>G</td><td>P</td><td>G</td></tr><tr><td>Mean</td><td>1.04</td><td>0.67</td><td> </td><td>2.18</td><td>2.63</td><td> </td><td>2.31</td><td>1.71</td></tr><tr><td>S.D</td><td>1.22</td><td>0.98</td><td> </td><td>1.70</td><td>2.88</td><td> </td><td>2.06</td><td>2.21</td></tr><tr><td>Mann-Whitney Test (P X G)</td><td>0.288</td><td> </td><td> </td><td>1.00</td><td> </td><td> </td><td>0.396</td><td> </td></tr></table> |
efae721e4dd946bef869c12e7dc23659b64568529fac85fb24667d23635a3ad9.png | complex | <table><tr><td rowspan="2" colspan="2"></td><td colspan="6">Magnetic Detection</td><td colspan="3">Microbiological Tests</td></tr><tr><td colspan="3">Anti-<i>Streptococcus agalactiae</i></td><td colspan="3">Anti-GB Streptococci</td><td colspan="3"></td></tr><tr><td>Mastitic Milk Isolates</td><td></td><td colspan="2">Correctly Identified</td><td></td><td colspan="2">Correctly Identified</td><td></td><td colspan="2">Correctly Identified</td><td></td></tr><tr><td></td><td>n</td><td>n</td><td>%</td><td>MI <sup>1</sup></td><td>n</td><td>%</td><td>MI</td><td>n</td><td>%</td><td>MI</td></tr><tr><td><i>S. aureus</i></td><td>1</td><td>0</td><td>0.0</td><td>0</td><td>1</td><td>100.0</td><td>0</td><td>0</td><td>0.0</td><td>1</td></tr><tr><td><i>S. agalactiae</i></td><td>13</td><td>7</td><td>70.0</td><td>3</td><td>2</td><td>25.0</td><td>6</td><td>13</td><td>100.0</td><td>0</td></tr><tr><td><i>S. uberis</i></td><td>11</td><td>3</td><td>33.3</td><td>6</td><td>5</td><td>62.5</td><td>3</td><td>8</td><td>72.7</td><td>3</td></tr><tr><td><i>Streptococcus</i> spp.</td><td>4</td><td>0</td><td>0.0</td><td>3</td><td>2</td><td>50.0</td><td>2</td><td>1</td><td>25.0</td><td>3</td></tr><tr><td><i>Staphylococcus</i> spp.</td><td>2</td><td>0</td><td>0.0</td><td>0</td><td>1</td><td>50.0</td><td>1</td><td>2</td><td>100.0</td><td>0</td></tr><tr><td><i>Enterococcus</i> spp.</td><td>7</td><td>3</td><td>75.0</td><td>1</td><td>1</td><td>33.3</td><td>2</td><td>0</td><td>0.0</td><td>7</td></tr><tr><td><i>Escherichia coli</i></td><td>3</td><td>0</td><td>0.0</td><td>1</td><td>1</td><td>50.0</td><td>1</td><td>3</td><td>100.0</td><td>0</td></tr><tr><td>Yeasts</td><td>3</td><td>0</td><td>0.0</td><td>2</td><td>1</td><td>100.0</td><td>0</td><td>2</td><td>66.7</td><td>1</td></tr><tr><td><i>Prototheca</i></td><td>2</td><td>0</td><td>0.0</td><td>2</td><td>1</td><td>50.0</td><td>1</td><td>2</td><td>100.0</td><td>0</td></tr><tr><td>TOTAL</td><td>46</td><td>13</td><td>41.9</td><td>18</td><td>15</td><td>48.4</td><td>16</td><td>31</td><td>67.4</td><td>15</td></tr></table> |
9bad03f9ecfb1b697d5f32279abd3634dea053cafa1ecc46839d3544f8105a10.png | simple | <table><tr><td></td><td>NPWT (n = 19)</td><td>Usual care (n = 21)</td><td>Total (n = 40)</td></tr><tr><td>Age (years)*</td><td>58·8(15·1)</td><td>56·9(13·9)</td><td>57·8(14·4)</td></tr><tr><td>Sex ratio (M : F)</td><td>11 : 8</td><td>11 : 10</td><td>22 : 18</td></tr><tr><td>BMI (kg/m<sup>2</sup>)*</td><td>29·2(5·6)</td><td>29·0(6·0)</td><td>29·1(5·7)</td></tr><tr><td>Diabetes</td><td>12</td><td>12</td><td>24</td></tr><tr><td>Peripheral arterial disease</td><td>7</td><td>7</td><td>14</td></tr><tr><td>Tobacco use</td><td></td><td></td><td></td></tr><tr><td>None</td><td>13</td><td>10</td><td>23</td></tr><tr><td>Ex‐smoker</td><td>1</td><td>6</td><td>7</td></tr><tr><td>Current (≤ 1 pack/day)</td><td>2</td><td>4</td><td>6</td></tr><tr><td>Current (> 1 pack/day)</td><td>3</td><td>1</td><td>4</td></tr><tr><td>Previous history of SWHSI</td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>5</td><td>5</td><td>10</td></tr><tr><td>No</td><td>11</td><td>15</td><td>26</td></tr><tr><td>Unknown</td><td>3</td><td>1</td><td>4</td></tr><tr><td>Wound area (cm<sup>2</sup>)†</td><td>18·2 (0·2–122·5)</td><td>20·4 (2·3–93·2)</td><td>19·3 (0·2–122·5)</td></tr><tr><td>< 28</td><td>10</td><td>11</td><td>21</td></tr><tr><td>≥ 28</td><td>9</td><td>10</td><td>19</td></tr><tr><td>Wound duration (days)†</td><td>7 (0–27)</td><td>12 (1–142)</td><td>7 (0–142)</td></tr><tr><td>Wound infected</td><td></td><td></td><td></td></tr><tr><td>Yes</td><td>5</td><td>8</td><td>13</td></tr><tr><td>No</td><td>14</td><td>13</td><td>27</td></tr><tr><td>Wound location</td><td></td><td></td><td></td></tr><tr><td>Foot</td><td>11</td><td>13</td><td>24</td></tr><tr><td>Abdomen</td><td>3</td><td>3</td><td>6</td></tr><tr><td>Leg</td><td>3</td><td>1</td><td>4</td></tr><tr><td>Breast</td><td>1</td><td>1</td><td>2</td></tr><tr><td>Groin</td><td>0</td><td>2</td><td>2</td></tr><tr><td>Buttocks</td><td>0</td><td>1</td><td>1</td></tr><tr><td>Perianal area</td><td>1</td><td>0</td><td>1</td></tr><tr><td>Type of surgery‡</td><td></td><td></td><td></td></tr><tr><td>Elective</td><td>12</td><td>18</td><td>30</td></tr><tr><td>Emergency</td><td>6</td><td>3</td><td>9</td></tr><tr><td>Contamination level of surgery</td><td></td><td></td><td></td></tr><tr><td>Clean</td><td>6</td><td>2</td><td>8</td></tr><tr><td>Clean‐contaminated</td><td>9</td><td>12</td><td>21</td></tr><tr><td>Contaminated</td><td>4</td><td>7</td><td>11</td></tr></table> |
80679c5830d76b26fb0ff6bfab0c9304f6f48a5d3ebab9d3b30411513dce0e6c.png | complex | <table><tr><td colspan="3">SPACE</td><td colspan="3">ESPACE</td></tr><tr><td>No.</td><td>Gene</td><td>Degree</td><td>No.</td><td>Gene</td><td>Degree</td></tr><tr><td>1</td><td>PRC1</td><td>26</td><td>1</td><td>AURKA</td><td>36</td></tr><tr><td>2</td><td>RRM2</td><td>17</td><td>2</td><td>NKX2-1</td><td>35</td></tr><tr><td>3</td><td>GPR116</td><td>16</td><td>3</td><td>RRM2</td><td>18</td></tr><tr><td>4</td><td>NKX2-1</td><td>16</td><td>4</td><td>CYP2B7P1</td><td>16</td></tr><tr><td>5</td><td>CYP2B7P1</td><td>15</td><td>5</td><td>GPR116</td><td>16</td></tr><tr><td>6</td><td>SFTPB</td><td>15</td><td>6</td><td>SFTPB</td><td>15</td></tr><tr><td>7</td><td>HOP</td><td>13</td><td>7</td><td>HOP</td><td>12</td></tr><tr><td>8</td><td>C1orf116</td><td>12</td><td>8</td><td>HSD17B6</td><td>11</td></tr><tr><td>9</td><td>HSD17B6</td><td>12</td><td>9</td><td>PRC1</td><td>11</td></tr><tr><td>10</td><td>TFF1</td><td>12</td><td>10</td><td>TFF1</td><td>11</td></tr><tr><td>11</td><td>CD302</td><td>10</td><td>11</td><td>C1orf116</td><td>10</td></tr><tr><td>12</td><td>FMO5</td><td>10</td><td>12</td><td>CD302</td><td>10</td></tr><tr><td>13</td><td>TPX2</td><td>8</td><td>13</td><td>FMO5</td><td>10</td></tr><tr><td></td><td></td><td></td><td>14</td><td>UBE2C</td><td>10</td></tr><tr><td></td><td></td><td></td><td>15</td><td>APC</td><td>8</td></tr><tr><td></td><td></td><td></td><td>16</td><td>CDKN3</td><td>8</td></tr><tr><td></td><td></td><td></td><td>17</td><td>TPX2</td><td>8</td></tr></table> |
18ac7c1cf39b0a2c4d031345891d78c74583d0ba46b8acc5234bc9e961fa2c0a.png | complex | <table><tr><td colspan="6">Model description</td></tr><tr><td></td><td>Y</td><td>No. of variables</td><td>No. of observations</td><td colspan="2">Degrees of freedom</td></tr><tr><td></td><td>SMR</td><td>3</td><td>2306</td><td>2303</td><td></td></tr><tr><td colspan="6">Model fit</td></tr><tr><td></td><td>R<sup>2</sup></td><td></td><td>Log likelihood</td><td>AIC</td><td></td></tr><tr><td></td><td>0.2238</td><td></td><td>-235.357</td><td>476.713</td><td></td></tr><tr><td colspan="6">Model estimation</td></tr><tr><td></td><td>Variable</td><td>Coefficient</td><td>Std. Error</td><td>t-Statistic</td><td><i>P</i></td></tr><tr><td></td><td><i>ρ</i></td><td>0.4962</td><td>0.0231</td><td>21.496</td><td>0.0000</td></tr><tr><td></td><td>CONSTANT</td><td>0.3605</td><td>0.0304</td><td>11.859</td><td>0.0000</td></tr><tr><td></td><td>AOD</td><td>0.5367</td><td>0.1522</td><td>3.527</td><td>0.0004</td></tr><tr><td>Diagnostic tests</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Tests</td><td>DF</td><td>Value</td><td><i>p</i></td></tr><tr><td>Heteroskedasticity</td><td colspan="2">Breusch-Pagan</td><td>1</td><td>0.156</td><td>0.6933</td></tr><tr><td>Spatial dependence</td><td colspan="2">Likelihood Ratio</td><td>1</td><td>434.813</td><td>0.2745</td></tr></table> |
101cea65750dbe5753ab56fc66ceef2af0078231f88db983e47ef42a8ffbfa37.png | simple | <table><tr><td>Cancer types</td><td>Key message(s)</td><td>Ref.</td></tr><tr><td>Breast cancer</td><td>Dephosphorylation of FOXO3a induced by Aplysin suppresses tumor growth by inhibiting cell proliferation and promoting apoptosis in cancer cells.</td><td>[89]</td></tr><tr><td>Prostate cancer</td><td>Deregulation of FOXO3a promotes prostate cancer progression in TRAMP mice.</td><td>[90]</td></tr><tr><td>Acute myeloid leukemia</td><td>Dephosphorylation of FOXO3a induced by hypomethylating agents promote apoptosis by upregulation of BIM and PUMA expression.</td><td>[91]</td></tr><tr><td>Colon cancer</td><td>Activation of FOXO3a by aldose reductase induces human colon cancer cell apoptosis by upregulating both DR5 and DR4.</td><td>[92]</td></tr><tr><td>Lung cancer</td><td>Deregulation of FOXO3a promotes DNMT3B overexpression leading to tumor growth in lung cancer.</td><td>[93]</td></tr><tr><td>Glioma</td><td>A high expression of FOXO3a is associated with glioblastoma progression and FOXO3a level independently indicates poor prognosis in Glioma patients.</td><td>[94]</td></tr><tr><td>Thyroid cancer</td><td>Nuclear FOXO3a promotes cell cycle progression by transcriptional upregulation of cyclin A1 and accelerates proliferation of human ATC cells.</td><td>[95]</td></tr><tr><td>Lung adenocarcinoma</td><td>FOXO3a gene inactivation occurs frequently in carcinogen-induced lung adenocarcinoma.</td><td>[96]</td></tr><tr><td>Oral squamous cell carcinoma</td><td>Constitutively active form of FOXO3a induces significant G1-phase arrest and apoptosis in OSCC cells</td><td>[97]</td></tr><tr><td>Neck cancer</td><td>Tumor patients with low FOXO3a expression have a poor prognosis compared with patients with high FOXO3a.</td><td>[98]</td></tr><tr><td>Urothelial cancer</td><td>FOXO3a suppresses invasiveness of urothelial cancer through regulation of Twist1, YB-1 and E-cadherin.</td><td>[99]</td></tr><tr><td>Osteosarcoma</td><td>Activation of FOXO3a by ionizing radiation induces cell apoptosis in osteosarcoma.</td><td>[100]</td></tr><tr><td>Bladder cancer</td><td>Upregulation of FOXO3a by Nkx2.8 suppresses bladder cancer proliferation.</td><td></td></tr><tr><td>Gastric cancer</td><td>FOXO3a cooperates with RUNX3 to induce apoptosis by activating <i>Bim</i> in gastric cancer cells.</td><td>[60, 101]</td></tr><tr><td>Neuroblastoma</td><td>Inactivation of FOXO3a by AKT is essential for neuroblastoma cell survival.</td><td>[102]</td></tr><tr><td>Ovarian cancer</td><td>Inhibition of FOXO3a phosphorylation by BrMC upregulates Bim expression and leads to apoptosis in ovarian cancer cells.</td><td>[103]</td></tr></table> |
fdb119dfc9407771df0b1d38118e41a70e4032f97b8e275ebbb5dc4945e75fb0.png | complex | <table><tr><td>Rate of failure in control group (%)</td><td colspan="6">Rate of failure in the intervention group (%)</td></tr><tr><td></td><td colspan="2">10</td><td colspan="2">15</td><td colspan="2">25</td></tr><tr><td></td><td>80% power</td><td>90% power</td><td>80% power</td><td>90% power</td><td>80% power</td><td>90% power</td></tr><tr><td>25</td><td>100</td><td>133</td><td></td><td></td><td></td><td></td></tr><tr><td>30</td><td>62</td><td>82</td><td>121</td><td>161</td><td></td><td></td></tr><tr><td>35</td><td>43</td><td>57</td><td>73</td><td>97</td><td>329</td><td>440</td></tr></table> |
63c2d6cb17efe648df5a160dec34230b4cadf4e6aa0f2a6ad6e169951ba263e0.png | simple | <table><tr><td>Variables</td><td>Renal cell carcinoma (n = 76)</td></tr><tr><td>Age (mean, years)</td><td>61.3 ± 13.5</td></tr><tr><td>Sex</td><td> </td></tr><tr><td>Male</td><td>45</td></tr><tr><td>Female</td><td>31</td></tr><tr><td>Tumor type</td><td> </td></tr><tr><td>Clear cell</td><td>59</td></tr><tr><td>Papillary</td><td>11</td></tr><tr><td>Chromophobe</td><td>4</td></tr><tr><td>Sarcomatoid carcinoma</td><td>2</td></tr><tr><td>Pathologic grade</td><td> </td></tr><tr><td>Grade 1 and 2</td><td>57</td></tr><tr><td>Grade 3 and 4</td><td>19</td></tr><tr><td>Tumor stage</td><td> </td></tr><tr><td>Stage 1 and 2</td><td>52</td></tr><tr><td>Stage 3 and 4</td><td>24</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.